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Abstract 
 
Tendon injuries of the hand are common with nearly one-third of a million digital 
flexor tendon injuries per year in the United States. Injuries in zone II of the flexor 
tendon are notoriously difficult to repair and the main complications are either tendon 
rupture or adhesion formation. Adhesions remain a problem despite many attempts at 
prevention using various chemicals and physical barrier techniques. The overall aim 
of this thesis was to further understand the biology of tendon adhesion formation and 
to develop novel treatments targeting this process.  
 
Uninjured flexor tendons were obtained from New Zealand White rabbits. Tenocytes 
derived from different parts of the flexor tendon-sheath complex were grown using 
standard tissue culture techniques. Each of the three different cell types (endotenon, 
epitenon and tendon sheath) was subjected to various assays (proliferation/toxicology, 
cell adhesion, and mRNA expression,) using TGF-β1 and our proposed treatments; 
epigallocatechin-3-gallate (EGCG), Resveratrol and Pumactant. 
 
A further study then compared the three treatments in vivo. New Zealand White 
rabbits (n=8 per group; 32 in total) were anaesthetised and the flexor digitorum 
profundus (FDP) of digits 2 and 4 of the forepaw was subjected to a partial tenotomy. 
The three treatments (compared with control groups) were infiltrated into the flexor 
sheath of immobilised tendons and the wound was then sutured closed. After two 
weeks the tendons were harvested and randomised to either mechanical or histological 
assessment of adhesion formation. 
 
The major findings from the in vitro study were as follows: TGF-β1 showed a 
statistically significant increase in collagen type I gene expression in epitenon cells at 
24 and 48 hours and an increase in collagen type III in sheath cells between 6 and 24 
hours. There was a statistically significant down-regulation of collagen type III in 
endotenon and epitenon cells at various time points. Resveratrol showed a statistically 
significant increase in collagen type I gene expression in epitenon cells with a 
corresponding down-regulation of fibronectin and PAI-1 in both epitenon and sheath 
cells. Resveratrol also up-regulated collagen type III at late time points in tendon 
 4 
sheath cells. Pumactant also showed some therapeutic advantages at the gene 
expression level with a statistically significant increase in collagen type III in 
endotenon cells at late time points, corresponding with an overall down-regulation of 
PAI expression in the same cell type and sheath cells.    
 
The results from the in vivo study were that all three treatments showed a statistically 
significant reduction of tendon adhesion formation when compared to operated 
controls in both mechanical and histological assessments (p<0.05). However, 
Pumactant was the only treatment to demonstrate a statistically significant reduction 
in adhesion formation when compared to the H20-group using both methods (p<0.05). 
 
All three treatments displayed potential therapeutic advantages. However, Pumactant 
showed the most promising in vivo results and it would be worthwhile investigating 
this further with an in vivo model of tendon healing and if successful a pilot clinical 
trial. Hopefully this could act as a suitable adjunct to tendon repair in the future and 
improve the lives of patients with disabling tendon injuries.   
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1.1 Introduction 
Tendon injuries of the hand are common and can result directly from trauma or 
indirectly from chronic diseases such as rheumatoid arthritis. These injuries provide a 
large proportion of the workload for plastic and reconstructive hand surgeons. Repair 
of tendons is normally achieved using standard surgical techniques. However, 
although the repair is often satisfactory and strong enough to withstand early 
mobilisation, the problem remains that of the formation of excess scar tissue, 
otherwise called „adhesions‟. Adhesions form between the tendon and the surrounding 
structures and thus inhibit the movement or natural glide of the tendon through the 
tendon sheath. Subsequently, this leads to a reduction in the range of movement of the 
affected digit and overall, a poor functional outcome (Gelberman and Manske, 1985).  
 
It is estimated that there are nearly one-third of a million digital flexor tendon injuries 
per year in the United States (Pennisi, 2002). Adhesion formation within the digital 
synovial sheath is particularly severe (Potenza, 1962) with repair to zone II flexor 
tendon injury being optimal in 69% (Peck et al., 1998) to 89% (Kitsis et al., 1998) of 
cases. Adhesions may be the single most common and costly surgical problem.  
 
Tendon adhesions are not exclusive. Many other surgical conditions are also caused or 
complicated by adhesions. These restrictive fibrous bands of extracellular matrix form 
between normally separate gliding tissue layers following surgery, injury or 
inflammation. This process invariably results in alteration to the tissue or organ 
structure and ultimately a loss of function. Occurring after more than 90% of 
abdominal surgery (Liakakos et al., 2001), they are also common following 
gynaecological and urological surgery. Adhesions may lead to debilitating pain, 
infertility, visceral obstruction and death (Jeekel, 1997; Parker et al., 2001).  
 
The overall aim of this thesis was to further understand the biology of tendon 
adhesion formation and to develop novel treatments targeting this process. If 
successful this may lead to clinical trials and eventually improve the functional 
outcome for patients undergoing surgical tendon repair.  
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1.2 Histology and Structure of Tendons  
The structural components of the tendon are the collagen fibrils of which consist of 
proteoglycan matrix and fibroblasts, arranged in parallel rows, although most tendons 
are relatively acellular. The primary collagen present is type I, which accounts for 
approximately 86% of the tendon dry weight, and is composed of glycine, proline and 
hydroxyproline. There are also small quantities of collagen type III and IV. Collagen 
fibrils are orientated in a longitudinal fashion to from fibres (Figure 1.1), which 
together with the tenocytes (tendon fibroblasts), are encased by a loose connective 
tissue. Tendon size and thickness depends on the relative size and strength of the 
muscle acting upon it. Digital flexor tendons can either be intrasynovial or 
extrasynovial i.e. with or without a surrounding fibrous synovial sheath.  
 
 
 
 
Figure 1.1 The hierarchical structure of a tendon (Kastelic et al., 1978). 
 
Fibroblasts are found in all parts of the tendon and at different levels may represent 
different sub-populations. Each has a modified role in cell migration and matrix 
production in response to wounding.  Other cell types, in addition to the indolent sub-
populations of fibroblast may be found within the tendon substance. These can 
include endothelial and nerve cells as well as an inflammatory infiltrate in response to 
injury, made up of macrophages, neutrophils and lymphocytes.  
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Classically, the tendon inner core has been referred to as the endontenon and in 
intrasynovial tendons the outer surface layer is called the epitenon. This surface layer 
is analogous to the visceral surface of the flexor sheath. In extrasynovial tendons there 
is a loose covering of connective tissue and elastic fibres, with a vascular network that 
also contains elastic fibres, referred to as paratenon. For the purpose of this thesis, sub 
populations of fibroblasts are of three types (i) endontenon (core-derived) (ii) epitenon 
(surface-derived) or (iii) tendon sheath (sheath-derived).  
 
1.3 Flexor Tendon Anatomy 
There are two main digital flexor tendons in the human forearm (excluding flexor 
indicis and flexor pollicis longus, the flexors to the index finger and thumb 
respectively): The flexor digitorum superficialis (FDS) and the flexor digitorum 
profundus (FDP).  
 
1.3.1 Flexor Digitorum Superficialis 
Function 
The FDS is a deep flexor muscle of the forearm and acts to flex the proximal 
interphalangeal (PIP) joint, the metacarpophalangeal (MCP) joint, only after flexion 
has been initiated, and the wrist along with other muscles, which flex the wrist.  
 
Anatomy 
The FDS lies superficial to the FDP in the anterior compartment of the forearm. This 
muscle is the largest of the superficial forearm flexors, and arises from two heads. The 
ulnar head arises from the common flexor origin, (the medial epicondyle), the anterior 
band of the ulnar collateral ligament, the medial side of the coronoid process, and the 
intermuscular septa. The radial head arises from an area distal to the radial tuberosity.  
 
Progressing distally, the superficialis muscle forms four distinct bundles in the middle 
aspect of the forearm. The tendons to the middle and ring fingers lie superficial to the 
tendons of the index and little fingers and enter the carpal tunnel in the same 
orientation. Once in the palm, the tendons bifurcate, allowing the transmission of the 
deeper profundus tendon, which itself becomes more superficial at a site 
corresponding to the level of the A2 pulley. At the point of bifurcation the central 
fibres continue into two equal slips. After the two slips have formed, they insert into 
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the anterior surface of the middle phalanx, blending with the fibro-osseous junction of 
the A4 pulley. 
 
Blood supply  
The arterial blood supply of this muscle is provided by the branches of the artery of 
the median nerve, muscular branches of the ulnar artery and, occasionally branches of 
the radial artery. The FDS tendons to the index, middle, ring and little fingers insert 
into the respective middle phalanx of the digit. 
 
Nerve supply  
Innervation to the superficialis muscle is provided by the C7, C8 and T1 distribution 
of the median nerve.  
 
1.3.2 Flexor Digitorum Profundus     
Function 
The FDP is a deep flexor muscle of the forearm and acts to flex the distal 
interphalangeal (DIP) joint, as well as the PIP joint, the MCP joint (only after flexion 
has been initiated) and the wrist.  
 
Anatomy  
The FDP originates from the proximal three quarters of the medial and anterior 
surfaces of the ulna, the deep forearm fascia and the interosseous membrane. 
Occasionally, there is a proximal attachment to the radius just distal to the radial 
tuberosity. As the single muscle belly travels distally deep to FDS in the forearm, it 
separates into an ulnar bundle and a radial bundle. It then divides into four tendons, 
which gain entry into the palm via the carpal tunnel deep to the flexor retinaculum. At 
the musculotendinous junction, the radial bundle forms the profundus tendon of the 
index finger. The ulnar bundle forms interdigitating slips covered by a single 
paratenon, ultimately forming the individual profundus tendons of the middle, ring 
and little fingers. The insertion is the palmar base of each respective distal phalanx. 
 
Blood Supply 
The blood supply of the FDP is comprised of muscular branches from the ulnar artery, 
anterior interosseous artery, and common interosseous artery.  
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Nerve Supply  
Motor branches from the C8 and T1 distribution of the ulnar nerve provide 
innervation for the ring and small finger muscle bellies. The anterior interosseous 
branch of the median nerve (C8 and T1) innervates the index and middle finger 
muscle bellies. 
 
1.3.3 The Flexor Tendon Sheath 
The flexor tendon sheath is a fibro-osseous tunnel, which encases the long flexors to 
the fingers and thumb. It is lined with synovium, which produces synovial type fluid. 
There are, as with other body cavities, two layers: an outer parietal, and inner visceral 
layer, which is adherent to anything within the sheath, such as the tendon surface, 
vinculae, and nerves. The thumbs' sheath continues into the palm, as does that of the 
little finger. The thumbs' sheath commences approximately 2cm distal to the radial 
styloid (Doyle and Blythe, 1977). In the little finger, the proximal aspect is in 
common with the palmar flexor sheath, which envelops all superficialis and profundus 
tendons as they emerge from the carpal tunnel. It is for this reason that infections, 
such as a paronychia of the little finger, may spread proximally so rapidly as there is 
no physical barrier. The anatomy of the sheaths encompassing the middle three digits 
is different. They commence at the level of the distal palmar crease, which equates to 
the metacarpal neck. All finger digital sheaths terminate at, or just beyond, the distal 
interphalangeal joint, whilst the thumbs sheath ends just distal to the interphalangeal 
joint.  
 
Function  
The synovial sheath has been proposed to have three main functions: 
(i) To facilitate gliding of the tendons by virtue of their smooth synovial 
lining. 
(ii) As a bursa, containing synovial fluid, to bathe the tendons and aid in its 
nutrition (Lundborg et al., 1980). 
(iii) The retinacular component acts as a fulcrum, adding a mechanical 
advantage to flexion; acting as an efficient mechanism to hold the tendons 
close to the digital bone and joint (Idler, 1985).   
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Biomechanical Function 
Biomechanical laws dictate that the greater the distance from the axis of joint rotation, 
the greater the moment, resulting in less motion around that joint, and vice versa. 
Hence, the closer the tendon is held to the bones and joints, the more the resulting 
movement. Loss of portions of the digital pulleys significantly alters the normal 
integrated balance between the flexor, intrinsic, and extensor tendons. The A2 and the 
A4 pulleys (Figure 1.2) are the most biomechanically important; the loss of a 
substantial portion of either may diminish digital motion and power and lead to 
flexion contractures of interphalangeal joints or a bowstringing deformity.  
 
 
 
Figure 1.2 Diagram demonstrating the importance of the A2 and A4 pulleys in 
maintaining biomechanical function and tendon position during flexion (Neumann, 
2002). 
 
Recent advances in our understanding of the mechanism of tendon sliding 
(Guimberteau et al., 2010) have challenged previous theories. Their study suggested 
that tendon sliding is explained by the existence of a mechanical adaptable 
multimicrovacuolar network and fibrillar tissue. This tissue enables complete sliding 
without any dynamic influence on the surrounding tissues. This new theory is based 
on a polyhedric fibrillar framework, apparently chaotic and complex, subtending the 
microvacuolar gel, a concept that is to be found everywhere in the human body. 
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The Pulley System 
The fingers have five thickenings of the sheath whose collagenous fibres arch 
transversely over the tendons. They vary in size, position and functional importance 
[Figure 1.4]. Initially, it was thought that there were only four pulleys present until the 
description of the fifth annular pulley by Doyle (1988). The narrow A1, A3 and A5 
pulleys all lie over joints: the MCP, PIP and DIP joints respectively. As mentioned 
above, the functionally more important are the A2 and A4 pulleys, which are broader 
and lie over the base of the proximal and middle phalanx respectively. There are also 
three cruciate pulleys (C1-3), which run diagonally across the tendon and 
perpendicular to each other. C1 lies between A2 and A3, C2 lies between A3 and A4, 
and C3 lies between A4 and A5. Finally there is the singular palmar aponeurosis 
believed to be the mouth of the flexor sheath situated at the level of the distal palmar 
crease.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 The anatomy of the digital sheath within the human finger. Specialised 
transverse thickenings within the sheath (annular pulleys) are labelled A1 to A5. The 
three cruciate pulleys are labelled C1 to C3. The palmar aponeurosis is labelled PA 
(Strickland, 1999). 
 
The thumb has a slightly different pulley system having one oblique and two annular 
pulleys (A1 and A2) that encase the flexor pollicis longus. A1 lies over the MCP joint 
and A2 lies over the interphalangeal (IP) joint, with the oblique pulley lying between 
the two (Figure 1.4). The latter was believed to be more important and it runs from the 
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ulnar to the radial border proximal to distal (Doyle and Blythe, 1977). A further 
anatomical and biomechanical study showed a distinct pulley between A1 and oblique 
pulleys (Bayat et al., 2002). This was named the variable annular pulley or Av pulley 
(with 3 discrete forms, type I to III). This study challenged previous understanding as 
they found that the oblique pulley did not prevent bowstringing when A1 and Av 
pulleys were sectioned. This has implications for clinical procedures such as pulley 
reconstruction and trigger thumb release.             
 
 
 
Figure 1.4 The anatomy of the digital sheath within the human thumb. The transverse 
orientated specialised thickenings of the sheath (annular pulleys) are labelled A1 and 
A2. In between these is the larger oblique pulley of the thumb (Kaplan, 1965). 
 
Tendon Injury Zones 
Tendon injuries of the hand can be divided up into zones. For surgeons, this is a 
helpful way of describing such injuries as the anatomy differs in each zone (Figure 
1.5). The five zones are as follows: zone 1, distal to the FDS insertion; zone 2, from 
the A1 pulley to the FDS insertion; zone 3, from the distal end of the carpal tunnel to 
the A1 pulley; zone 4, carpal tunnel; and zone 5, proximal to the carpal tunnel. The 
thumb has the same number of zones but different anatomical demarcations: zone 1, 
distal to IP joint; zone 2, from the A1 pulley to the IP joint; zone 3, the thenar 
eminence; zone 4, carpal tunnel; zone 5, proximal to the carpal tunnel.  
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Figure 1.5 The zones of injury of the flexor tendons to the digits of the hand. The 
four fingers all have the same boundaries to their zones (Z1-5). Z1, distal to the FDS 
insertion; Z2, from the A1 pulley to the FDS insertion; Z3, from the distal end of the 
carpal tunnel to the A1 pulley; Z4, carpal tunnel and Z5, proximal to the carpal tunnel. 
The thumb flexor has slightly different zones of injury (T1-5). T1, distal to the 
interphalangeal joint; T2, from the A1 pulley to the interphalangeal joint; T3, thenar 
eminence; T4, carpal tunnel and T5, proximal to the carpal tunnel (Spivak, 1999).  
 
1.4 Tendon Nutrition 
It was not until the late nineteenth century that tendons were found to contain blood 
vessels (Ludwig, 1872). Since then attention has focused on the source and 
importance of these vessels. Tendons receive their blood supply from three main 
sources: the musculotendinous junction, the osseotendinous junction, and the vincular 
vessels as shown by Mayer (1916). He documented palmar avascular zones within the 
intrasynovial segment of the FDP tendon. Later studies showed that the three sources 
as described by Mayer in fact contributed in different proportions; the segmental 
vincular blood supply was the most important and the two other sources relatively 
minor.  
Z1     
Z2                          
Z3 
Z4 
Z5 
T1 
T2 
T3 
T4 
T5 
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There have been many different anatomical studies examining the blood supply of 
tendons. These have been performed using cadaveric and post-mortem material, not 
only from humans, but also from other species. Perfusion studies have included the 
use of India ink (Lundborg, 1976), methyl methacrylate (Ochiai et al., 1979) and 
latex-gelatin mixtures (Warren et al., 1988). Due to the variety of injection materials 
and species used there have been some differences in the description of flexor tendon 
blood supply. Lundborg and Myrage (1977) reported a sizeable avascular zone on the 
palmar aspect of the tendon relating to an area between the A2 and A4 pulley in 
human cadaveric material. However the dorsum of the tendon in this region was well 
vascularised due to a continuation of the longitudinal vessels. In contrast, a later 
study, using canine forepaw long flexors, showed that the avascular area in this 
species was total with an absence of blood vessels in both dorsal and palmar aspects 
(Gelberman et al., 1991a).    
    
Extrasynovial Tendon Vasculature 
From their musculotendinous origin to the level of the A1 pulley, the flexor tendons 
receive their blood supply from the surrounding paratenon. The paratenon is a thin 
layer of connective tissue that invests the tendon. Segmental blood vessels arise 
within the tissue, enter the tendon, and run longitudinally between fascicles to supply 
nutrients.  
 
Intrasynovial Tendon Vasculature 
When the tendons enter the flexor sheath, they are no longer surrounded by paratenon 
but are incorporated within the visceral lining of the synovium. Here blood can 
penetrate into the tendons from major branches via vinculae.  
 
1.4.1 The Vinculae 
Vinculae are remnants of mesotenon and provide blood supply and nutrition to the 
flexor tendons. One short and one long vinculum supply each FDS and FDP tendon 
(Figure 1.6).  The FDS receives a short vinculum at the level of the PIP joint. The 
FDP receives a short vinculum at the level of the DIP joint. The vinculae receive their 
blood vessels through transverse communicating branches of the proper digital artery 
located on the dorsum of the flexor tendons. Vinculae provide the blood supply that is 
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essential to the early healing of flexor tendons and they also serve as a checkrein to 
limit proximal retraction of a lacerated tendon.  
 
 
 
Figure 1.6 Diagram showing the anatomical relationship between the short and long 
vinculae supplying the FDS and FDP tendons. The vincula are labelled as follows: 
vinculum brevis profundus (VBP), vinculum longus profundus (VLP), vinculum 
brevis superficialis (VBS) and the vinculum longus superficialis (VLS) (Strickland, 
1999). 
 
1.4.2 Synovial Fluid 
Potenza in 1963, proposed that the metabolic requirements of a tendon could be met 
entirely by the diffusion of synovial fluid into the tendon substance. He deduced this 
by enclosing a vascularised intrasynovial tendon in a synthetic tube. The tendon was 
thus isolated from the synovial fluid, and started to degenerate. This seemed to be 
corroborated by work carried out by Matthews (1976), who devascularised a portion 
of a rabbit‟s long flexor tendon in an intact synovial sheath, and found that the tendon 
survived. It was found that the segments were free from adhesions in all digits and 
had a smooth surface formed from new collagen. All but the very central cells 
appeared to remain viable. A year later, McDowell and Snyder (1977) examined the 
interface between the vinculae and longitudinal vessels within the tendon. They 
hypothesized that these „capillary loops‟ acted as a dialysing membrane with the 
exuding fluid made available to the tendon substance for metabolism. 
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With the advent of radioisotope technology Manske et al., (1978) and others 
performed radiolabelled uptake studies, confirming the importance of synovial 
derived nutrition over and above the tendons blood supply. These findings began to 
challenge the widely held surgical belief that volar sutures were detrimental, that 
grafts required adhesional vascular in-growth for survival, and that the sheath should 
be resected. However, in the light of studies in the early eighties it is now thought 
prudent to close the sheath wherever possible, a fact hinted at earlier by Codivilla in 
1889. Codivilla is credited as being the first to recognise the importance of sheath 
preservation.  
 
In practice, trauma to the digits requiring repair is never as exact as that produced in 
the laboratory setting. Therefore, the general consensus is that both vascular and 
synovial fluid, do play a role in tendon nutrition, but there is still debate as to what 
proportion and in what setting. 
  
1.5 Tendon Healing 
Tendon healing studies have mostly been performed on transected animal tendons or 
ruptured human tendons. The mechanisms by which tendons repair have been closely 
studied and mostly understood, however we are still far from knowing the exact 
pathways involved. 
 
Tendon healing occurs in three phases: inflammatory, proliferative and remodelling 
phases. During the inflammatory phase erythrocytes and inflammatory cells, in 
particular neutrophils enter the site of injury. In the first twenty-four hours, monocytes 
and macrophages predominate and phagocytosis of necrotic material occurs. 
Vasoactive and chemotactic factors are released which leads to increased vascular 
permeability, initiation of angiogenesis, stimulation of tenocyte proliferation, and 
recruitment of more inflammatory cells (Murphy et al., 1994). Tenocytes slowly 
migrate into the wound and Type III collagen synthesis commences (Oakes, 2003).  
 
The proliferative phase begins after a few days. Collagen type III synthesis peaks 
during this stage and lasts for a few weeks. Water content and glycosaminoglycan 
concentrations remain high during this period (Oakes, 2003).  
 
Chapter 1 
 
 35 
The remodelling phase begins after approximately six weeks, with a reduction in 
cellularity and a reduction of collagen and glycosaminoglycan synthesis. This phase 
can be further sub-divided into a consolidation stage and maturation stage (Tillman, 
1996). The consolidation stage begins at about six weeks and continues for up to ten 
weeks. During this time the tissue changes from cellular to fibrous. The metabolism 
of tenocytes remains high and tenocytes and collagen fibers become aligned in the 
direction of stress (Hooley and Cohen, 1979). A higher proportion of collagen type I 
is produced throughout this stage (Abrahamsson, 1991).  The maturation stage then 
occurs at around ten weeks, with a gradual change of the fibrous tissue to scar-like 
tendon tissue over the course of one year (Abrahamsson, 1991; Hooley and Cohen, 
1979; Farkas et al., 1973). Towards the end of this stage tenocyte metabolism and 
vascularity decline (Amiel et al., 1983).  
 
Tendon healing can occur intrinsically, by proliferation of epitenon and endontenon 
tenocytes, or extrinsically, by invasion of cells from the surrounding sheath and 
synovium (Gelberman et al., 1984; Manske and Lesker, 1984; Potenza, 1962). 
Epitenon tenoblasts initiate the repair process through proliferation and migration. 
Cells from the epitenon alone can achieve healing of severed tendons without reliance 
on adhesions for vascularity or cellular support (Gelberman et al., 1986). Endotenon 
cells contribute to the intrinsic repair process and secrete larger and more mature 
collagen fibers than the epitenon cells (Fujita et al., 1992). It has been shown that 
initially collagen is synthesised by the epitenon cells, with the endontenon cells 
producing collagen later (Ingraham et al., 2003; Lundborg and Rank, 1980; Russell 
and Manske, 1990; Becker et al., 1981). The relative contribution of each cell type 
may be influenced by the type of trauma sustained, the anatomical location, the 
presence of a synovial sheath, and the amount of stress induced by motion after repair 
has taken place (Koob, 2002). 
 
In theory intrinsic healing should result in better biomechanics and fewer 
complications; in particular, a normal gliding mechanism within the tendon sheath is 
preserved (Koob and Summers, 2002). In extrinsic healing, scar tissue results in 
adhesion formation, which disrupts tendon gliding (Strickland, 1999).  
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Wounding and inflammation also stimulates the release of growth factors and 
cytokines from platelets, polymorphonuclear leukocytes, macrophages and other 
inflammatory cells (Evans, 1999; Woo et al., 1999; Sciore et al 1998; Chang et al., 
1998; Chan et al., 1997). These growth factors induce neovascularisation, chemotaxis, 
proliferation and collagen synthesis in fibroblasts and tenocytes (Marui et al., 1997; 
Abrahamsson and Lohmander, 1996).       
 
1.6 Animal models in the study of tendon healing and adhesion formation 
For advances to be made in tendon research animal models are essential. They allow 
for the investigation of the normal tendon healing response, disease pathogenesis and 
the study of potential treatments. There are important considerations to be made when 
choosing a model so that any conclusions formed can be directly compared, as 
accurately as possible, to the human condition under investigation. „The size of the 
animal should be large enough to allow adequate and reproducible tissue 
manipulation; the animal must be available and affordable, giving sufficient numbers 
to allow statistical comparison; finally the tissue must be amenable to measurement in 
a controlled reproducible fashion‟ (Carpenter et al., 1999).     
 
Many different animal models have been employed for the investigation of tendons 
including the rat (Harrison et al., 2003; Matthew et al., 1987; McNeilly et al., 1996), 
chicken (Becker et al., 1981), mouse (Michna, 1987), rabbit (Abrahamsson et al., 
1989; Abrahamsson et al., 1991; Chang et al., 1997; Chang et al., 1998; Kang and 
Kang, 1999; Kakar et al., 1998; Khan et al., 1996; Manske et al., 1984; Matthews and 
Richards, 1976; Rank et al., 1980), dog (Gelberman et al., 1991a; Gelberman et al., 
1984; Lundborg et al., 1980; Potenza, 1962), cow (Rodeo et al., 1994; Vogel and 
Meyers, 1999), monkey (Russell and Manske, 1990), and  even horse (Smith et al., 
2003; Gaughan et al., 1991; Watkins et al., 1985) and comparison between species 
have been conducted (Gelberman et al., 1984).   
 
In all these different animal models the type of injury inflicted has varied greatly. It 
may range from complete transection and repair (Frykman et al., 1993), partial 
transection (Manske et al., 1984), crush injury, avulsion injury or partial window 
tenotomy (Khan et al., 1996; Iwuagwu and McGrouther, 1998). The conclusions 
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drawn have often been contradictory or in part confusing. It is perhaps unsurprising 
due to the range of material studied. 
 
For the purpose of this thesis the rabbit model has been chosen, as it is the most 
commonly used in vivo flexor tendon model and has gained popularity due to its ease 
of use and accessibility of the deep flexor tendons of the forepaw. The rabbit flexor 
tendon essentially functions in the extended position in contrast to the human where it 
functions mainly in flexion; however there are anatomical and physiological 
similarities, described below, which outweigh this difference and allow its usefulness 
as an animal model. The partial tenotomy injury model has been chosen for 
comparing the effect of our different treatments. This is a good flexor tendon model as 
the injury can be easily made with a scalpel; a measured standard tenotomy window 
can be produced; the tenotomy area of tendon can be returned to the intrasynovial 
region after releasing traction; there are few confounding factors such as suture 
material or tendon sheath injury; the formation of adhesions is reliable; and 
processing of samples is straightforward. This flexor tendon model has been refined 
and used on several occasions at RAFT and has been described in studies from this 
research unit (Jones et. al., 2002; Branford et al., 2008).       
 
Unfortunately, there have been some inconsistencies in the literature regarding the 
number of annular pulleys observed along the anatomical path of the long flexor 
tendons of both the hind and forepaw. This number varies between 3 (Hagberg and 
Gerdin, 1992), 4 (Abrahamsson et al., 1989; Wiig et al., 1996) and 6 in number 
(Hanff and Hagberg, 1998). Other authors have given a description of the site of 
injury by relating it to either the proximal (Matthews and Richards, 1976) or distal 
pulley (Moro-oka, T, 1999).  Further anatomical studies by Jones, at RAFT (2001) 
confirmed there were actually 5 annular pulleys when the Lop-eared Rabbit was 
studied. Although the fifth pulley was often small it was consistently present. His 
work showed that in fact there is an even greater similarity between this species of 
rabbit and humans confirming its usefulness as an appropriate tendon-healing model. 
He also showed that adhesion formation in injured rabbit tendons was a more reliable 
finding when compared to the rat tendon model.  
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1.7 Tendon Adhesion Formation 
Tendon adhesions are fibrous bands that form post tendon injury and connect the 
affected area to its' surrounding anatomical structures. Work by Potenza in the early 
1960‟s found that they were made from fibroblasts and endothelial cells. From his 
observations he deduced that invasion of this granulation tissue was a necessary part of 
the postulated extrinsic healing process and formed in proportion to the amount of 
tissue injury with resultant new collagen formation  (Potenza, 1962, 1964).  Although 
acting as conduits for neovascularisation of the injury, adhesions have been shown to 
be detrimental to mobility and lead to a reduction in hand function (Gelberman and 
Manske, 1985). It was later shown that in order for adhesions to develop, a combination 
of tendon suturing, immobilisation and, or concurrent digital sheath injury are required 
(Matthews and Richards, 1976). They showed that the counter-experiment of an 
incompletely divided tendon, without suture material and lying freely within an 
otherwise uninjured digital sheath, healed normally without the appearance of 
adhesions. In the same year Furlow (1976) put forward a counter hypothesis to that of 
Potenza's, concluding that intrasynovial tendon injury healed through an intrinsic 
capacity and adhesions were not necessary for the process. In addition he showed that 
early motion prevented or disrupted new adhesion formation. The general consensus is 
that adhesions represent an inflammatory response to the traumatic stimulus. A recent 
study supports this view in a genetically tractable mouse model of flexor tendon 
adhesion formation (Wong et al., 2009). They confirmed that immobilization of the 
injured tendon led to increased adhesion formation and that the subcutaneous tissue was 
always the site of greatest inflammatory, proliferative, synthetic, vascularization and 
apoptotic activity.  
 
1.7.1 Tendon Adhesion Types 
There are few studies in the literature that have focused on the structure, biological 
composition or mechanics of tendon adhesions tissue. Weeks and Wray (1973) 
classified adhesions into two groups (i) loose adhesions, which are easily released by 
physical activity to allow improved tendon glide, and (ii) dense adhesions, which are 
not easily released. Furthermore, they observed that the adhesive tissues arising from 
the subcutaneous tissue and the fat became loose adhesions, while those from the 
palmar fascia, volar plate, tendon sheath and the periosteum became dense adhesions.  
Masuda et al. (2002), described adhesions histologically depending on the location of 
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the adhesion in relation to the sheath. The scar tissue in their outside-sheath group 
was composed of long, coarse fibrous elements (loose adhesions), while in their 
sheath-excised group; the fibrous tissue was composed of a crossing arrangement of 
dense fibrous elements (dense adhesion). Following tenorraphy, biochemical analysis 
of adhesion tissue samples from each of these groups was performed. The ratio of 
collagen type III to collagen type I in the outside-sheath group was higher than that in 
the sheath-excised group at 12 weeks and approached an almost normal value at 24 
weeks. The collagen type III/I ratio remained low in the sheath-excised group. They 
concluded that biochemical properties are different between loose and dense 
adhesions and pathological collagen turnover occurs even at 24 weeks after tendon 
repair.  
 
Recent research undertaken at RAFT, (Branford personal communication) has 
attempted to further classify adhesion types based on the micromechanical properties 
of the cells within adhesion tissue. For the first time confocal microscopy has been 
used to observe the dynamic properties of tendon adhesion tissue under local strain. 
Various adhesion types have been observed using this method. In some, the labelled 
nuclei appear to stretch easily in the direction of the applied force, whereas in others 
they move in a more random pattern unrelated to the directional forces. It may be that 
the former are the so-called „loose adhesions‟ and the latter are the „dense adhesions‟ 
as described by previous authors. Non-specific shearing and tearing of adhesion tissue 
has also been demonstrated in both adhesion types. 
 
When studying adhesions histologically various quantitative and qualitative methods 
have been employed. Tang et al. (1994) classified adhesions into four grades: no 
adhesions, slight adhesions, moderate adhesions, and severe adhesions. This grading 
was based on the presence of adhesions, the extending length of adhesions, and the 
density of filamentous fibres. Akali et al. (1999) described adhesions histologically as 
the substance that obliterates the synovial space, thus separating the tendon from the 
synovial sheath. Consequently, no clear margin can be delineated between the tendon 
and the synovial sheath. They devised a system for assessing the magnitude of 
adhesion formation with the aid of a graticule placed in the light microscope‟s 
eyepiece. They measured: (i) synovial thickness at the site of adhesion 
commencement (inflection); (ii) cell counts within a standardised area at the site of 
Chapter 1 
 
 40 
inflection; and (iii) the proportion (percent) of the volar surface of the tendon covered 
by adhesions. Qualitative assessment using cell morphology was also used to compare 
samples. Accurately defining and measuring adhesions is challenging and has led to 
difficulties in comparing studies. However, for the purpose of this thesis rabbit flexor 
tendon adhesions will be examined using a combination of the latter two methods.       
   
1.8 Methods used for the reduction of tendon adhesion formation 
Tendon adhesions still complicate surgical repair despite recent advances in surgical 
technique and materials used. Attempts to reduce the occurrence of adhesions, has 
involved manipulation of the healing response to tendon injury not only at the time of 
operation, but also both pre and post operatively.  
 
It is well recognised that motion prevents adhesion formation (Strickland, 1999; 
Gelberman et al., 1986; Gelberman and Manske, 1985; Gelberman et al., 1981; Green 
et al., 1986). There is not a specific amount of motion that is needed, only a relative 
amount i.e. enough to overcome the problems of scarring and adhesion formation. If it 
were possible to decrease the amount of adhesion formation independently of 
movement, less motion would be required.  This approach would eliminate the need 
for aggressive postoperative motion protocols that place the tendon repair site at risk 
of dehiscence. If the ideal inhibitor of adhesion formation could be found, the patient 
could be treated with post-operative immobilisation in a cast or splint until the tendon 
healed, allowing the repair to heal in a mechanically protected environment without 
concern about adhesions.  
 
1.8.1 Pre-operative methods of adhesion reduction 
Many different methods of pre-operative adhesion reduction have been studied over 
the last fifty years. For example the systemic administration of different drugs has 
been investigated with varying degrees of success. Systemic or local injection of 
steroids has been shown to reduce adhesion formation in vivo. One study examined 
the role of parenteral Cortisone in reducing adhesion formation of rabbit extensor 
hallucis longus tendons following surgery (Carstam, 1953). If started several days 
prior to surgery and continued post-operatively, Cortisone therapy resulted in 
suppression of adhesion formation, as measured by tensiometer testing. This was in 
contrast to those rabbits started on parenteral steroids three weeks after repair. Also, 
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groups that received no treatment or local application of steroid showed no significant 
reduction in adhesion formation. Even though these findings were promising pre- and 
post-operative parenteral steroid courses have not led to routine clinical use due to the 
associated increased rupture and infection rates (Douglas et al., 1967). Other 
researchers then investigated the role of Beta-aminoproprionitrile and demonstrated 
that it could reduce peritendinous adhesions. However, their success was later 
dampened as the compound produced side effects, such as hepatotoxicity, fever and 
dermatitis after 20 days of administration (Peacock and Madden, 1969). Adhesion 
formation was thought to be part of an inflammatory process hence the focus turned 
towards the use of non-steroidal anti-inflammatory drugs (NSAIDs). Ibuprofen, 
administered parenterally, was shown to reduce intra-abdominal adhesion formation 
in a rabbit model (Bateman et al., 1982). Kulick et al., (1984) then injected a topical 
application of ibuprofen at the time of tendon repair and showed over a 50% reduction 
in adhesion formation. Further work by this group also showed the benefits of oral 
ibuprofen in reducing tendon adhesions in a primate model. However, there was also a 
reduction in breaking strength of the completely divided and repaired tendons (Kulick 
et al., 1986). This latter finding suggests that ibuprofen may also lead to an increase in 
tendon rupture rates.     
 
1.8.2 Intra-operative methods of adhesion reduction 
While studies on pre-operative methods of adhesion prevention were being carried 
out, research was also focusing on ways to reduce tendon adhesion formation at the 
time of surgical repair. The strategies employed included different techniques of 
tenorrhaphy, different suture materials and the use of barrier methods and the 
application of various chemicals around the repair site.     
 
The observation that mobilisation led to a reduction in adhesion formation, as shown 
by some researchers (Matthews and Richards, 1976), led to further work to optimise 
tendon repair. The theory being, that if the strength of tendon repairs could be 
improved then post-operative mobilisation would rely less on splinting and allow an 
earlier and more aggressive active mobilisation regime. The ideal repair would be 
strong enough to mobilise without rupture but allow for healing between the damaged 
tendon ends. Additionally, it should be simple to perform and prevent gap formation 
or bunching at the repair site. Ketchum (1985) demonstrated that during the 
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immediate post-operative period the strength of repair was dependent on two main 
factors: the suture material and the technique of insertion. Most suturing techniques 
have two components, a central core suture and an outer peripheral (epitendinous) 
suture. The role of the epitendinous suture was initially believed to be solely aesthetic 
but there is evidence that it does in fact improve overall strength and reduce gap 
formation (Wade et al., 1989; Trail et al., 1992; Kubota et al., 1996). This benefit may 
have been due to the specific placement of the peripheral suture as Mashadi and Amis 
(1992) showed that if tendon fibres were included the repair was 83% stronger than 
the classic pure epitendinous suture. 
 
Although it can often be difficult to compare new techniques of suture repair due to 
the huge variety in methodology, there is an overall agreement that two strand 
methods are comparable. Generally, the greater the number of times the suture crosses 
the repair site the stronger it is. However, Savage and Risitano (1989) showed that a 
six-strand method was at least three times the strength of the most popular two strand 
Modified Kessler technique. Other studies have corroborated these findings (Thurman 
et al. 1998; Wagner et al., 1994). This technique has been shown to withstand the 
additional forces of early active mobilisation (Sanders et al., 1997). However, this 
repair has not been widely accepted as it has been argued that the increase in suture 
material with the multiple strand method would impair normal tendon healing. 
 
The type of suture material has greatly improved during recent years. The ideal suture 
should be strong, securely knottable, easy to handle, non-reactive and inelastic.  The 
most commonly used materials are either; a synthetic braided (e.g. Ticron), or 
monofilament suture (e.g. Prolene). The former resulting in less gap formation, 
however the latter has the advantage of ease of use. When a repaired tendon ruptures 
it is usually at the repair site. Some authors, with this in mind, have studied several 
synthetic material analogues with a degree of success. An example of this is a human 
cadaveric investigation of an internal tendon Dacron splint (Aoki et al., 1994). This 
had similar strength when compared to the Savage six-strand method and also showed 
significantly lower gap formation than any other repair method tested. However, there 
were potential limitations as the material added too much bulk to the repair site and 
would therefore increase the work of flexion.                 
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Meticulous repair of the tendon sheath has been recognised as an important factor in 
reducing adhesion formation. Codivilla of Bologna (1889) had first documented this 
at the end of the nineteenth century (Adamson and Wilson, 1961). This finding has 
been supported by more recent experiments (Matthews and Richards, 1976; Lister, 
1985). In fact such importance has been placed on sheath presence that its 
reconstruction has been encouraged in situation where primary closure is not possible. 
Autologous methods have included veins (Strauch et al., 1985), synovial bursae, 
sheaths from toes and even neighbouring digits (Rank et al., 1977). Synthetic methods 
have included cellulose tubes (Ashley et al. 1959), silastic (Ashley et al. 1964), 
Sterispon wrapping (Austin and Walker, 1979) and expanded polytetrafluoroethylene 
diffusible membrane (Hanff and Hagberg, 1998). These inter-positions whether used 
to recreate a defective sheath or placed between an intact sheath and the repair site 
have all been reported as physical barriers that help reduce or prevent adhesion 
formation.        
 
One example of a commercial physical barrier to adhesions is ADCON T/N (Wright 
Medical Group Inc). This is a resorbable carbohydrate gel that was initially approved 
in the European Union (EU), but following a negative Food and Drug Administration 
(FDA) review in 2005, further product development was suspended. An initial study 
showed promising results. 59 patients were randomised into control or ADCON-T/N 
treated groups and all followed an early mobilisation regime following tendon repair. 
Tendon rupture rates were comparable between the control and ADCON-T/N treated 
patients. At six months follow-up, the ADCON-T/N treated group had better proximal 
interphalangeal motion (Liew et al., 2001). However, a prospective double blind 
randomised controlled clinical trial including 45 patients with 82 flexor tendon repairs 
in 50 digits, demonstrated higher rupture rates (33%) when compare to the control 
group (20%), although this difference was not significant. However, the mean time to 
rupture in the ADCON-T/N group was 3 weeks, compared to 2 weeks in the control 
group (p=0.016) suggesting that ADCON-T/N interferes with tendon healing in some 
way. Also, the final ranges of motion at six months were the same (Golash et al., 
2003). Essentially, there appears to be no clinical advantage from using ADCON-T/N 
and although not significant, tendon rupture in one third of patients was deemed 
unacceptable. 
 
Chapter 1 
 
 44 
Another liquid barrier is lubricin, also known as superficial zone protein (SZP) and 
proteoglycan 4 (PRG4), found in synovial fluid, cartilage, meniscus and tendon (Rees 
et al., 2002). It is best-known for its excellent boundary lubricating properties and 
appears to be expressed ubiquitously in the canine FDP tendon with variations 
relating to regional mechanical requirements (Sun et al., 2006). More recently, a 
lubricin-containing gel compound has been shown to decrease post-operative flexor 
tendon adhesions in a canine model, although there was some impairment of tendon 
healing (Zhao et al., 2010). Additionally, lubricin, phospholipids and hyaluronic acid 
all appear to be involved in maintaining low gliding resistance of tendons (Sun et al., 
2008). One of the most promising recent advances in gel barrier technology was a 
randomized controlled multicentre clinical trial using a hyaluronan-based gel, 
Hyaloglide, in the prevention of recurrence of adhesions after tenolysis of flexor 
tendons in Zone II (Riccio et al., 2010). Patients (45 total, 19 controls, 26 treated) in 
the Hyaloglide treated group had a statistically better recovery of finger motion at all 
time intervals and returned earlier to work and daily activities. There was no apparent 
increase in complication rate however there was no discussion regarding its use in 
primary Zone II flexor tendon repairs and the potential direct effects on tendon 
healing. 
      
Various chemicals have been applied to the repair site, at the time of surgery, with the 
aim to modify the inflammatory response and reduce excessive scarring or adhesion 
formation around the healing tendon. As already mentioned in the pre-operative 
section, topical ibuprofen has also been studied intra-operatively, again due to its anti-
inflammatory actions (Kulick et al., 1984). Other substances include dextran 70 
(Green et al., 1986), sodium Hyaluronate (Hagberg, 1992; Salti et al., 1993; Weiss et 
al., 1986), aprotinin (Komurcu et al., 1997), 5-Fluorouracil (Moran et al., 2000; Khan 
et al., 2000), neutralising antibodies to transforming growth factor beta-1 (TGF-β1) 
(Chang et al., 2000) and fibrin sealant (Frykman et al., 1993) or a human-derived 
form of fibrin sealant called Vivostat® (Jones et al, 2002), all with differing results. 
Fibrin sealant has been used for almost half a century. It is now regularly used as a 
surgical adjunct for haemostasis in hepatic and cardiothoracic surgery (Chisholm et 
al., 1989; Holcomb et al., 1999; Matthew et al., 1990). Most sealants are synthetic or 
derived from pooled human plasma. Therefore there is a risk of foreign body 
reactions, or the transmission of blood born pathogens. Unfortunately, this is an 
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unacceptable risk for the commercial use of a fibrin sealant as a treatment for the 
prevention of tendon adhesions.  
 
1.8.3 Post-operative methods of adhesion reduction 
The importance of mobilisation following tendon surgery has been documented as 
early as 1912 by Erich Lexer, of Jena. He was the first to describe a series of ten free 
flexor- tendon grafts in the hand and emphasised the importance of avoiding 
adhesions by careful suturing and early motion six days after operation. He also 
recognised that local skin flaps needed to be shifted to prevent skin-to-tendon scar 
adherence and the need for long and patient post-operative care (Adamson and 
Wilson, 1961). This theory of movement following tendon repair was challenged by 
Potenza (Potenza, 1961). It was his belief that a period of immobilisation was 
required to allow adhesion formation, which he thought was required for adequate 
tendon healing. This once gold standard treatment is now only accepted for very 
young or uncooperative children. The key turning point in post-operative management 
followed the work of Kleinert (Kleinert et al., 1972), who confirmed that post-
operative mobility was essential for improved results. Controlled passive motion after 
surgery led to 87% of cases with either good or excellent results. The Kleinert regime 
incorporated a rubber band fixed to the nail of the affected digit, which is then 
attached to the flexor aspect of the forearm allowing active extension but passive 
flexion.  
 
Some authors have shown improved outcome with passive mobilisation, and 
displayed evidence that it enhances healing by stimulating maturation of the tendon 
wound in parallel with the remodelling of the tendon scar (Gelberman and Manske, 
1985). Others have added to these studies with their observations that active (in 
contrast to passive) mobilisation applies stress to the sutured tendon, increases the 
strength of the repair, enhances the biological response, and obviates the loss of 
tensile strength during the first three weeks of healing (Hitchcock et al., 1987; Aoki et 
al., 1994). Small in the late 1980‟s reported the results of patients that had routine 
tenorrhaphy followed by early active mobilisation. He achieved 77% of patients with 
either good or excellent results with a rupture rate of 9.4% (Small et al., 1989). In the 
same year there was a smaller series that reported 64% of cases with either good or 
excellent results with a rupture rate of 6% (Cullen et al., 1989). Later, other studies 
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confirmed slightly improved results with early active mobilisation when compared to 
the Kleinert post-operative regime (Elliot, 1994; Baktir et al., 1996). When 
considering all of the research to date, it has been clinically accepted that the most 
effective method of returning strength and excursion to repaired tendons involves the 
use of a strong gap- resistant suture technique followed by the application of early 
post-repair controlled motion stress.       
 
Adhesions once formed, are likely to cause a restriction of movement to the affected 
digit. After extensive post-operative physiotherapy, if the passive range of movement 
is greater than the active range, tenolysis is indicated. It should be remembered that 
this is a salvage procedure and might not improve the situation but may even make it 
worse. It involves the surgical release of the restrictive adhesion to free the adherent 
tendon and therefore allow an improved range of movement.            
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1.9 Rationale for proposed anti-adhesion treatments 
The increased rupture rates, foreign body reactions and other adverse events 
associated with the chemical and barrier treatments as mentioned above, have forced a 
change to our anti-adhesion treatment strategy. In this study, we therefore examined 
the role of more naturally occurring compounds in the search for an optimal 
treatment. A treatment that ideally can reduce tendon adhesions, allow normal or 
improved tendon healing but without these potential complications. The three 
compounds chosen for this particular study are as follows: Epigallocatechin-3-gallate 
(EGCG), an extract from green tea; Resveratrol, a natural extract from several plants 
including grapes; and lastly Pumactant, a mixture of two naturally occurring 
phospholipids (supplied by Britannia Pharmaceuticals).   
 
1.9.1 Epigallocatechin-3-gallate (EGCG) 
During the last phase of in vitro experiments at RAFT, Mount Vernon Hospital, a 
natural product was being tested for its potential clinical application in tendon 
adhesion reduction. A naturally occurring product if found to have beneficial clinical 
effects would have the advantage of being relatively easy to manufacture, have low 
costs and potentially have less side effects when compared with previous treatments.       
 
 
 
 
Figure 1.7  Chemical structure of epigallocatechin-3-gallate (EGCG) (Wan, 2005). 
  Molecular formula: C22H18O11.  
  Molecular weight: 458.372 g/mol. 
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The product used was Epigallocatechin-3-gallate (EGCG) (Figure 1.8) an extract from 
green tea (Latin name: Camellia sinensis). It is the main active and water-soluble 
catechin from green tea. Other less active catechins in green tea include epicatechin 
gallate (ECG), (+)-epicatechin and (-)-gallocatechin gallate (GCG). It accounts for 9-
13% of green tea in net weight. EGCG possesses strong anti-oxidant activities and 
plays an important role in preventing cancer (Ahmad et al., 1997) and cardiovascular 
disease (Basu et al., 2007).  Recent studies have shown that EGCG suppresses 
collagen production and may have therapeutic potential for keloid scarring and liver 
fibrosis (Zhang et al., 2006). Further, EGCG appears to be able to prevent 
transforming growth factor-beta 1 (TGF-β1) stimulated collagen contraction through a 
number of mechanisms, including reducing myofibroblast differentiation and the 
reduction of connective tissue growth factor expression (Klass et al., 2010). Other 
mechanisms of action have been studied; one theory is that EGCG reduces 
interleukin-1 (IL-1) stimulated expression of collagenase and stromelysin messenger 
ribonucleic acid (mRNA) via c-jun N-terminal kinase (JNK/SAPK) pathway (Corps et 
al., 2004). Other theories suggest that EGCG inhibits extracellular matrix (ECM) gene 
expression, by interrupting TGF-β1 signalling through attenuating oxidative stress 
(Yumei et al., 2006), or that it enhances transcription of type 1 collagen (although 
collagen production was actually inhibited in this study) and tissue inhibitor of 
metalloproteinase-1 (TIMP-1) and reduces the transcription of matrix 
metalloproteinase-1 (MMP-1) (Nakumata et al., 2005). The specific collagen types 
affected by EGCG have not been examined. Also, due to its action on collagen 
synthesis and the ECM its possible role in tendon healing and prevention of adhesions 
should be explored.  
 
1.9.2 Resveratrol 
Another naturally occurring compound, in this study, is Resveratrol (trans-3, 4, 5- 
trihydroxystilbene) (Figure 1.9). This is a natural polyphenolic phytoalexin found in 
some plants including grapes and their related products. Phytoalexins are antibacterial 
and antifungal chemicals produced by plants as a defence against infection. It is also a 
stilbenoid, a derivative of stilbene, and is produced with the help of the enzyme 
stilbene synthase.  Resveratrol has also been produced by chemical synthesis and is 
sold as a nutritional supplement.  
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Figure 1.8  Chemical structure of resveratrol (trans-3,5,4‟-trihydroxystilbene) 
(Choi, 2010) 
  Molecular formula C14H12O3  
  Molecular weight 228.25g/mol 
 
A recent study using a rat model demonstrated a reduction in peritoneal adhesions 
following laparotomy and intra-operative application of resveratrol when compared to 
saline (Sogutlu et al., 2006). Twenty-one Wistar-Albino rats were assigned into three 
groups (7 in each). After a midline laparotomy a 1cm area of caecum was abraded in 
two of the groups. They were either given resveratrol (Group 1) or saline (Group 2) 
intraperitoneally. Group 3 rats (sham operation) received no treatment, without 
serosal damage. After two weeks the rats were killed and the adhesion score was 
determined according to Mazuji‟s adhesion grade scale. The mean adhesion grade in 
the resveratrol group was 1.0 ± 0.0, in the saline group 2.57 ± 1.51, and zero in the 
sham operated group (p<0.05 between the resveratrol and saline groups). Tissue 
levels of malondialdehyde (MDA) and nitric oxide (NO) were significantly reduced in 
the resveratrol group whereas glutathione (GSH) levels were increased. From these 
findings they concluded that resveratrol reduces surgically induced peritoneal 
adhesions possibly through reduction of lipid peroxidation products.   
 
Other studies have shown that resveratrol has anti-inflammatory, antioxidant, anti-
platelet and anti-tumour effects (Brakenhielm et al., 2001; Sgambato et al., 2001; Surh 
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et al., 1999). In a dermal wound-healing mouse model, Resveratrol treatment was 
associated with a more well-defined hyperproliferative epithelial region, higher cell 
density, enhanced deposition of connective tissue and improved histological 
architecture (Khanna et al., 2002). Another study showed that Resveratrol can prevent 
fibrosis in a rat cirrhosis model, and that its action is probably associated with its 
ability to reduce nuclear factor-kappa (NF-kappa) activation and thus reduce levels of 
profibrinogenic transforming growth factor-beta (TGF-β) (Chavez et al., 2007). There 
are close associations between wound healing, fibrosis, excess scarring and adhesion 
formation. Hence, following these studies it would be worthwhile investigating the 
effects of resveratrol on tendon healing and whether peri-tendinous adhesion 
formation can be reduced.  
 
1.9.3 Pumactant 
Cells on the tendon surface are known to contain lipid-containing vesicles and it has 
been estimated that lipids account for up to 43 percent of the epitenon matrix whereas 
collagen accounts for only 23 percent (Banes et al., 1988).  
 
Pumactant is a mixture of two naturally occurring phospholipids (a 7:3 mixture of 
dipalmitoylphosphatidycholine and unsaturated phosphatidylglycerol). It was 
originally developed for neonatal respiratory distress syndrome (RDS) and results of a 
large multi-centred trial showed a 48 percent reduction in neonatal mortality in babies 
less than 32 weeks gestation. The product was withdrawn due to commercial reasons 
in 2000 following unfavourable comparison with the market leader at that time. 
However, Pumactant has been investigated in the prevention of adhesion formation, 
focusing initially on post-surgical abdominal adhesions in two randomised, and 
partially double blinded clinical trials. The results of two Phase III clinical trials were 
equivocal in respect to efficacy. The confidence and interpretation of the results were 
confounded by reports of inadequate and unsatisfactory delivery. Improvements have 
been made since then and in a murine abdominal adhesion model there was a dose 
dependent reduction in adhesion formation (unpublished studies at Cardiff 
University). 
 
Pumactant has also been found to accelerate mesothelial and keratinocyte cell 
proliferation (Topley & Woodcock, 2010). This proliferation appeared to be unique to 
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this specific compound, as other phospholipids appear to inhibit cell proliferation and 
cause a reduction in cell viability. A number of publications have either identified 
phospholipids in tendons and tendon sheath fluid (Mills et al., 2005) or a role for 
phospholipids in the prevention of adhesion formation (Moro-oka et al., 2000). In the 
latter study two experiments were conducted using Japanese White rabbit flexor 
tendon models: the first investigated the effect on the friction coefficient using a 
mixture of dipalmitoyl phosphatidylcholine and sodium hyaluronate (PHA), saline or 
sodium hyaluronate alone (HA). In this experiment the hindpaw flexor tendons were 
fixed using a clamp and strain gauge at either ends. The type of lubricant was varied 
while the load and preload were kept constant. The friction force was obtained from 
the difference between the tensions at the ends of the tendon, as measured by the 
strain gauge. They concluded that the decrease in friction coefficient in the PHA 
group indicates that dipalmitoyl phosphatidylcholine complements the boundary-
lubricating ability of the tendon. In the second experiment, rabbit hindpaw flexor 
tendons were subjected to injury and then immobilised. Three weeks later the rabbits 
were terminated, the tendons were harvested and prepared for mechanical testing. In 
the HA group there was a tendency for less work to be required to tear off the 
adhesion but this was not significant (p=0.171). In the PHA group, the difference 
between the right (treated paw) and left paw (operated but untreated) showed a 
statistically significant difference (p=0.027). In summary the PHA mixture was shown 
to significantly reduce tendon friction and adhesion formation. Hyaluronic acid is 
known to be a naturally occurring joint lubricant and in a similar study it was again 
combined with a phospholipid (Kawano et al., 2003). Phospholipids appear to have an 
additional effect (when combined with HA) on reducing tendon friction and joint 
lubrication when compared to just HA alone. In neither study did they investigate the 
actions of phospholipid alone. For the purpose of this current study Pumactant was 
used alone. In addition there is evidence (Topley & Woodcock, 2010) to suggest that 
Pumactant may achieve some of its effects through the induction of HA synthase, 
which presents the possibility that phospholipids might aid lubrication and also 
participate, through HA production, in tendon repair and healing.   
 
The ideal treatment would promote tendon healing and reduce or modify adhesion 
formation thus allowing the tendon to glide freely within the tendon sheath and allow 
for optimal function.  
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1.10 Rationale for in vitro mRNA gene selection   
In this thesis various genes known to be involved in healing and fibrosis were 
selected. In general, collagen type I and collagen type III are important for tendon 
healing, whereas fibronectin, plasminogen activator inhibitor 1 (PAI-1) and tissue 
plasminogen activator (t-PA) are associated with adhesion formation. By studying the 
different gene responses to each of the treatments better insight into the molecular 
processes involved could be gained. This in turn, should allow a more targeted 
approach to modifying tendon healing and adhesion formation.    
 
1.10.1 Collagen type I and Collagen type III 
Collagen (as already discussed in sections on histology, structure and tendon healing) 
is known to be important in maintaining the mechanical properties of the tendon and 
transmitting the forces generated by muscle fibers to the skeletal system (Benjamin et 
al., 2002; Purslow, 2002). Although there are numerous collagen types, collagen type 
I and type III appear to play the most significant role in tendon healing. In the 
uninjured tendon approximately 95% of the collagen is type I. Following injury the 
tendon ECM undergoes remodelling with breakdown of collagen fibres and the 
production of a new collagen framework. Collagen type III levels increase in the early 
inflammatory and proliferative stages of tendon healing whereas collagen type I 
production is increased in the later remodelling stages of tendon healing replacing 
collagen type III. Our treatments should aim to allow normal or optimised 
transcription and deposition of these collagen sub-types. Any reduction in production 
or alteration of collagen ratios may lead to inadequate tendon healing and probable 
tendon rupture.   
 
1.10.2 Fibronectin  
Fibronectin is a high molecular-weight glycoprotein containing approximately 5% 
carbohydrate and binds to membrane spanning receptors also known as integrins. It 
can also bind to ECM components such as collagen and fibrin.   
 
Fibronectin is deposited during the granulation stage of tendon healing, and it has 
been proposed that this preliminary fibronectin matrix allows tendon cells to move 
into the wound site (Williams et al., 1984) and remodel the ECM forming an 
adhesion-bridge between the tendon and tendon sheath. 
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Wojciak and Crossan (1993) investigated the accumulation of inflammatory cells in 
synovial sheath and epitenon during adhesion formation in healing rat flexor tendons. 
They concluded that the presence of inflammatory cells in the synovial sheath and 
epitenon during tendon healing induces synovial fibroblasts and epitenon cells to 
increase their production of fibronectin, which provides a scaffold for subsequent 
adhesion formation. Our treatments, if able to block the expression and excess 
production of fibronectin may inhibit adhesion formation via this mechanism.  
 
1.10.3 Plasminogen Activator Inhibitor 1 (PAI-1) and Tissue Plasminogen Activator 
(t-PA) 
During the normal fibrinolytic process (Figure 1.10) plasminogen is converted to 
plasmin via the action of t-PA. Plasmin then converts excess fibrin to fibrin 
degradation products allowing for clot dissolution around the site of healing.  Excess 
fibrin around the site of tendon healing is believed to form the framework for 
adhesion formation between the tendon surface and its surrounding sheath. Low 
expression of t-PA would lead to a reduction of plasmin, a persistence of fibrin and 
therefore increase the potential for adhesion formation around the tendon. 
Furthermore, increased levels of PAI-1 would inhibit the effect of t-PA and 
exacerbate this effect. The cells most associated with these changes are those of the 
tendon surface and sheath. If this process occurs at the surface-sheath interface during 
tendon healing then there is a greater likelihood of adhesion formation at the site that 
will impair normal tendon gliding. 
 
Indeed, studies have shown that PAI-1 may play a role in the formation of peritoneal 
adhesions (Cheong et al., 2001). In contrast, increased t-PA has been found to 
decrease adhesion formation (Dorr et al., 1992; Orita et al., 1991; Doody et al., 1989; 
Menzies & Ellis, 1991). Fibrinous adhesions appear to be the precursors of fibrous, 
permanent adhesions in the pelvis (Holmdahl, 1997). Other studies (Di Filippo et al., 
2006; Ivarsson et al., 1998) have shown that post-surgical peritoneal adhesions show 
an alteration of local fibrinolytic components, with the formation of adhesions being 
the result of an imbalance between fibrinogenesis (excess PAI-1) and fibronolysis 
(increased levels of tissue plasminogen activator; t-PA). These compounds have yet to 
be examined in tendons and warrant further investigation.    
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Ideally treatments should aim to increase plasma and tissue levels of t-PA but reduce 
the levels of PAI-1. This, in theory, would allow more efficient fibrin degradation and 
reduce the risk of adhesion development.    
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Figure 1.9 A flow diagram showing the influence of the fibrinolytic pathway on the 
formation of adhesion formation involving plasminogen activator inhibitor-1 (PAI-1) 
and tissue plasminogen activator (t-PA). White arrows represent activation and the 
black arrow represents inhibition.   
 
t-PA 
PAI-1 
Plasmin Plasminogen 
Fibrin FDP‟s 
Adhesion 
Formation 
Excess 
Fibrin 
Chapter 1 
 
 56 
1.11 Rationale for Thesis 
Flexor tendon injuries are common and can be surgically repaired but are frequently 
complicated by either rupture or peritendinous adhesion formation. Adhesion 
formation leads to a reduction in movement of the affected digit and overall hand 
function for patients. Although early post-operative mobilisation has reduced the 
occurrence of some adhesions this is not without an increased risk of tendon rupture. 
To date there is still no accepted or effective treatment to prevent adhesions from 
occurring altogether. The treatments that have shown promise have also had unwanted 
side effects. The naturally occurring compounds that have been carefully selected for 
this study have all shown potential as anti-adhesion treatments and should also allow 
for normal or optimised tendon healing. Should one or all of these treatments show 
positive results then clinical trials will follow on from this work. Ultimately, the aim 
is to improve hand function and the lives of patients following tendon injury and 
surgical repair.            
 
1.11.1 Thesis Hypothesis 
The aim of this thesis was to test the following hypothesis: 
 
‘The three novel compounds, EGCG, Resveratrol and Pumactant are able to reduce 
or modify flexor tendon adhesion formation’. 
 
1.11.2 Thesis Objectives 
 Establish rabbit tendon cell cultures, including endotenon, epitenon and 
tendon sheath cells, to allow in vitro testing on the each part of the tendon-
sheath complex using our three proposed treatments. 
 
 Determine the effect of transforming growth factor beta-1 TGF-β1 on flexor 
tendon cells of different origin.  
 
 Perform cell proliferation studies to determine optimal doses of specific 
treatments. 
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 Determine the in vitro effect on the production of collagen sub-types and other 
extracellular matrix components important for tendon healing or adhesion 
formation using the different treatments on each cell type. 
 
 Determine the effect that the treatments have on in vitro cell adhesion with 
each tendon cell type. 
 
 Determine if the treatments can reduce adhesion formation following tendon 
injury using an in vivo flexor tendon model.   
 
 Compare and explain the differences between the three treatments and various 
cell types.  
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2.1 Tissue Sampling and the Isolation of Cells  
2.1.1 Tendon Sampling 
Uninjured fresh New Zealand White (NZW) rabbit forelimbs were obtained following 
Schedule 1 Termination (procedures were carried out following the regulations of the 
Home Office Code of Practice for the Housing and Care of Animals Used in 
Scientific Procedures (1989) and the Animals (Scientific Procedures) ACT 1986 
(ASPA)). The limbs were submerged in industrial methylated spirit (IMS) for 1 
minute and the skin was carefully removed and washed three times with warmed 
phosphate buffered saline (PBS, Gibco) prior to dissection. All dissection was carried 
out using a standard operating light microscope (Leica), a sterile scalpel and forceps.  
 
Under sterile conditions the forepaw flexor tendons were exposed at the level of the 
mid-metacarpal region (A1 pulley) to the level of the distal phalanx (A5 pulley). 
Three separate cell components from this flexor tendon region (Zone II) were 
dissected out in preparation for tissue explants including: the tendon core (endotenon), 
the tendon surface (epitenon) and the tendon sheath (Figure 2.1). The flexor digitorum 
superficialis (FDS) tendon was excised to further expose the larger flexor digitorum 
profundus (FDP) tendon. The sheath was easily removed from the latter of these 
tendons thus exposing the whole length of the tendon and pulley system. The sheath 
tissue was kept in a sterile container until further processing. The pulleys were 
released to allow removal of the FDP tendon. The tendon itself was then dissected 
into surface and core. The surface tissue was identified as the outside layer of cells 
approximately 0-0.5mm maximum depth.  
 
After the surface tissue was removed the core was then identified. Each of the three 
tissue types were placed in sterile containers and the tissue finely diced. The tissues 
were placed into ten T25 tissue-culture flasks (plastic ware from Greiner) per tissue 
type containing pre-warmed normal growth medium (NGM; Dulbecco‟s Modified 
Eagle Medium containing 4500mg/L glucose and 4mM L-glutamine, Gibco) 
supplemented with 10% fetal calf serum (FCS, Gibco) and 1% 5000U/ml penicillin 
and 5000mg/ml streptomycin, (Gibco) and incubated under standard cell culture 
conditions (37ºC and 5% CO2).  After one week, growth of tendon fibroblasts was 
observed under light microscopy, the media was replaced with NGM (as described 
above) and the original tissue specimen carefully removed and discarded.               
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Figure 2.1 Showing the location within the tendon-sheath complex that each cell type 
was sampled from in preparation for tissue culture.    
 
2.2 Cell Culture Techniques  
2.2.1 Cell Passage and Counting  
All cell culture techniques were performed using class II laminar flow hoods. When 
confluence was reached in T25 flasks, cells were then transferred to T75 tissue culture 
flasks, and eventually maintained in T175 tissue culture flasks. Cells were passaged 
when 85-90% confluence was reached. At this confluence level media was removed 
and the cells were washed with Versene (Gibco). This was removed and a pre-
warmed Trypsin/Versene solution was added to the cell layer and incubated under 
standard cell culture conditions for 5 minutes, then knocked gently, until the cells 
detached from the base of the flask. 10ml of NGM was then added to the cell 
suspension to inactivate the Trypsin and the solution centrifuged at 1000 rpm for 5 
minutes. Only cells of passages 1-6 were used for experimentation. 
  
2.2.2 Cryopreservation 
Exponentially growing cells were trypsinised and neutralised as above. After 
centrifuging, the supernatant was removed and 3mls of cryopresevative solution 
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(4.5mls FCS and 0.5mls dimethyl sulfoxide (DMSO; Sigma-Aldrich)) added slowly 
to the cell pellet. Cell suspension aliquots were transferred into labelled cryogenic 
vials. Insulated cryovials were slowly frozen by placing into a -80C freezer for 24 
hours before being transferred to liquid nitrogen for long-term storage. 
 
To culture cells from frozen the cryovials were rapidly thawed in a water bath at 
37ºC. Cells were then plated into T75 tissue culture flasks and cultured as previously 
described. 
 
2.3 In Vitro Flexor Tendon Cell Assays   
All experiments were performed on passage one to six cells and n=3 for each 
individual cell strain: endotenon (tendon core), epitenon (tendon surface) and tendon 
sheath-derived cells unless otherwise specified. 
 
2.3.1 Toxicology Assay  
Tendon cells were seeded at 3 x 10
3
 cells/well, of a 96-microtitre plate (Greiner, 
Stonehouse, Glos) and left to attach and spread overnight in minimal media 
(Dulbecco's Modified Eagle Medium (DMEM) with 0.4% FCS). One plate was 
removed at time zero (no treatment added) and other plates had their media aspirated 
and replaced with minimal media and serial dilutions of the treatment being studied 
over the time course of 3, 7 and 10 days. The media and treatment were changed 
twice a week.  
 
Cell number was assessed using the WST-1 assay (Roche, Lewes). Due to the 
viscosity or colour of treatment a prewash step had to be performed. Treatment and 
media was carefully aspirated from the wells and each well was washed twice with 
200µl of minimal media. Minimal media was then replaced and 20µl WST-1 was 
added to each well (10µl WST per 100µl of minimal media) and left for 1 hour 
(previously optimised) in standard tissue culture conditions. The plate was shaken for 
one minute before reading of absorbance on a Bio-Rad plate reader at a frequency of 
440nm. WST-1 is based on the cleavage of the tetrazolium salt WST-1 by 
mitochondrial dehydrogenases in viable cells. The intensity of the dye is proportional 
to viable cells.    
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2.3.2 Cell Adhesion Assay 
Matrix Coating 
Matrix proteins: collagen type I, collagen type III and fibronectin were diluted in ice 
cold Dulbecco‟s PBS (without calcium and magnesium, Gibco) to achieve 10µg/ml, 
0.5mg/ml and 3.57µg/ml respectively. 50µl of each solution was pipetted into 
separate Nunc maxasorb 96 well culture plates. Triplicate wells were set up for each 
treatment. Plates were incubated for 1hour at 37ºC. Excess matrix was aspirated and 
replaced with a blocking solution, PBS containing 1% bovine serum albumin (BSA; 
Sigma-Aldrich, tissue grade), for 1hour at room temperature and washed with PBS. 
 
Cell Preparation 
Cells were removed from tissue culture flasks using Acutase (Innovative Cell 
Technologies) and the cells were re-suspended into NGM at 2x10
4
 cells/well in 100µl. 
Cells were incubated with treatment at 37ºC for 30 minutes in suspension. 
 
Assay Set Up           
The PBS in each well was aspirated, cells were re-suspended and 100µl aliquots of 
treatment/cell suspension were plated into the pre-coated wells. Plates were incubated 
at 37ºC in humidified 5% CO2 for 2 hours. Cells were observed, using inverted 
microscopy, for signs of attachment prior to the next stage. The treatment was 
carefully aspirated from the wells and the wells were gently washed with 100µl of 
PBS. Adhered cells were fixed and stained with 0.5% crystal violet (Sigma-Aldrich) 
(0.5% crystal violet, 5% formal saline, 50% ethanol, 0.85% NaCl). Excess crystal 
violet was removed and the wells carefully washed with 200µl of PBS and drained by 
inverting onto tissue. Bound crystal violet was solubilised in 100µl of 33% acetic acid 
and left for 10mins. Optical density was measured at 595nm with a Bio-Rad plate 
reader.  
 
Data Analysis 
Cell adhesion was compared between treated and untreated cells on the different 
extracellular matrices in each cell type. Statistical analysis was performed using the 
Student t-test.   
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2.3.3 Quantitative Real-Time Polymerase Chain Reaction (QRT-PCR)  
Cell Culture 
Experimental groups were placed in serum free media (DMEM, 2mM glutamine, 
100U/ml penicillin and 100mg/ml streptomycin; SFM) for 24 hours before addition of 
treatment. Treatments were as follows: SFM only, recombinant TGF-β1 (R&D 
Systems), 2ng/mL; Resveratrol 50µM, EGCG 50µM and Pumactant 1mg/mL 
(following optimisation).  
  
A comprehensive time course (0, 1, 2, 4, 6, 8, 16, 24 and 48 hours) was used to study 
early changes in gene activation. The time zero (untreated) was used to compare with 
treatments at various time points.           
 
RNA Isolation 
Quiescent rabbit tendon cells (endotenon, epitenon and sheath) were either treated or 
untreated for 0-48 hours in SFM. Total RNA was extracted using TRIzol (Gibco, 
Paisley Invitrogen).  
 
Trizol Method for RNA Extraction 
Trizol (500µl) was added to each cell monolayer at the appropriate time points. The 
flasks were then incubated at room temperature for 5 minutes and cells were removed 
from the base using a rubber policeman. The TRIzol /cell suspension was placed in 
(RNA/DNA free) centrifuge tubes and stored at 4ºC until ready for RNA preparation. 
100µl of chloroform was added to each tube, shaken vigorously for 15 seconds to mix 
well, and incubated at room temperature for 3 minutes. The mixture was then 
centrifuged at 10,000g at 4ºC for 10-30 minutes to separate into phases.  The upper 
phase was removed and placed in a fresh sterile centrifuge tube. 0.5ml of isopropanol 
(molecular grade; Sigma-Aldrich) was added mixed and left to incubate at room 
temperature for 10 minutes. The tubes were centrifuged at 11,000g at 4ºC for 30 
minutes to pellet RNA. The supernatant was removed and 1ml of 75%-ethanol 
(Hayman Ltd.) dissolved in diethylpyrocarbonate (DEPC; Sigma-Aldrich) treated 
H2O was added and placed in a vortex on low speed for 5-10 seconds to wash the 
pellet. A further centrifuge at 6,000g at 4ºC for 5 minutes was required to re-pellet the 
RNA. The supernatant was then removed and the pellet allowed to air-dry at room 
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temperature for 5-10 minutes. Finally, the dried pellet was dissolved in DEPC-H2O 
(30µl) by gentle pipetting and incubated for 5-10 minutes. Samples were then stored 
at -80C until ready for use. 
 
Quantification of RNA (Quant-iT™ Ribogreen® RNA Reagent)  
Background 
The Quant-iT™ Ribogreen® RNA Reagent (Invitrogen) is a fluorescent nucleic acid 
stain used for quantitating RNA in solution. The excitation maximum for Quant-iT™ 
Ribogreen® RNA Reagent bound to RNA is ~500nm and the emission range is 
~525nm. Sensitivity is higher than ethidium bromide assays by 200-fold and exceeds 
the ultraviolet (UV) absorbance by 1,000 fold. 
 
Protocol 
Two different dye concentrations are required to achieve the full linear dynamic range 
of the assay. Before preparing the working solutions it was necessary to establish if a 
high range (20ng/ml to 1µg/ml RNA) or a low range assay (1ng/ml to 50ng/ml) or 
both was required. For the purpose of this thesis a high range assay was found to be 
appropriate for all samples.  
 
Assay Buffer Preparation 
Sterile (nuclease and DNA free) TE buffer (10mM Tris-HCL, 1mM 
ethylenediaminetetraacetic acid (EDTA), pH 7.5) was used for diluting the Quant-
iT™ Ribogreen® RNA Reagent and for diluting RNA samples.  TE working solution 
was prepared by diluting in DEPC- H2O. Quant-iT™ Ribogreen® RNA Reagent was 
then diluted in TE. 
 
For a high range assay: There was a 200-fold dilution e.g. the working solution was 
prepared for 20 samples in 200µl volumes, 10µl Quant-iT™ Ribogreen® RNA 
Reagent was added to 1.99mls TE. The working solution was protected from light by 
covering in foil, as it is susceptible to photo degradation. 
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RNA Standard Curves 
A 2µg/ml solution of RNA was prepared in TE. Ribosomal RNA (100µg/ml) was 
diluted 50-fold in TE to make a 2µg/ml working solution (Table 2.1). 
 
Volume (µl) of TE Volume (µl) of 
2µg/ml RNA stock 
Volume of 200 fold 
diluted Quant-iT™ 
Ribogreen® RNA 
Reagent 
Final RNA 
concentration in 
Quant-iT™ 
Ribogreen® Assay 
0 100 100 1µg/ml 
50 50 100 500ng/ml 
90 10 100 100ng/ml 
98 2 100 20ng/ml 
100 0 100 0 
 
Table 2.1 Showing protocol for preparing a high-range standard curve: After dilution 
of the 2µg/ml RNA as shown in the table above, 200µl of the working solution was 
added to a 96 well polymerase chain reaction (PCR) plate (Stratagene). This was 
mixed well and incubated for 2-5 minutes at room temperature in the dark. The 
fluorescence was measured using the fluorescein isothiocyanate (FITC) wavelength 
and end point plate recorder on the MX3000P. The fluorescence value of the reagent 
blank was subtracted from that of each of the samples. Corrected data was then used 
to generate a standard curve of fluorescence versus RNA concentration. 
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Sample Analysis 
The experimental RNA solution was diluted in TE to a final volume of 100µl. 100µl 
of aqueous working solution of the Quant-iT™ Ribogreen® reagent was added to 
each sample. This was incubated for 2-5minutes at room temperature and protected 
from light. A blank 100µl TE and 100µl Ribogreen was run as a control.  The 
fluorescence of the sample was measured using the Stratagene™ MX3000P. The 
fluorescence value of the reagent blank (100µl TE and aqueous solution) was 
subtracted and the RNA concentration of each sample was determined from the 
standard curve.    
 
To check the RNA for quality and minimal DNA contamination the RNA samples 
were run on a 1% agarose gel to ensure the integrity of the total RNA samples by 
visualisation of both the 18S and 28S ribosomal RNA as discrete bands. 
 
First-Strand cDNA Synthesis Protocol  
This procedure is optimised to convert 1ng to 5ng of total RNA or up to 250ng of 
poly (A) + RNA into first strand cDNA. This protocol is optimised for the first step of 
a two-step RT-PCR procedure.  
 
The first-strand cDNA synthesis reaction was prepared in a DNA/RNAase free 
microcentrifuge tube by adding the following components in order: 1ng-5µg of total 
RNA (quantity determined previously), RNAase-free water to total volume 15.7µl and 
1.0µl of oligo (dt) primer (0.5 µg/µl; all from Stratagene) and incubated at 65°C for 
5 minutes. The reaction was cooled at room temperature for ~10 minutes to allow the 
primers to anneal to the RNA. The following components were added, in order, for a 
final reaction volume of 20µl: 2.0µl of First Strand Buffer, 0.8µl of 
deoxyribonucleotide triphosphate (dNTP) mix (25mM each dNTP), 0.5µl RNAase 
Block Ribonuclease Inhibitor (40 U/µl) and 1µl of AffinityScript Multiple 
Temperature RT (all from Stratagene). The reaction components are mixed gently, 
and the tubes placed in a temperature-controlled thermal block at 45°C for 1hr. 
Finally the reaction is terminated by incubating at 70°C for 15 minutes. The 
completed first-strand cDNA was frozen at -80C until ready for use.  
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Primers were all confirmed on BLAST and were purchased from MWG and diluted 
with DEPC-water to a dilution of 100pmol/l. Primers were optimised to ensure 
minimal primer dimmer formation by analysing the PCR reaction using different 
concentrations of both forward and reverse primers and performing a dissociation 
curve. Primer efficiency was required for the mathematical logarithm (REST-MCS) 
used for analysis (described later), each primer following optimisation was used for 
amplification using a range of cDNA (ng). The mathematical logarithm determines 
the primers efficiency.  
 
Quantitative Real-Time Polymerase Chain Reaction (QRT-PCR) 
Two microlitres of the first-strand cDNA product was used for amplification in 
triplicate in a 25μL reaction solution containing 12.5μL of SYBR Green PCR Master 
Mix (Stratagene™) and 10pM of each primer as per the manufacturer‟s instructions. 
The primer sequences are shown in Table 2.2. The PCR reaction was performed on an 
MX3000P (Stratagene). The PCR program consisted of an initial denaturation 
where the reaction was incubated for 10 minutes at 95°C; in the second step the DNA 
was amplified for 40 cycles of 30 seconds at 95°C, with an annealing of primers for 1 
minute at 60°C and an extension at 72°C for 30 seconds. A dissociation curve was 
performed to ensure that no primer-dimers were present at the end of each PCR run. 
 
 
Chapter 2 
 
 
68 
 
Gene Sequence 
Collagen type I (α2) F 5‟ TTCTTGGTGCTCCTGGCATTC 3‟ 
R 5‟ GCAATCCGTTGTGTCCCTTTATG 3‟ 
 
Collagen type III (pro α1)  
 
F 5‟CAAACCTCTTCCTGAAGCC 3‟ 
R 5‟ATTATAGCACCATTGAGAC 3‟ 
 
Fibronectin F 5‟ TCGGGAGGAAGAAGACAGATGAGC 3‟ 
R 5‟ ACCACTGCCAAAGCCTAAGCAC 3‟ 
 
PAI-1 F 5‟ GGATTTGGCCGCATTG 3‟ 
R 5‟ CAACATCCACTTTGCCAGAGTTAA 3‟ 
 
t-PA F 5‟ GAGGCTCACGTCCGGCTGTACCCCTCCA 3‟ 
R 5‟TCCTTCTGCCCACAGCCCAGCCCCCAG C 3‟ 
 
GAPDH F 5‟ GGATTTGGCCGCATTGG 3‟ 
R 5‟ CAACATCCACTTTGCCAGAGTTAA 3‟ 
ACTB F 5‟ GCTCGTCGTCGACAACGGCTG 3‟ 
R 5‟ CAAACATGATCTGGGTCATCTTCTC 3‟ 
 
 
Table 2.2 Showing primers used: PAI-1, plasminogen activator inhibitor-1; t-PA 
tissue plasminogen activator; ACTB, β-actin; GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase.  
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QRT-PCR Data Analysis 
The relative expression software tool (REST-MCS
©
) was used for the calculation of 
the relative expression levels in real time PCR. This mathematical model is based on 
the PCR efficiencies and the mean crossing point deviation between the treated and 
control cells (Figure 2.2). The target gene expression was normalised by the two 
housekeeping genes: glyceraldehyde-3-phosphate dehyrdogenase (GAPDH) and β-
actin (ACTB). Statistical analysis of group differences was performed by the Pair 
Wise Fixed Reallocation Randomisation Test
©
, implemented in the REST-XL 
software (Pfaffl et al., 2002), and the coefficient of variance was given. 
 
 
 
Figure 2.2 Showing equation used by the relative expression software tool (REST-
MCS
©
). 
 
 
 
( Etarget )
ΔCPtarget ( MEAN control – MEAN sample )
R =
( Eref )
ΔCPref ( MEAN control – MEAN sample )
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2.4 In Vivo Model of Flexor Tendon Adhesion Formation 
All procedures were carried out following the regulations of the Home Office Code of 
Practice for the Housing and Care of Animals Used in Scientific Procedures (1989) 
and the Animals (Scientific Procedures) ACT 1986 (ASPA). 
 
New Zealand White (NZW) rabbits were anaesthetised for surgery using general 
anaesthesia with recovery. A partial tenotomy was conducted on digits 2 and 4 of the 
right forepaw of 8 NZW rabbits in each treatment group, with injured untreated 
tendons acting as adhesion controls (n=8). All injured tendons were immobilised via 
a proximal tendon transection (described below). Only one paw per rabbit was 
subjected to an operation so as to minimize suffering to the animal after recovery 
from anaesthesia. The left paw acted as the unoperated untreated control.  
 
General anaesthesia, using induction with Hypnorm
®
 (VetaPharma Ltd.; Fentanyl 
citrate and fluanisone) 0.5ml/kg and diazepam (Diazemuls
®
, Alpharma) 0.1ml/kg via 
intramuscular injection, was followed by maintenance with inhaled Isoflurane 
(Baxter) 2-3% mixed with O2 2L/minute, was performed in rabbits.  
 
Antibiotic, enrofloxacin (Baytril
®
, Bayer HealthCare) was administered on induction 
via subcutaneous injection 0.3ml/kg. Analgesia, buprenorphine (Vetergesic
®
, Reckitt 
Benckiser Healthcare (UK) Ltd.) 0.01-0.05mg/kg, was administered peri-operatively 
and if necessary continued for up to 24 hours post operatively.  
 
2.4.1 Operative Procedure 
The right paw was shaved and cleaned with betadine (Figure 2.3). General 
anaesthesia was administered as described above. A „V‟-Shaped incision was made in 
the palmar aspect of the right forepaw (Figure 2.4), proximal to the 
metacarpophalangeal (MCP) joints to access both flexor digitorum profundus (FDP) 
tendons (Figure 2.5) and to avoid direct injury to the synovial sheath. The flexor 
digitorum superficialis (FDS) tendons were excised limiting adhesions to those 
formed between FDP and the sheath. The FDP was then retracted to expose the 
intrasynovial tendon. With a scalpel a partial tenotomy was performed (Figure 2.6) 
i.e. a section of tendon was removed whilst maintaining the continuity of the tendon 
(half the width of the tendon and 5mm in length). Synovial sheath injury was avoided 
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(to reduce added injury variables). In order to immobilise each specific tendon, a 
proximal transection (a transverse cut across the whole width of the tendon) was 
performed at the level of the carpus (Figure 2.7).  
 
The tendon sheath was infiltrated with the treatment (0.5mls of Sterile H2O or 1mM 
EGCG or 10mM Resveratrol or 10 mg/ml Pumactant per sheath) using a 24-gauge 
cannula with the needle removed (Figure 2.8). The partial tenotomy controls received 
no treatment. Both digits 2 and 4 of each paw were given the same treatment to allow 
for leakage between tendon compartments. Following the administration of treatment 
the tendon was allowed to return to the intrasynovial position by extending the digits 
and the wound closed. Two weeks following partial tenotomy and the application of 
treatment the rabbits were humanely killed by anaesthetic overdose (Schedule 1). 
Tendons and associated tissues were harvested at post mortem (Figure 2.9). 
 
Harvested digits were then randomised to either mechanical assessment of adhesion 
strength or histological analysis.  
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Figure 2.3 Showing a New Zealand White rabbit right forepaw prior to dissection of 
volar tissues. 
 
 
 
 
Figure 2.4 Showing the „V‟-shaped skin incision to expose flexor tendons of a New 
Zealand White rabbit right forepaw. 
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Figure 2.5 Showing the skin flap retracted proximally to expose the FDS and FDP 
tendons. 
 
 
 
 
Figure 2.6 Showing a partial tenotomy (PT) created in the FDP of the 4
th
 digit.
FDS 
FDP 
PT 
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Figure 2.7 Showing the tendon immobilisation technique via proximal transection 
(PxT) of the FDP‟s to the 2nd and 4th digits.  
 
 
 
 
Figure 2.8 Showing infiltration of treatment into the flexor tendon sheath (TS) via a 
paediatric 24-gauge cannula.
PxT 
TS 
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2.4.2 Mechanical Assessment of Adhesion Strength 
Forepaws were freshly assessed. Prior to testing the V-shaped wounds were re-
opened and the proximal free ends of each treated tendon were identified. A distal 
transection was made over the insertion of the FDP into the distal phalanx. This 
allows the tendon to lie freely within the sheath, disconnected at either end such that 
a force applied proximally would measure solely the strength of any adhesion 
between the tendon and the sheath. The digital claw was held using a clamp and the 
proximal FDP tendon transfixed to a tensile testing machine (Mecmesin) (Figure 
2.10). The proximal tendon was then pulled from its sheath at a rate of 5mm/min 
until the adhesion failed (Figure 2.11A & 2.11B). The peak force was measured in 
newtons via a connecting laptop computer using Mecmesin Emperor Software 
(Figure 2.12).   
 
2.4.3 Histological Analysis 
This is necessary to assess microscopic evidence of tendon adhesion formation. The 
tendon-adhesion complex of each digit (Figure 2.13) was fixed and paraffin 
embedded. Haematoxylin and Eosin (H&E) staining was carried out (Appendix I). 
Presence of a characteristic dense cellular band, connecting tendon to the surrounding 
tissues, was recorded as an adhesion. Semi-quantitative analysis was carried out 
using the method described by Tang (Tang et al, 1996) (Table 2.3). Tendon and 
adhesion specimens were also stained with Masson‟s trichrome stain to identify 
collagen fibril formation (Appendix I).  
 
The average cell count for each adhesion was assessed by examination under a light 
microscope (x40 magnification) following H&E staining. Images were recorded 
(using a digital camera and saved as tagged image file format (TIFF) files) and with 
the use of a 100 x 100μm grid {Akoli et al, 1999} and image analysis software 
(Adobe Systems, Inc., San Jose, Calif.), the average cell count was calculated. This 
was performed by counting the number of cells in 5 random squares and the mean 
used to determine cell number.  
 
For both scoring methods described above three independent blinded observers were 
used and mean scores recorded.        
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Figure 2.9 Showing preparation and harvest of the flexor tendons (FDP‟s to 2nd and 
4
th
 digits) two weeks following operation. A distal transection of the tendon was 
made at the level of the DIP joint to allow the tendon to lie freely within the tendon 
sheath. Hence, the only structures restricting movement of the tendon were adhesions 
or vinculae.   
 
 
 
Figure 2.10 Showing the mechanical tensiometer device (Mecmesin) connected to a 
laptop. Force readings were measured and recorded using Emperor Software 
(supplied by Mecmesin).  
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  A 
 
  B 
 
Figure 2.11A Showing the flexor tendon (FDP) being pulled out from its respective 
flexor tendon sheath.  
 
Figure 2.11B Showing the tendon completely pulled out following rupture of an 
adhesion and the hollow sheath is now visible.   
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Figure 2.12 Showing a typical reading from an adhesion pullout (Mecmesin Emperor 
Software). The displacement (mm) lies along the x-axis and the force (N) lies on the 
y-axis. The peak force (PF) required to break the adhesion is recorded. 
 
 
 
 
Figure 2.13 Showing a histology specimen before being place in formalin for 
fixation and further processing. The specimen is a rabbit forepaw digit including the 
metacarpal (MC), proximal phalanx (PP), distal phalanx (DP), claw (C), FDP and 
respective flexor sheath (TS). 
PF 
FDP 
MC PP DP C 
TS 
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Points Features of Adhesions 
 
0 
1 
2 
3 
Quantity  
No apparent adhesions 
A number of scattered filaments 
A large number of filaments 
Countless filaments 
 
0 
1 
2 
3 
Quality 
No apparent adhesions 
Regular, elongated, fine, filamentous 
Irregular, mixed, shortened, filamentous 
Dense, not filamentous 
 
0 
2 
3,4 
5,6 
Grading of adhesions 
No adhesions 
Slight adhesions 
Moderate adhesions 
Severe adhesions 
 
Table 2.3 Showing the grading criteria of adhesions in histological evaluation (Tang, 
et al., 1996).  
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2.4.4 Data Analysis 
For all in vitro and in vivo data statistical analysis was performed using the Student t-
test or unpaired Rank Sum Mann-Whitney Test where appropriate.   
 
For the QRT-PCR the relative expression software tool (REST-MCS
©
) was used as 
described previously (Pfaffl et al., 2002). 
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THE IN VITRO FLEXOR TENDON CELL 
RESPONSE TO TGF-β1 
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3.1 Introduction  
Flexor tendon injuries of the hand are common and despite accurate surgical repair 
and rehabilitation, tendon surgery remains a clinical challenge. The main 
complications involve rupture at the repair site or adhesion formation. Studies 
attempting to modify adhesion formation using either chemicals or physical barriers 
have as yet proved unsuccessful (as discussed in Chapter 1). To develop a more 
targeted treatment, a better understanding of the molecular basis of tendon repair and 
adhesion formation is required.   
 
Transforming growth factor-β1 (TGF-β1) is part of a family of multipotent growth 
factors that are consistently associated with fibrosis and scarring in a number of 
tissues including tendon (Coker and Laurent, 1998; Okuda et al., 1990; Bissell et al., 
2001; Chang et al., 1997; Klein et al., 2002). TGF-β1 is also known to affect a 
number of cellular processes: proliferation, differentiation, extracellular matrix 
(ECM) deposition, immunosuppression and apoptosis in a number of cell types. There 
are three mammalian isoforms of TGF-β1, β2 and β3 sharing 60-80% homology. 
TGFβ-1 is known to play an important role in both wound healing and scarring 
(reviewed in Klass et al., 2009). One group has studied the impact of neutralizing 
TGF-β1 via antibodies in a murine surgical model of abdominal adhesions which 
showed little effect (Gorvy et al., 2005) however, recent studies have shown the 
importance of TGF-β1 in flexor tendon healing and adhesion formation (Chang et al., 
1997; Chang et al., 2000; Klein et al., 2002). 
 
Collagens are known to be essential ECM components of tendons, and their formation 
and configuration are important factors determining tendon structure, function and 
repair. Although there are numerous collagen types, collagen type I and type III 
appear to play the most significant role in tendon healing. In general, collagen type III 
levels increase in the early inflammatory and proliferative stages of tendon healing 
whereas collagen type I production is increased in the later remodelling stages of 
tendon healing replacing collagen type III.  
 
TGF-β1 is known to be able to regulate extracellular matrix turnover and has been 
shown to increase the deposition of fibronectin in fibroblasts (Balza et al., 1988). 
Fibronectin has been shown to be deposited during the granulation phase of tendon 
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healing. While others have proposed that this preliminary fibronectin matrix allows 
tendon cells to move into the wound site, remodel the ECM, and form an adhesion-
bridge between the tendon and tendon sheath (Williams et al., 1984).  
 
Plasminogen activator-1 (PAI-1) is a known early TGF-β response gene (Kurtz et al., 
2001) and may play a role in the formation of peritoneal adhesions (Cheong et al., 
2001). Other studies (Di Filippo et al., 2006; Ivarsson et al., 1998) have shown that 
post-surgical peritoneal adhesions show an alteration of local fibrinolytic components, 
with the formation of adhesions being the results of a balance between fibrinogenesis 
(excess PAI-1) and fibronolysis (increased levels of tissue plasminogen activator; t-
PA) (Figure 1.10).   
 
The role of TGF-β1 in gene expression in a number of genes known to be involved in 
both tendon repair and adhesion formation was studied. A comprehensive time course 
studying the stimulatory effect of TGF-β1 on quiescent cells derived from different 
regions of the tendon-sheath complex (sheath, endotenon, epitenon) using real time 
PCR was employed. The time course was selected as others have shown that in vitro 
TGF-β1 stimulated gene expression can occur in a short time span (Rolfe et al., 2007) 
which has also been seen in tendon derived cells in vitro (Fu et al., 2005). 
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3.1.1 Hypothesis 
The aim of this chapter was to test the hypothesis: 
 
TGF-β1, a multipotent growth factor involved in tendon healing and adhesion 
formation, has different effects on proliferation and gene expression on each cell type 
within the tendon-sheath complex. 
 
3.1.2 Objectives  
 
 Establishment of tendon cell lines of different origin (endotenon, epitenon, and 
tendon sheath) using tissue culture techniques. 
 Assessment of the effect of TGF-β1 on the proliferation of these different cell 
types.  
 Assessment of the transcription of specific genes known to be involved in 
either tendon healing or adhesion formation, using the QRT-PCR method, 
following TGF-β1 treatment on each cell type. 
 This study will be used as a baseline in vitro investigation to compare our 
proposed anti-adhesion treatments (Chapter 4). 
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3.2 Materials and Methods 
3.2.1 Cell Culture 
All animal care complied with the “UK Home Office Guide for the Care and the Use 
of laboratory animals” 1996. Uninjured New Zealand White rabbit digital tendon 
complexes were isolated and dissected into synovial sheath, epitenon, and endotenon. 
Fibroblasts from these different areas were established using the method described in 
Chapter 2. All experiments were performed on passage one to six cells and n=3 for 
each cell type. Experimental groups were placed in serum free media (DMEM, 2mM 
glutamine, 100U/ml penicillin and 100mg/ml streptomycin; SFM) for 24 hours before 
stimulation with recombinant TGF-β1 (R&D Systems, Abingdon, Oxon), and 
viability was verified using trypan blue (Sigma Dorset, UK, data not shown). The 
concentration of TGF-β1 used throughout the experiments was 2ng/mL following 
optimisation. 
  
3.2.2 Proliferation (Toxicology) Assay 
Cells were trypsinised, normal growth media (NGM) added, then centrifuged, counted 
and plated (as described in Chapter 2, section 2.3.1). One plate was removed at time 
zero (no treatment added) and other plates had their media aspirated and replaced with 
minimal media with various concentrations of treatment (TGF- β1) to be studied over 
a time course of 24, 48 and 72 hours. TGF-β1 treatment was diluted as per 
manufactures instructions at a stock concentration of 2ng/μl. Concentrations of 
4ng/ml, 2ng/ml, 1ng/ml, 0.5ng/ml and 0.25ng/ml were diluted in minimal media 
(DMEM with 0.4% FCS). WST-1 (Roche) reagent was added to each well and 
absorbance read on a plate reader (as described in Chapter 2, section 2.3.1).  
 
3.2.3 RNA Isolation and Real-Time Polymerase Chain Reaction (QRT-PCR)   
A comprehensive time course was used to study early changes in gene expression that 
were more likely to be a direct response to TGF-β1. The time zero (untreated) acted as 
the control for all samples.           
 
Quiescent rabbit tendon cells (endotenon, epitenon and sheath) were treated with or 
without TGF-β1 (2ng/ml) for 0-48 hours in SFM. RNA extraction and real-time 
polymerase chain reaction was performed (as described in Chapter 2, section 2.3.4) 
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3.2.4 Data Analysis 
For the proliferation assay data was compared using the Student T-test where 
appropriate. SigmaStat 3.5 (Systat Software, Inc.) software was used to confirm 
statistically significant findings.  
  
The relative expression software tool (REST
©
) (Pfaffl et al., 2002) was used for the 
calculation of the relative expression levels in real time PCR. This mathematical 
model is described in full detail in Chapter 2, section 2.3.4. Sigma Plot was used to 
illustrate the logarithmic graphs.  
 
3.3 Results 
3.3.1 Proliferation Assay 
Endotenon cells also showed no significant increase in proliferation at 24, 48 or 72 
hours with TGFB-1 for any concentration when compared to cells grown in minimal 
media (Figure 3.1). 
 
Epitenon cells in TGF- β1 showed no significant change compared to cells in minimal 
media at 24 or 48 hours (Figure 3.2). However, at 72 hours epitenon cells in 2ng/ml of 
TGF-β1 showed a statistically significant increase (p= 0.003) compared to cells grown 
in minimal media.  
 
Tendon sheath cells showed no statistical increase in response to any concentration of 
TGF-1 at 24 or 48 hours (Figure 3.3). However, at 72 hours there was a statistically 
significant increase (p=0.001) identified at 0.5ng/ml of TGF-1 compared to cells 
grown solely in serum free media.  
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Figure 3.1 Graph represents the average (n=3) optical density (OD as measured using 
absorbance on a Bio-Rad plate reader) and SD for endotenon cells at 24, 48, and 72 
hours after treatment with various concentrations of TGF-β1. 
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Figure 3.2 Graph represents the average (n=3) optical density (OD as measured using 
absorbance on a Bio-Rad plate reader) and SD for epitenon cells at 24, 48, and 72 
hours after treatment with various concentrations of TGF-β1. Statistically significant 
difference: *p= 0.003. 
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Figure 3.3 Graph represents the average (n=3) optical density (OD as measured using 
absorbance on a Bio-Rad plate reader) and SD for tendon sheath cells at 24, 48, and 
72 hours after treatment with various concentrations of TGF-β. Statistically 
significant difference: *p= 0.001. 
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3.3.2 Quantitative Real-Time Polymerase Chain Reaction (QRT-PCR) 
The expression of five different genes: collagen type I, collagen type III, fibronectin, 
plasminogen activator inhibitor I (PAI-1), and tissue plasminogen activator (t-PA), 
were examined.   
 
All genes examined were expressed at detectable levels in the three cell types in the 
absence of stimulation with TGF-β1.  
 
Time Zero  
Time zero (or equivalent of cell types before treatment with TGF-β1) shows a 
statistically significant difference between epitenon and sheath cells with collagen 
type I gene expression (p=0.007). There was also a statistically significant difference 
between endotenon and epitenon cells with collagen type I (p=0.032) and collagen 
type III (p=0.009) (Figure 3.4).     
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Figure 3.4 Showing time zero gene expression for TGF-β1 treated endotenon, 
epitenon and sheath derived cells (all were corrected for the housekeeping gene 
GAPDH). Statistically significant differences are shown as follows: *p= 0.007; †p= 
0.032; **p=0.009. Error bars=SD, n=3. 
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Endotenon Cells 
Endotenon cells showed no statistical change in collagen type I gene transcription 
over the 48-hour time course (Figure 3.5). Whereas collagen type III gene 
transcription showed a statistically significant down regulation in the early stages of 
the time course 2, 6 and 8 hours (p=0.03), however, at the later time points collagen 
type III showed an up regulation which did not reach statistical significance (Figure 
3.5).  
 
Fibronectin gene transcription (Figure 3.5) showed at 6 hours a statistically significant 
down regulation (p=0.024), which was later, reversed with a statistically significant 
up regulation at 24 and 48 hours (p<0.05). PAI-1 (Figure 3.6) showed an up 
regulation of gene transcription at 2 and 4 hours but this was only statistically 
significant at 2 hours (p=0.001). However, t-PA (Figure 3.6) showed a statistically 
significant down-regulation in gene transcription at 1, 2, 6, 8 and 24 hours (p=0.01) 
and 16 hours (p=0.002). 
 
Epitenon Cells  
Epitenon cells stimulated with TGF-β1 showed a statistically significant down-
regulation of collagen type III at various points throughout the specified time course:  
1, 2, 6, 16 and 48 hours (p<0.05) (Figure 3.7). In contrast, there was a statistically 
significant up-regulation of collagen type I at later time points: 24 (p=0.025) and 48 
hours (p=0.04) when compared to untreated controls, despite the relatively high 
sample variation. Fibronectin showed a statistically significantly up-regulation at 24 
hours (p=0.03). Also, there was a statistically significant up-regulation of PAI-1 at 4 
hours (p=0.026) however there was not a significant change in the expression of t-PA 
at any of the time points examined (Figure 3.8).  
 
Tendon Sheath Cells  
Tendon sheath cells treated with TGF-β1 demonstrate a statistically significant up-
regulation of collagen type III gene expression at various time points: 6, 8, 16, and 24 
hours (p<0.05) when compared to untreated controls (Figure 3.9). This is in contrast 
to the endotenon and epitenon cell types that both showed a significant down-
regulation of collagen type III as mentioned above. Unexpectedly, collagen type I and 
fibronectin gene expression levels were relatively unchanged at all time points. 
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However, collagen type I expression in sheath cells showed high sample variation, 
especially at early time points and this may account for the lack of significance. There 
was a significant down-regulation of t-PA at early and late time points: 2 hours 
(p=0.013), 4 hours (p=0.001) and 24 hours (p=0.001), respectively, when compared to 
untreated controls (Figure 3.10). This finding was similar to the down-regulation of t-
PA seen in the endotenon cells (Figure 3.6). In comparison, there was an apparent 
increase in PAI-1 levels in sheath cells but these changes were not statistically 
significant.  
 
A summary of the statistically significant findings is shown in Figure 3.11.    
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Figure 3.5 The absolute gene regulation of endotenon cells (n=3) from basal levels 
induced by transforming growth factor beta 1 (TGF-β1) is plotted over time 
(normalised with two house-keeping genes) for collagen type I, collagen type III, and 
fibronectin. The table demonstrates the coefficient of variation, CV (%), between each 
gene. * = Statistical Significance. 
Time Coll 
I 
Coll 
III 
Fn 
48 5.77 3.77 12.85 
24 6.81 1.03 4.57 
16 3.17 0.89 0.29 
8 4.35 1.96 0.27 
6 11.07 3.53 0 
4 8.87 1.52 1.38 
2 6.27 1.07 0.34 
1 3.57 0 0.7 
* 
* 
* 
* 
* 
* 
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Figure 3.6 The absolute gene regulation of endotenon cells (n=3) from basal levels 
induced by transforming growth factor beta 1 (TGF-β1) is plotted over time 
(normalized with two house-keeping genes) for plasminogen activator inhibitor 1 
(PAI-1) and tissue plasminogen activator (t-PA). The table demonstrates the 
coefficient of variation, CV (%), between each gene. * = Statistical Significance. 
 
 
Time PAI-1 t-PA 
48 1.2 1.28 
24 0.88 0.67 
16 0.34 0.67 
8 0.04 0.57 
6 2.76 3.73 
4 0.61 4.66 
2 0.53 3.26 
1 0.8 3.6 
* 
* 
* 
* 
* 
* 
* 
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Figure 3.7 The absolute gene regulation of epitenon cells (n=3) from basal levels 
induced by transforming growth factor beta 1 (TGF-β1) is plotted over time 
(normalised with two house-keeping genes) for collagen type I, collagen type III, and 
fibronectin. The table demonstrates the coefficient of variation, CV (%), between each 
gene. * = Statistical Significance. 
Time Coll 
I 
Coll 
III 
Fn 
48 12.41 2.98 15.17 
24 16.9 2.4 1.99 
16 2.19 2.8 3.62 
8 14.12 0.63 6.18 
6 8.46 4.04 11.52 
4 22.31 1.88 4.7 
2 2.91 0.82 2.29 
1 11.61 2.41 8.27 
* 
* 
* 
* 
* 
* 
* 
* 
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Figure 3.8 The absolute gene regulation of tendon epitenon cells (n=3) from basal 
levels induced by transforming growth factor beta 1 (TGF-β1) is plotted over time 
(normalised with two house-keeping genes) for plasminogen activator inhibitor 1 
(PAI-1) and tissue plasminogen activator (t-PA). The table demonstrates the 
coefficient of variation, CV (%), between each gene. * = Statistical Significance.  
Time PAI-1 t-PA 
48 1.28 1.2 
24 3.96 0.17 
16 4.32 3.94 
8 6.83 4.0 
6 9.38 0.45 
4 7.82 2.08 
2 4.9 1.81 
1 5.99 2.22 
* 
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Figure 3.9 The absolute gene regulation of tendon sheath cells (n=3) from basal 
levels induced by transforming growth factor beta 1 (TGF-β1) is plotted over time 
(normalised with two house-keeping genes) for collagen type I, collagen type III, and 
fibronectin. The table demonstrates the coefficient of variation, CV (%), between each 
gene. * = Statistical Significance. 
Time Coll 
I 
Coll 
III 
Fn 
48 15.56 0.99 0.91 
24 13.55 9.15 16.19 
16 25.95 0.13 20.94 
8 20.92 1.08 10.9 
6 24.14 1.02 2.8 
4 14.86 0.43 11.38 
2 31.66 0.43 19.7 
1 32.21 3.15 23.09 
* 
* 
* 
* 
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Figure 3.10 The absolute gene regulation of tendon sheath cells (n=3) from basal 
levels induced by transforming growth factor beta 1 (TGF-β1) is plotted over time 
(normalised with two house-keeping genes) for plasminogen activator inhibitor 1 
(PAI-1) and tissue plasminogen activator (t-PA). The table demonstrates the 
coefficient of variation, CV (%), between each gene. * = Statistical Significance. 
Time PAI-1 t-PA 
48 0.65 2.48 
24 12.41 2.91 
16 12.89 2.86 
8 12.14 0.86 
6 2.45 1.39 
4 7.93 2.48 
2 13.7 1.15 
1 13.94 1.98 
* 
* 
* 
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 (i) Endotenon 
 1h 2h 4h 6h 8h 16h 24h 48h 
Collagen I         
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PAI-1         
t-PA         
 
 
(ii) Epitenon 
 1h 2h 4h 6h 8h 16h 24h 48h 
Collagen I         
Collagen III         
Fibronectin         
PAI-1         
t-PA         
 
 
(iii) Tendon Sheath 
 1h 2h 4h 6h 8h 16h 24h 48h 
Collagen I         
Collagen III         
Fibronectin         
PAI-1         
t-PA         
 
 
Figure 3.11 Summary of results showing tendon cell gene expression induced by 
transforming growth factor beta 1 (TGF-β1) for collagen type 1, collagen type III, 
fibronectin, plaminogen activator inhibitor 1 (PAI-1) and tissue plasminogen activator 
(t-PA) in (i) endotenon cells; (ii) epitenon cells and; (iii) tendon sheath cells. Grey = 
no significant change; white = statistically significant gene up-regulation (p<0.05) and 
; black = statistically significant down-regulation (p<0.05). 
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3.4 Discussion 
TGF-β1 has been implicated in both tendon healing (Chang et al., 1997; Klein et al., 
2002; Tsubone et al., 2006) and tendon adhesion formation (Chang et al, 2000). 
Chang in his early study (1997) demonstrated that TGF-β1 mRNA was produced by 
normal unwounded tenocytes and tendon sheath cells and that it was transcribed in the 
tendon wound environment. This same group also demonstrated that the TGF-β 
receptors were up-regulated after injury and repair and there was a strong correlation 
between the expression of the receptors and ligands (Ngo et al., 2001) indicating that 
tenocytes may be responsive to TGF-β signalling. Further, during tendon healing 
other groups have shown an increase in TGF-β1 m-RNA (Berglund et al., 2006) 
suggesting that TGF-β1 may play a role in this process (Hsu et al., 2004). Although 
neutralising antibodies to TGF-β1 have been shown to prevent tendon adhesions 
(Chang et al., 2000), others have shown that TGF-β1 neutralisation can decrease 
tensile strength and enhance the deterioration of collagen fascicles in a tissue-cultured 
tendon matrix (Azuma et al., 2007). Berglund et al., (2006) noted that after injury 
there were a number of differences in gene expression both in the spatial and temporal 
response of the tendon. Therefore it is important to understand the effect that TGF-β1 
plays on the different regions of the uninjured tendon which may allow a greater 
understanding of the biology of both tendon healing and adhesion formation. 
Understanding the role that TGF-β1 has on the different regions of the tendon-sheath 
complex should help the development of strategies to reduce adhesion formation in 
association with optimal tendon healing. 
 
Three distinct membrane receptors have been identified (TGFβRI, TGFβRII and 
TGFβRIII) which bind the TGF-β isoforms with varying degrees of specificity. 
Tendon injury and repair have been shown to cause the up-regulation of all three 
receptors with the highest expression being seen in the sheath and epitenon derived 
cells (Ngo et al., 2001). TGF-β1 is known to stimulate a wide variety of genes that 
can be categorized into basic cell functions e.g. metabolism, protein synthesis, gene 
transcription, genes of unknown function along with genes associated with matrix 
formation and remodelling (Chambers et al., 2003; Verrechia et al., 2001). In this 
study a number of genes known to be involved in tendon healing and adhesion 
formation were examined but focus on specific TGF-β1 receptor levels could not be 
explored due to time constraints.  
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In this study the proliferation results demonstrate that when sheath cells were treated 
with TGF-β1 there was a statistically significant increase at 0.5ng/ml at 72 hours but 
not at 24 or 48 hours.  Epitenon cells showed a similar significant response with FCS 
compared to SFM. Also, although there was not an early increase (24 and 48 hours) in 
proliferation with TGF-β1 compared to cells grown in minimal media there was a 
statistically significant increase at 72 hours when using a higher dose (2ng/ml). 
Endotenon cells showed no significant increase in proliferation with TGF-β1 when 
compared to SFM and this is likely to be due to the general slow proliferation and 
non-reactivity of this cell type demonstrated throughout this thesis. It appears that 
epitenon and sheath cells are behaving differently to endotenon cells in such a way 
that reflects modern tendon healing concepts (Berglund et al., 2006). 
 
It has been established in fibroblasts derived from other tissues that collagen gene 
expression is increased in response to TGF-β1 (Rolfe et al., 2007; Varga et al., 1987; 
Tiggleman et al., 1995; Chai et al., 2003). Collagen is known to be important in 
maintaining the mechanical properties of the tendon and transmitting the forces 
generated by muscle fibres to the skeletal system (Benjamin et al., 2002; Purslow, 
2002). However, collagen type III is composed of small fibrils deficient in cross-
linking resulting in less tensile strength when compared to collagen type I.  Collagen 
type I is the main constituent in uninjured tendons. While collagen type III is rapidly 
deposited after injury its presence appears only temporary as during the remodelling 
phase of tendon healing collagen type III is replaced with collagen type I (Jaibaji, 
2000). Similarly to our study, but in an injured in vivo model, Gelberman et al found 
that the epitenon cells showed an increase in collagen type I, whereas the endotenon 
cells showed no detectable expression during the early healing phases (Gelberman et 
al., 1992). Klein using cells derived from an uninjured tendon demonstrated that all 
three isoforms of TGF-β caused an up regulation of protein expression for both 
collagen type I and III (Klein et al., 2002). It has been suggested that the surface 
tendon fibroblasts are more active in both proliferation and in the production of 
collagen type I in tendon repair restoring the gliding surface and tensile strength of the 
tendon (Gelberman et al., 1992). Others have also suggested that endotenon cells play 
a minimal role in tendon repair, which certainly appears the case in this current study 
when studying production of collagen type I gene expression (Russell and Manske, 
1990).  
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Interestingly stimulation of epitenon cells with TGF-β1 showed no increase in 
collagen type III expression over the whole time course though both sheath and 
endotenon derived cells showed some statistically significant increase during the time 
course. Similarly Berglund et al., (2006) also showed an increase in collagen type III 
in both tendon and tendon derived sheath cells in an in vivo model, over a longer 
period of time and in a post injury model, however their tendon cells were not 
classified as either epitenon or endotenon derived (Berglund et al., 2006). Further 
Klein et al., (2002) also demonstrated an increase in collagen type III production, 
following TGF-β1 treatment, in all three cell types at day 4 post treatment (Klein et 
al., 2002). In this study the time points were associated with uninjured cells under 
culture conditions rather than days post injury. There were limitations in this study as 
after 48 hours in SFM the cell number and viability is reduced, therefore meaningful 
results are not achievable beyond this point.   
 
TGF-β1 is known to be able to alter the production of fibronectin (Saika et al., 1998), 
further it is also known that fibronectin can alter tendon gene expression in response 
to TGF-β1 (Fu et al., 2005). Fibronectin is known to be deposited at an early stage of 
tendon healing (granulation phase) and is thought to play a role in the formation of an 
adhesion bridge (Kurtz et al., 2001) Fibronectin is also known to bind and activate 
TGF-β therefore enhancing the effect of TGF-β (Fava and McClure, 1987). This 
present study showed that all tendon-derived cells showed at some time point a 
statistically significant increase in fibronectin gene expression compared to the 
untreated controls. Wojciak and Crossan concluded that the presence of inflammatory 
cells during tendon healing induces synovial fibroblasts and epitenon cells to increase 
their production of fibronectin, which provides a scaffold for subsequent adhesion 
formation (Wojciak and Crossan, 1993). Inflammatory cells are known to secrete 
TGF-β1 and cause the deposition of the extra cellular matrix (Kehrl et al., 1986). 
Fibronectin is believed to play a role in adhesion formation possibly through its role 
in cross-linking of fibrin, and through its role in fibroblast chemotaxis and adherence 
of cells to the substratum during tendon healing (Gelberman et al., 1991).  
 
TGF-β1 is known to cause the increase in plasminogen activator inhibitor 1 (PAI-1) 
gene transcription in a number of cell types (Rolfe et al., 2007; Zhao et al., 2006). An 
increase in PAI-1, and therefore an increase in the inhibition of fibrinolysis has been 
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shown to be associated with post-surgical peritoneal adhesion formation (Di Filippo et 
al., 2006) while increased tissue plasminogen activator (t-PA) has been associated 
with a decrease in adhesion formation in the peritoneum and pelvis (Orita et al., 1991; 
Doody et al., 1989). PAI-1 gene expression was found to be statistically significantly 
increased compared to untreated controls in endotenon cells in the early part of the 
time course, whereas sheath derived cells showed a statistically significant increase at 
48 hours. Others, studying mesothelial cells have also shown an increase in PAI-1 
gene transcription in response to TGF-β1 and a reduction in t-PA (Falk et al., 2001).  
Interestingly, all tendon-derived cells showed a reduction in t-PA gene expression 
over the time course with endotenon and sheath derived cells showing a statistically 
significant down regulation.  The increase in PAI-1 in sheath-derived cells in 
conjunction with a decrease in t-PA, following treatment with TGF-β1, could 
potentially lead to adhesion formation. Excess fibrin and the cross-linking with 
fibronectin around the wound site could form a framework for adhesion formation 
between the tendon surface and its surrounding sheath. Low expression of t-PA would 
lead to a reduction of plasmin, a persistence of fibrin and therefore increase the 
potential for adhesion formation around the tendon (Figure 1.10). Furthermore, 
increased levels of PAI-1 would inhibit the effect of t-PA and exacerbate this effect. 
This mechanism could be one explanation for the excess scarring and adhesion 
formation associated with TGF-β1.  
 
Traditional models of flexor tendon healing have been described as simply intrinsic or  
extrinsic, however to study tendon healing more precisely it is important to observe 
the behaviour of cells from the three main areas of the tendon-sheath complex i.e. the 
endotenon, the epitenon and the sheath. During tendon healing each cell type plays a 
different role but it is the epitenon-sheath interface where adhesion formation occurs. 
We acknowledge there are differences with cells grown in culture to those in vivo. 
However, in vitro studies allow a tightly controlled environment whereby various 
experimental conditions can be measured which is not possible in an in vivo model. 
This study allowed the study of the role that TGF-β1 alone plays in gene expression 
on the cells derived from different areas of the tendon. Though tendon cells in vitro 
are believed to have undergone differentiation due to culture conditions it is also 
believed that during tendon healing the cells also undergo some forms of 
differentiation (Gelberman et al., 1985). 
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Having studied the effects of this important growth factor on flexor tendon cells a 
baseline investigation has been established to compare against our anti-adhesion 
treatments. Additionally, the three novel treatments may act via TGF-β1 pathways 
which may be further manipulated to achieve an optimal therapy.        
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4.1. Introduction 
There have been many different chemical (Kulick et al., 1984; Green et al., 1986; 
Hagberg, 1992; Moran et al., 2000; Chang et al., 2000) and physical barrier (Austin 
and Walker, 1979; Hanff and Hagberg, 1998; Golash et al., 2003) methods studied to 
improve tendon repair, but to date none have proven to be successful. Problems with 
previous treatments have included increased rupture rates, infection, side effects and 
increased bulkiness preventing tendon glide. The aim of this study was to look at 
specific treatments, which could potentially inhibit adhesion formation and allow 
optimal tendon healing, but without unwanted side effects. 
 
4.1.1 Epigallocatechin-3-gallate (EGCG) 
EGCG is the main active catechin extract from green tea (Camellia sinensis). Other 
less active catechins in green tea include epicatechin gallate (ECG), (+)-epicatechin 
and (-)-gallocatechin gallate (GCG). EGCG accounts for 9-13% of green tea in net 
weight. EGCG possesses strong antioxidant activities and may play a role in 
preventing cancer (Ahmad et al., 1997) and cardiovascular disease (Basu et al., 2007). 
EGCG appears to alter a number of fibrotic mechanisms: reduces the expression of 
collagenase and stromelysin mRNA via various pathways (Corps et al., 2004), inhibits 
extracellular matrix (ECM) gene expression, by interrupting TGF-β1 signalling 
through attenuating oxidative stress (Yumei et al., 2006), inhibits collagen production 
and tissue inhibitor of metalloproteinase-1 (TIMP-1) and reduces the transcription of 
matrix metalloproteinase-1 (MMP-1) (Nakumata et al., 2005). Recent studies have 
shown that EGCG suppresses collagen production and may have therapeutic potential 
for keloid scarring and liver fibrosis (Zhang et al., 2006; Abe et al., 2007). Further, 
EGCG appears to be able to prevent TGF-β1 stimulated collagen contraction through 
a number of mechanisms, including reducing myofibroblast differentiation and the 
reduction of connective tissue growth factor expression (Klass et al., 2010). EGCG 
appears to play a role in not only preventing fibrosis but also appears to enhance 
wound healing (Kapoor et al., 2004; Zhang et al., 2006; Nakamuta et al., 2005), and 
may therefore, have a potential therapeutic role in flexor tendon healing.  
 
4.1.2 Resveratrol  
Resveratrol (trans-3, 4, 5- trihydroxystilbene) is a natural polyphenolic phytoalexin 
found in some plants including grapes and their related products. Phytoalexins are 
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antibacterial and antifungal chemicals produced by plants as a defence against 
infection. Resveratrol is also a stilbenoid, a derivative of stilbene, and is produced 
with the help of the enzyme stilbene synthase.   
 
There is evidence to suggest that Resveratrol has the potential to reduce adhesions 
following tendon repair. Sogutlu et al., (2006) demonstrated a reduction in peritoneal 
adhesions following laparotomy (with abrasion of the caecum to create adhesions) 
with an intra-operative application of Resveratrol, compared to saline in an animal 
model. A more recent study showed a reduction in postoperative adhesion formation 
in a rat uterine horn model with repeated subcutaneous injections of Resveratrol 
(Utsűn et al., 2007). Other studies have shown that Resveratrol has anti-inflammatory, 
antioxidant, anti-platelet and anti-tumour effects in a number of tissue types 
(Brakenhielm et al., 2001; Sgambato et al., 2001; Surh et al., 1999). In a dermal 
wound-healing mouse model, Resveratrol treatment was associated with improved 
histological architecture and faster wound closure (Khanna et al., 2002). Resveratrol 
appears also to have a role in preventing fibrosis in a rat cirrhosis model, and its 
action is probably associated with its ability to reduce NF-kappa activation and thus 
reduce levels of TGF-β (Chavez et al., 2007). There are close associations between 
wound healing, fibrosis, excess scarring and adhesion formation. It, therefore, appears 
that Resveratrol may have a role in reducing peri-tendinous adhesions without 
affecting wound healing.  
 
4.1.3 Pumactant 
Pumactant is a mixture of two naturally occurring phospholipids: a 7:3 mixture of 
dipalmitoylphosphatidylcholine and unsaturated phosphatidylglycerol. It was 
originally developed for neonatal respiratory distress syndrome (RDS), but this 
application of use was discontinued for commercial reasons in 2000. However, there 
has never been any suggestion of toxicity or side effects of Pumactant requiring 
regulatory action. The use of Pumactant in asthma and other respiratory conditions 
has also been investigated (Babu et al., 2003). More recently, in a murine post-
surgical peritoneal adhesion model it has been shown that Pumactant powder 
produced a dose-dependent reduction in adhesion formation so long as the powder 
was completely dissolved when applied to the caecum and sidewall (unpublished 
studies at Cardiff University).   
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Pumactant has also been found to accelerate mesothelial and keratinocyte cell 
proliferation. This proliferation appeared to be unique to this specific compound, as 
other phospholipids appear to inhibit cell proliferation and cause a reduction in cell 
viability (Topley and Woodcock, 2010). A number of publications have either 
identified phospholipids in tendons and tendon sheath fluid (Mills et al., 2005) or a 
role for phospholipids in the prevention of adhesion formation in animal models 
(Moro-oka et al., 2000).  
 
The ideal treatment would promote tendon healing and reduce or modify adhesion 
formation thus allowing the tendon to glide freely within the tendon sheath and allow 
for optimal function.  
 
4.1.4 Hypothesis 
The aim of this chapter was to test the hypothesis: 
 
The three novel compounds, EGCG, Resveratrol and Pumactant are able to influence 
cell adhesion and gene expression in different cells from the tendon-sheath complex. 
These effects may lead to a reduction or modification of flexor tendon adhesion 
formation. 
 
4.1.5 Objectives 
 Establishment of tendon cell lines of different origin (endotenon, epitenon, and 
tendon sheath) using tissue culture techniques. 
 Evaluation of cell proliferation to determine optimal doses of specific 
treatments. 
 Assessment of the transcription of specific genes known to be involved in 
either tendon healing or adhesion formation, using the QRT-PCR method, 
following the three treatments on each tendon cell type. 
 Evaluation of the effect that the treatments have on in vitro cell adhesion with 
each tendon cell type. 
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4.2 Materials and Methods 
To study specific changes occurring at the cellular level initially flexor tendon cells 
were isolated and cultured in the laboratory. Uninjured New Zealand White rabbits 
were terminated via a Schedule 1 technique (as described in Chapter 2, section 2.1.1). 
The fresh uninjured forepaw tendons were dissected under a microscope and three 
different tissue types were isolated and cultured separately: endotenon (core), 
epitenon (surface), and tendon sheath cells (as described in Chapter 2, section 2.2.1). 
Established cell lines were then incorporated into the following assays:       
 
4.2.1 Toxicology Assay  
A toxicology assay was performed to determine the optimal dose for each treatment. 
WST-1 was used over a time course of 10 days (as described in Chapter 2, section 
2.3.1).  
 
4.2.2 Cell Adhesion Assay 
A cell adhesion assay was performed to determine the adherence of each different cell 
type to various ECM components in response to the three treatments under 
investigation (as described in Chapter 2 section 2.3.3).   
 
4.2.3 Quantitative Real-Time Polymerase Chain Reaction (QRT-PCR) 
Quantitative real-time PCR was used to determine the effects of each treatment on 
gene expression. Genes chosen are thought to be involved in tendon healing and/or 
adhesion formation. The regulation of specific genes in vitro will indicate the possible 
actions in vivo and predict the cell type responsible. QRT-PCR was performed using 
the Stratagene real-time PCR machine (as described in Chapter 2, section 2.3.4).  
 
4.3 Results 
4.3.1 Toxicology Assay  
EGCG  
Endotenon cells treated with various concentrations of EGCG (12.5μM, 25μM, 50μM, 
100μM, 500μM and 1000μM) a reduction in proliferation was shown after 25μM 
although these changes were not statistically significant (Figure 4.1). Epitenon cells 
treated with various concentrations of EGCG showed a statistically significant 
increase in proliferation by day 7 (12.5μM, p=0.01 and 25μM, p=0.01) and day 10 
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(12.5μM, p=0.01; 25μM, p=0.03 and 50μm, p=0.018). However, at higher 
concentrations (500μM, p=0.006 and 1000μM, p=0.044) there was a statistically 
significant increased toxic effect on this cell type by day 3 (Figure 4.2). Lastly, tendon 
sheath cells showed a statistically significant reduction in proliferation by day 3 at 
mainly high concentrations (25μM, p=0.034; 100μM, p=0.04 and 500μM, p=0.005) 
and at day 7 with 50μM of EGCG (p=0.039) (Figure 4.3).  
 
Resveratrol  
Endotenon cells treated with Resveratrol at various concentrations (12.5μM, 25μM, 
50μM, 100μM, 500μM and 1000μM) showed a marked reduction in proliferation after 
treatment with a dose greater than 25μM. These findings were not statistically 
significant. Also, there appears to be an increase in proliferation at very high 
concentrations of Resveratrol (1000μM) but again this was not found to be significant 
(Figure 4.4). Epitenon cells show a statistically significant reduction in proliferation at 
day 3 (12.5μM, p=0.003 and 50μM, p=0.045), day 7 (12.5μM, p= 0.02 and 50μM, 
p=0.002) and day 10 (50μM, p=0.001). Unexpectedly, there was a statistically 
significant increase in proliferation at day 10 with 1000μM of Resveratrol (p=0.002) 
(Figure 4.5). Tendon sheath cells showed a wide variability in response to treatment 
with Resveratrol (as shown by the large standard deviation error bars); however, there 
was a statistically significant reduction in proliferation at day 10 with a dose of 25μM 
(Figure 4.6). 
 
Pumactant 
Endotenon cells treated with various concentrations of Pumactant (1mg/ml, 2mg/ml, 
4mg/ml, 8mg/ml and 10mg/ml) showed a statistically significant increase in 
proliferation on day 3 with 10mg/ml (p=0.03). There does not appear to be a 
significant toxic effect at any concentrations with this cell type (Figure 4.7). Epitenon 
cells treated with Pumactant also showed a statistically significant increase in 
proliferation at day 3 (1mg/ml, p=0.04 and 8mg/ml, p=0.01) and day 10 (1mg/ml, 
p=0.045) (Figure 4.8). Tendon sheath cells treated with Pumactant showed a 
statistically significant reduction in proliferation at day 7 with 2mg/ml (p=0.027) but a 
statistically significant increase in proliferation at day 10 with 10mg/ml (p=0.02) 
(Figure 4.9).  
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Figure 4.1 Toxicology of EGCG at various doses for endotenon cells at day 3, day 7 
and day 10 (n=3; Error bars=SD; N.S. =No statistical significance). 
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Figure 4.2 Toxicology of EGCG at various doses for epitenon cells at day 3, day 7 
and day 10 (n=3; Error bars=SD; *p<0.05; **p<0.05 day 3 only). 
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Figure 4.3 Toxicology of EGCG at various doses for tendon sheath cells at day 3, day 
7 and day 10 (n=3; Error bars=SD; *p<0.05). 
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Figure 4.4 Toxicology of Resveratrol at various doses for endotenon cells at day 3, 
day 7 and day 10 (n=3; Error bars=SD; N.S. =No statistical significance). 
 
Resveratrol Toxicology for Epitenon Cells
0.3
0.4
0.5
0.6
0.7
0.8
10 100 1000
Dose uM 
O
D
Day 3
Day 7
Day 10
 
 
Figure 4.5 Toxicology of Resveratrol at various doses for epitenon cells at day 3, day 
7 and day 10 (n=3; Error bars=SD; *p<0.05). 
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Figure 4.6 Toxicology of Resveratrol at various doses for tendon sheath cells at day 
3, day 7 and day 10 (n=3; Error bars=SD; *p<0.05). 
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Figure 4.7 Toxicology of Pumactant at various doses for endotenon cells at day 3, 
day 7 and day 10 (n=3; Error bars=SD; *p<0.05). 
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Figure 4.8 Toxicology of Pumactant at various doses for epitenon cells at day 3, day 
7 and day 10 (n=3; Error bars=SD; *p<0.05). 
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Figure 4.9 Toxicology of Pumactant at various doses for tendon sheath cells at day 3, 
day 7 and day 10 (n=3; Error bars=SD; *p<0.05). 
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4.3.2 Cell Adhesion Assay 
EGCG 
Interestingly treatment with EGCG (Figure 4.10) showed a statistically significant 
decrease in cells adhering to collagen type I in cells derived from the sheath (p=0.02). 
Conversely, treatment with EGCG made both endotenon and epitenon derived cells 
more adherent to collagen type III (p=0.02 and p=0.0007 respectively). Treating cells 
with EGCG showed no difference in cell adherence to fibronectin. 
 
Resveratrol     
Pre-treating the cells with Resveratrol (Figure 4.11) resulted in both epitenon and 
sheath derived cells showing less adhesion to collagen type I (p=0.003 and p=0.048 
respectively). No other cells or matrices showed any statistical significant differences. 
 
Pumactant 
Pre-treatment with Pumactant (Figure 4.12) showed no statistical significance for any 
group of cells or matrices. 
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Figure 4.10 Cell adhesion assay for EGCG (50μM), showing relative adhesion for all 
tendon cell types in the presence of different extracellular matrix components (n=4, 
Error bars=SEM, *p=0.02, **p=0.0007, †p=0.02). 
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Figure 4.11 Cell adhesion assay for Resveratrol (50μM), showing relative adhesion 
for all tendon cell types in the presence of different extracellular matrix components 
(n=4, Error bars=SEM, *p=0.003, **p=0.048). 
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Figure 4.12 Cell adhesion assay for Pumactant (1mg/ml), showing relative adhesion 
for all tendon cell types in the presence of different extracellular matrix components 
(n=4, Error bars=SEM). 
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4.3.3 Quantitative Real-Time Polymerase Chain Reaction (QRT-PCR) (For a 
summary of results see Tables 4.1-4.12) 
EGCG 
Quiescent endotenon cells were cultured in an optimal concentration of EGCG 
(50μM) and absolute gene expression was determined over a time course of 0-48   
hours (See Figures 4.13 and 4.14). EGCG caused a down-regulation of gene 
expression for all three genes studied, but the only statistical significance was seen in 
collagen type III gene expression at 4 hours (p=0.012, CV% 3.82). Although 
fibronectin and collagen type I showed a reduction in absolute gene regulation at 8 
hours these changes were not significant as the data represents high variance (CV% 
12.23 and 5.01 respectively). EGCG showed no effect on gene expression for t-PA. 
However, the PAI-1 gene was up-regulated up to 6 hours but only statistically up-
regulated at 4 hours (p=0.008, CV% 0.91). After 6 hours the gene expression for PAI-
1 was down regulated though this was not significant. Interestingly at longer time (16-
48 hours) no QRT-PCR results were identified for any of the genes studied. On 
further examination the EGCG appeared to bind to the RNA, as on extraction the 
RNA from cells treated over a long time course appeared brown in colour.   
 
Epitenon cells treated with EGCG showed a marked down-regulation of fibronectin at 
2, 4, 6, and 8 hours however these changes were not statistically significant (Figure 
4.15). However, there was a statistically significant down-regulation of t-PA at 2 
hours (p=0.023, CV% 3.91) and at 4 hours (p=0.022, CV% 2.25) (Figure 4.16). 
Although PAI-1 was also down-regulated these changes were not statistically 
significant.  
 
Tendon sheath cells treated with EGCG showed a marked down-regulation of 
collagen type III and an up-regulation of fibronectin and t-PA at most time points 
however none of these changes were statistically significant (Figure 4.17 and 4.18).  
 
Resveratrol  
Endotenon cells treated with Resveratrol showed no statistically significant changes 
for any specific genes, although there was an increase in collagen type III seen at 6, 8, 
16 and 24 hours (Figure 4.19 and 4.20).  
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Epitenon cells treated with Resveratrol (Figure 4.21) showed a statistically significant 
up-regulation of collagen type I at 4 (p=0.001, CV% 0.04) and 24 hours (p=0.001, 
CV% 0.45). Early collagen type III gene expression was down-regulated compared to 
basal levels and this was statistically significant at 1 hour (p=0.001, CV% 1.61). 
Epitenon cells stimulated with Resveratrol showed an up-regulation in collagen type 
III gene expression from 6 hours though this did not reach statistical significance. 
Resveratrol showed a down-regulation of fibronectin expression which was 
statistically significant at 6 (p=0.001, CV% 0.73) and 48 hours (p=0.001, CV% 0.06). 
Resveratrol caused no change in t-PA gene expression apart from a statistically 
significant down-regulation at 48 hours (p=0.001, CV% 0.19). Conversely, PAI-1 was 
statistically significantly down-regulated at 6 (p=0.001, CV% 0.16), 8 (p=0.001, CV% 
1.34), and 48 hours (p=0.001, CV% 0.09) (Figure 4.22).  
 
Tendon sheath cells treated with Resveratrol (Figure 4.23) showed a down-regulation 
of fibronectin at all time points and this was statistically significant at 2, 4, 6, and 24 
hours (p=0.001, CV% 2.77, 2.94, 1.72 and 4.62 respectively). There was a tendency 
for down-regulation of Collagen type I at all time points, though this was not 
statistically significant. Although collagen type III showed a statistically significant 
down-regulation at 4 hours (p=0.001, CV% 0.16), there was a statistically significant 
up-regulation at 16 (p=0.001, CV% 1.67) and 48 hours (p=0.001, CV% 0.11). A 
similar effect was seen with PAI-1 with an early down-regulation at 6 hours (p=0.001, 
CV% 0.02) followed by a statistically significant up-regulation at 48 hours (p=0.001, 
CV% 0.21) (Figure 4.24). There were no significant effects on t-PA gene regulation. 
 
Pumactant  
Endotenon cells treated with Pumactant (Figure 4.25) showed a statistically 
significant up-regulation of collagen type III at 24 (p=0.027, CV% 2.83) and 48 hours 
(p=0.025, CV% 2.17). Collagen type III was increased at all other time points but 
these changes were not significant. Conversely, collagen type I demonstrated down-
regulated at all time points but this effect was not statistically significant possibly due 
to high variability between cells (CV% range 14.76-36.99). PAI-1 also showed a 
statistically significant up-regulation (Figure 4.26) at 1 and 2 hours (p=0.001, CV% 
0.47 and 0.22 respectively). Followed by a significant down-regulation at 6, 8, and 16 
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hours (p=0.001, CV% 0.08, 0.53 and 1.26 respectively). There were no significant 
effects on fibronectin or t-PA gene regulation in endotenon derived cells. 
 
Epitenon cells showed no statistically significant changes in gene expression when 
treated with Pumactant (Figure 4.27 and 4.28). However, there was an observed 
down-regulation of collagen type I at all time points though there was also a high 
variability between cells (CV% range 8.57-15.49). There was also a marked down-
regulation of t-PA (CV% range 17.35-21.92) synchronous with an up-regulation of 
PAI-1 seen at all time points (not statistically significant).  
 
Tendon sheath cells when treated with Pumactant (Figure 4.29) showed a marked 
increase in fibronectin at all time points but this effect was not statistically significant 
(high variance; CV% range 24.61-35.27). There was a statistically significant down-
regulation of PAI-1 at 1 hour (p=0.001, CV% 0.79). As with epitenon cells, there was 
a down-regulation of t-PA at all time points but this was not statistically significant 
(Figure 4.30).  
Chapter 4 
 125 
Endotenon Cells Treated with EGCG
Absolute mRNA expression of Collagen I, III and Fibronectin
Absolute gene expression (2log)
-12 -10 -8 -6 -4 -2 0 2
T
im
e
 (
H
o
u
rs
)
1
2
4
6
8
Collagen I 
Collagen III 
Fibronectin 
 
 
 
Figure 4.13 The absolute gene regulation of endotenon cells (n=3) from basal levels 
induced by EGCG (50μM) is plotted over time (normalised with two house keeping 
genes: GAPDH and β-Actin) for collagen type I, collagen type III and fibronectin. 
The table demonstrates the coefficient of variation, CV%, between each gene. * = 
Statistical Significance (p=0.012). 
Time Col I Col 
III 
Fn 
8 12.23 0.361 5.01 
6 20.52 0.01 1.76 
4 6.94 3.82 5.89 
2 0.74 2.4 3.21 
1 1.24 2.62 4.67 
* 
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Figure 4.14 The absolute gene regulation of endotenon cells (n=3) from basal levels 
induced by EGCG (50μM) is plotted over time (normalised with two house keeping 
genes: GAPDH and β-Actin) for PAI-1 and t-PA. The table demonstrates the 
coefficient of variation, CV%, between each gene. * =Statistical Significance 
(p=0.008). 
Time PAI-1 t-PA 
8 2.29 0.36 
6 0.48 2.84 
4 0.91 0.29 
2 1.77 2.38 
1 2.32 3.16 
* 
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Figure 4.15 The absolute gene regulation of epitenon cells (n=3) from basal levels 
induced by EGCG (50μM) is plotted over time (normalised with two house keeping 
genes: GAPDH and β-Actin) for collagen type I, collagen type III and fibronectin. 
The table demonstrates the coefficient of variation, CV%, between each gene. * 
=Statistical Significance. 
 
 
 
 
 
Time Col I Col 
III 
Fn 
8 2.74 0.74 1.93 
6 0.62 0.64 5.11 
4 2.74 0.92 1.82 
2 2.27 0.03 1.6 
1 11.25 0.01 11.06 
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Figure 4.16 The absolute gene regulation of epitenon cells (n=3) from basal levels 
induced by EGCG (50μM) is plotted over time (normalised with two house keeping 
genes: GAPDH and β-Actin) for PAI-1 and t-PA. The table demonstrates the 
coefficient of variation, CV%, between each gene. * =Statistical Significance 
(p=0.023 at 2 hours, p=0.022 at 4 hours). 
Time PAI-1 t-PA 
8 1.86 3.73 
6 1.96 2.06 
4 3.26 2.25 
2 2.89 3.91 
1 7.03 3.11 
* 
* 
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Figure 4.17 The absolute gene regulation of tendon sheath cells (n=3) from basal 
levels induced by EGCG (50μM) is plotted over time (normalised with two house 
keeping genes: GAPDH and β-Actin) for collagen type I, collagen type III and 
fibronectin. The table demonstrates the coefficient of variation, CV%, between each 
gene. * =Statistical Significance. 
Time Col I Col 
III 
Fn 
16 0.63 6.47 5.31 
6 1.59 12.72 7.79 
4 2.92 4.66 6.24 
2 4.89 8.6 4.84 
1 2.93 9.71 3.65 
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Figure 4.18 The absolute gene regulation of tendon sheath cells (n=3) from basal 
levels induced by EGCG (50μM) is plotted over time (normalised with two house 
keeping genes: GAPDH and β-Actin) for PAI-1 and t-PA. The table demonstrates the 
coefficient of variation, CV%, between each gene. * =Statistical Significance. 
 
 
 
 
 
 
Time PAI-1 t-PA 
16 1.61 1.83 
6 1.7 2.22 
4 0.34 1.79 
2 3.42 1.02 
1 3.07 1.09 
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Figure 4.19 The absolute gene regulation of endotenon cells (n=3) from basal levels 
induced by Resveratrol (50μM) is plotted over time (normalised with two house 
keeping genes: GAPDH and β-Actin) for collagen type I, collagen type III and 
fibronectin. The table demonstrates the coefficient of variation, CV%, between each 
gene. * =Statistical Significance. 
Time Col 
I 
Col 
III 
Fn 
48 0.61 3.01 1.39 
24 0.87 3.57 3.49 
16 2.13 5.71 7.38 
8 0.22 3.99 2.75 
6 2.35 6.64 1.16 
4 0.22 5.69 3.77 
2 1.74 5.31 1.61 
1 1.87 6.53 4.23 
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Figure 4.20 The absolute gene regulation of endotenon cells (n=3) from basal levels 
induced by Resveratrol (50μM) is plotted over time (normalised with two house 
keeping genes: GAPDH and β-Actin) for PAI-1 and t-PA. The table demonstrates the 
coefficient of variation, CV%, between each gene. * =Statistical Significance. 
Time PAI-1 t-PA 
48 1.57 2.84 
24 1.39 2.09 
16 1.21 1.53 
8 1.03 3.61 
6 1.39 3.78 
4 0.67 2.77 
2 0.85 4.52 
1 3.48 4.61 
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Figure 4.21 The absolute gene regulation of epitenon cells (n=3) from basal levels 
induced by Resveratrol (50μM) is plotted over time (normalised with two house 
keeping genes: GAPDH and β-Actin) for collagen type I, collagen type III and 
fibronectin. The table demonstrates the coefficient of variation, CV%, between each 
gene. * =Statistical Significance (p=0.001). 
Time Col 
I 
Col 
III 
Fn 
48 0.24 2.55 0.06 
24 0.45 3.83 0.44 
16 0.82 1.13 0.92 
8 2.64 2.66 1.48 
6 0.94 5.71 0.73 
4 0.04 5.83 0.09 
2 2.34 0.81 1.98 
1 0.07 1.61 1.47 
* 
* 
* 
* 
* 
Chapter 4 
 134 
Epitenon Cells Treated with Resveratrol 
Absolute mRNA expression for PAI-1 and t-PA
Absolute gene expresion (2log)
-4 -3 -2 -1 0 1 2
T
im
e
 (
H
o
u
rs
)
1
2
4
6
8
16
24
48
PAI-1 
t-PA 
 
 
 
Figure 4.22 The absolute gene regulation of epitenon cells (n=3) from basal levels 
induced by Resveratrol (50μM) is plotted over time (normalised with two house 
keeping genes: GAPDH and β-Actin) for PAI-1 and t-PA. The table demonstrates the 
coefficient of variation, CV%, between each gene. * =Statistical Significance 
(p=0.001). 
Time PAI-1 t-PA 
48 0.09 0.19 
24 0.73 1.42 
16 0.25 0.65 
8 1.34 0.49 
6 0.16 0.01 
4 1.91 0.22 
2 1.18 0.81 
1 3.42 0.25 
* 
* 
* 
* 
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Figure 4.23 The absolute gene regulation of tendon sheath cells (n=3) from basal 
levels induced by Resveratrol (50μM) is plotted over time (normalised with two house 
keeping genes: GAPDH and β-Actin) for collagen type I, collagen type III and 
fibronectin. The table demonstrates the coefficient of variation, CV%, between each 
gene. * = Statistical Significance (p=0.001). 
Time Col 
I 
Col 
III 
Fn 
48 0.11 0.21 1.79 
24 0.21 0.11 4.62 
16 1.67 4.39 0.74 
8 0.03 4.09 3.29 
6 0.51 0.38 1.72 
4 0.16 0.11 2.94 
2 0.19 0.12 2.77 
1 0.92 1.61 2.76 
* 
* 
* 
* 
* 
* 
* 
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Figure 4.24 The absolute gene regulation of tendon sheath cells (n=3) from basal 
levels induced by Resveratrol (50μM) is plotted over time (normalised with two house 
keeping genes: GAPDH and β-Actin) for PAI-1 and t-PA. The table demonstrates the 
coefficient of variation, CV%, between each gene. * =Statistical Significance 
(p=0.001). 
Time PAI-1 t-PA 
48 0.21 1.53 
24 0.64 0.59 
16 7.79 8.57 
8 1.95 1.89 
6 0.02 0.67 
4 0.83 0.47 
2 0.18 1.56 
1 1.08 0.51 
* 
* 
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Figure 4.25 The absolute gene regulation of endotenon cells (n=3) from basal levels 
induced by Pumactant (1mg/ml) is plotted over time (normalised with two house 
keeping genes: GAPDH and β-Actin) for collagen type I, collagen type III and 
fibronectin. The table demonstrates the coefficient of variation, CV%, between each 
gene. * =Statistical Significance (p=0.027 at 24 hours, p=0.025 at 48 hours). 
Time Col I Col 
III 
Fn 
48 21.54 2.17 12.25 
24 16.92 2.83 11.97 
16 17.84 2.34 11.65 
8 15.53 11.71 12.99 
6 19.71 9.48 13.31 
4 14.76 12.74 13.69 
2 36.99 6.79 14.12 
1 25.83 7.66 18.99 
* 
* 
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Figure 4.26 The absolute gene regulation of endotenon cells (n=3) from basal levels 
induced by Pumactant (1mg/ml) is plotted over time (normalised with two house 
keeping genes: GAPDH and β-Actin) for PAI-1 and t-PA. The table demonstrates the 
coefficient of variation, CV%, between each gene. * =Statistical Significance 
(p=0.001). 
Time PAI-1 t-PA 
48 0.04 0.71 
24 7.16 0.61 
16 1.26 0.38 
8 0.53 0.89 
6 0.08 0.17 
4 0.64 0.91 
2 0.22 1.25 
1 0.47 2.05 
* 
* 
* 
* 
* 
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Figure 4.27 The absolute gene regulation of epitenon cells (n=3) from basal levels 
induced by Pumactant (1mg/ml) is plotted over time (normalised with two house 
keeping genes: GAPDH and β-Actin) for collagen type I, collagen type III and 
fibronectin. The table demonstrates the coefficient of variation, CV%, between each 
gene. * =Statistical Significance. 
Time Col I Col 
III 
Fn 
48 11.73 19.29 9.24 
24 15.31 11.49 8.89 
16 15.49 10.67 8.87 
8 13.45 0.75 8.88 
6 8.57 6.36 8.86 
4 15.17 6.63 15.35 
2 14.39 4.41 16.78 
1 15.48 17.81 18.03 
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Figure 4.28 The absolute gene regulation of epitenon cells (n=3) from basal levels 
induced by Pumactant (1mg/ml) is plotted over time (normalised with two house 
keeping genes: GAPDH and β-Actin) for PAI-1 and t-PA. The table demonstrates the 
coefficient of variation, CV%, between each gene. * =Statistical Significance. 
Time PAI-1 t-PA 
48 0.59 19.33 
24 0.08 18.85 
16 0.75 18.56 
8 0.54 21.92 
6 0.87 17.89 
4 1.03 17.76 
2 0.93 18.39 
1 1.53 17.35 
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Figure 4.29 The absolute gene regulation of tendon sheath cells (n=3) from basal 
levels induced by Pumactant (1mg/ml) is plotted over time (normalised with two 
house keeping genes: GAPDH and β-Actin) for collagen type I, collagen type III and 
fibronectin. The table demonstrates the coefficient of variation, CV%, between each 
gene. * =Statistical Significance. 
Time Col I Col 
III 
Fn 
48 13.92 4.23 23.24 
24 11.95 6.24 24.61 
16 16.55 3.81 35.27 
8 13.59 4.67 28.95 
6 10.96 2.75 27.34 
4 12.77 4.74 28.38 
2 11.78 6.19 27.74 
1 14.76 2.29 27.23 
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Figure 4.30 The absolute gene regulation of tendon sheath cells (n=3) from basal 
levels induced by Pumactant (1mg/ml) is plotted over time (normalised with two 
house keeping genes: GAPDH and β-Actin) for PAI-1 and t-PA. The table 
demonstrates the coefficient of variation, CV%, between each gene. * =Statistical 
Significance (p=0.001). 
Time PAI-1 t-PA 
48 0.02 5.86 
24 0.04 5.74 
16 0.05 3.75 
8 0.12 5.27 
6 0.09 5.88 
4 0.05 5.44 
2 0.09 9.15 
1 0.79 5.61 
* 
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 1h 2h 4h 6h 8h 16h 24h 48h 
Collagen I         
Collagen III         
Fibronectin         
PAI-1         
t-PA         
 
Table 4.1 Endotenon cells in response to TGF-1. Grey shows no statistical change in 
gene transcription. White demonstrates a statistically significant up-regulation in gene 
transcription whereas black demonstrates a statistical significant down-regulation in 
gene transcription. 
 
 1h 2h 4h 6h 8h 16h 24h 48h 
Collagen I         
Collagen III         
Fibronectin         
PAI-1         
t-PA         
 
Table 4.2 Epitenon cells in response to TGF-1. Grey shows no statistical change in 
gene transcription. White demonstrates a statistically significant up-regulation in gene 
transcription whereas black demonstrates a statistical significant down-regulation in 
gene transcription. 
 
 1h 2h 4h 6h 8h 16h 24h 48h 
Collagen I         
Collagen III         
Fibronectin         
PAI-1         
t-PA         
 
Table 4.3 Tendon Sheath cells in response to TGF-1. Grey shows no statistical 
change in gene transcription. White demonstrates a statistically significant up-
regulation in gene transcription whereas black demonstrates a statistical significant 
down-regulation in gene transcription. 
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 1h 2h 4h 6h 8h 16h 24h 48h 
Collagen I         
Collagen III         
Fibronectin         
PAI-1         
t-PA         
 
Table 4.4 Endotenon cells in response to EGCG. Grey shows no statistical change in 
gene transcription. White demonstrates a statistically significant up-regulation in gene 
transcription whereas black demonstrates a statistical significant down-regulation in 
gene transcription. 
 
 1h 2h 4h 6h 8h 16h 24h 48h 
Collagen I         
Collagen III         
Fibronectin         
PAI-1         
t-PA         
 
Table 4.5 Epitenon cells in response to EGCG. Grey shows no statistical change in 
gene transcription. White demonstrates a statistically significant up-regulation in gene 
transcription whereas black demonstrates a statistical significant down-regulation in 
gene transcription. 
 
 1h 2h 4h 6h 8h 16h 24h 48h 
Collagen I         
Collagen III         
Fibronectin         
PAI-1         
t-PA         
 
Table 4.6 Tendon sheath cells in response to EGCG. Grey shows no statistical change 
in gene transcription. White demonstrates a statistically significant up-regulation in 
gene transcription whereas black demonstrates a statistical significant down-
regulation in gene transcription. 
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 1h 2h 4h 6h 8h 16h 24h 48h 
Collagen I         
Collagen III         
Fibronectin         
PAI-1         
t-PA         
 
Table 4.7 Endotenon cells in response to Resveratrol. Grey shows no statistical 
change in gene transcription. White demonstrates a statistically significant up-
regulation in gene transcription whereas black demonstrates a statistical significant 
down-regulation in gene transcription. 
 
 1h 2h 4h 6h 8h 16h 24h 48h 
Collagen I         
Collagen III         
Fibronectin         
PAI-1         
t-PA         
 
Table 4.8 Epitenon cells in response to Resveratrol. Grey shows no statistical change 
in gene transcription. White demonstrates a statistically significant up-regulation in 
gene transcription whereas black demonstrates a statistical significant down-
regulation in gene transcription. 
 
 1h 2h 4h 6h 8h 16h 24h 48h 
Collagen I         
Collagen III         
Fibronectin         
PAI-1         
t-PA         
 
Table 4.9 Tendon sheath cells in response to Resveratrol. Grey shows no statistical 
change in gene transcription. White demonstrates a statistically significant up-
regulation in gene transcription whereas black demonstrates a statistical significant 
down-regulation in gene transcription. 
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 1h 2h 4h 6h 8h 16h 24h 48h 
Collagen I         
Collagen III         
Fibronectin         
PAI-1         
t-PA         
 
Table 4.10 Endotenon cells in response to Pumactant. Grey shows no statistical 
change in gene transcription. White demonstrates a statistically significant up-
regulation in gene transcription whereas black demonstrates a statistical significant 
down-regulation in gene transcription. 
 
 1h 2h 4h 6h 8h 16h 24h 48h 
Collagen I         
Collagen III         
Fibronectin         
PAI-1         
t-PA         
 
Table 4.11 Epitenon cells in response to Pumactant. Grey shows no statistical change 
in gene transcription. White demonstrates a statistically significant up-regulation in 
gene transcription whereas black demonstrates a statistical significant down-
regulation in gene transcription. 
 
 1h 2h 4h 6h 8h 16h 24h 48h 
Collagen I         
Collagen III         
Fibronectin         
PAI-1         
t-PA         
 
Table 4.12 Tendon Sheath cells in response to Pumactant. Grey shows no statistical 
change in gene transcription. White demonstrates a statistically significant up-
regulation in gene transcription whereas black demonstrates a statistical significant 
down-regulation in gene transcription. 
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4.4. Discussion 
The purpose of this investigation was to test our three proposed tendon anti-adhesion 
treatments in vitro to discover their potential to prevent adhesions and optimise the 
environment for tendon healing. This was assessed by first performing toxicology 
studies on cultured tendon cells derived of different origin (endotenon, epitenon and 
tendon sheath) to determine the appropriate doses to be used in later experiments. A 
cell adhesion assay was used to determine if treatment affected the cell binding 
properties of each cell type to different extracellular matrix components. 
Unfortunately, there are no ideal in vitro models of tendon healing or adhesion 
formation. However, the methods used in this study are based on similar studies 
(Berglund et al., 2006; Klein et al., 2002) investigating mRNA expression of various 
extracellular matrix components in flexor tendons following injury.  
 
4.4.1 EGCG 
EGCG is the major polyphenol and most potent antioxidant found in green tea 
(Ahmad and Mukhtar, 1999) and has been associated with a widespread biological 
activity (Cooper et al., 2005; Nagle et al., 2006). EGCG has been shown to play a role 
in treating a number of diseases (Suzuki and Isemura, 2001; Abe, 2007) including the 
reduction of fibrosis in a number of organs and improving scarring in wound healing 
(Kapoor et al., 2004; Nakamuta et al., 2005; Zhang et al., 2006; Klass et al., 2010).  
 
Epitenon cells showed a statistically significant increase in proliferation with EGCG 
at day 7 and day 10 with doses from 12.5μM-50μM. At higher concentrations there 
was an increase in toxicity. Although tendon sheath cells showed a slight reduction in 
proliferation at day 7 with a dose of 50μM, this dose was selected for further work as 
endotenon and epitenon cells showed no significant toxicity. Also, other studies have 
used a dose of 50μM to achieve non-toxic effects in stromal fibroblasts and activated 
hepatic stellate cells (Hung et al., 2005; Chen et al., 2002; Nakamuta et al., 2005).   
 
EGCG has shown that it has an ability to prevent the adhesion of a number of cell 
types particularly tumour cells to various components of the matrix (Sen et al., 2009; 
Lo et al., 2007). This has also been demonstrated in stromal fibroblasts which 
following pre-treatment with EGCG were unable to adhere to collagen type I, 
fibronectin and fibrinogen (Hung et al., 2005). This current study also showed that 
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fibroblasts derived from the tendon sheath showed a statistical significant reduction in 
adhesion to collagen type I following treatment with EGCG, though other tendon 
derived cells showed no significant difference. Hung et al, demonstrated that this was 
through EGCG interfering with α2β1 the major collagen type I receptor. EGCG 
treated endotenon and epitenon cells, however, showed no difference with adhesion to 
collagen type I, it is possible that they express more α1β1 also a collagen type I 
receptor. Others have shown in tendons derived from the patellar that fibroblasts from 
outside the tendon complex express different integrins than fibroblasts from within 
(Ikema et al., 2005). Unlike Hung et al., (2005) in this current study EGCG showed 
no effect on fibroblast adhesion to fibronectin, it remains unclear why EGCG appears 
not to alter the binding of fibroblasts derived from the tendon-sheath complex to 
fibronectin. Interestingly, both endotenon and epitenon derived cells showed a 
statistical significant increase in adhesion to collagen type III following treatment 
with EGCG. Collagen type III binds by both α1β1 and α2β1 and is known to have a 
novel binding site, which may explain the difference (Kim et al., 2005).  Interestingly, 
EGCG prevented any results being obtained from QRT-PCR over the long time 
course. Others have suggested (Kuzuhara et al., 2006) that EGCG can bind to both 
DNA and RNA in vitro. It is therefore feasible that in the current QRT-PCR the 
EGCG had bound to the RNA and therefore prevented the amplification of the genes 
being studied when the cells were cultured with EGCG over a long time course.  
 
Scar tissue, including adhesion formation, is characterized by the excessive 
production of collagen. However, collagen production is also a major component of 
tendon healing; therefore equilibrium must be maintained. EGCG down-regulated all 
the extracellular matrix genes being studied in endotenon and epitenon cells, though 
only collagen type III showed a statistically significant reduction when compared to 
quiescent untreated cells.  Sheath derived cells also showed a down-regulation of both 
collagen types, but an up-regulation of fibronectin though none reached statistical 
significance. Other experimental studies have shown that EGCG inhibits collagen 
type I production in a number of cell types (Zhang et al., 2006; Nakamuta et al., 2005; 
Hashem et al., 2008) even when the cells are exposed to a fibrotic stimuli (Klass et al., 
2010). In particular, collagen type I mRNA and protein levels were reduced in a dose-
dependent manner with in vitro EGCG treated keloid fibroblasts (via inhibition of the 
STAT3-signalling pathway) and remarkably the same group showed suppression of 
Chapter 4 
 149 
nodule development and collagen production in an in vivo keloid model (Park et al., 
2008). However, others have suggested that the collagen that is synthesised is of a 
better quality as EGCG appears to improve the maturity and organisation of the 
collagen fibres (Kapoor et al., 2004; Kim et al., 2008). Also, in human tendon 
fibroblasts, EGCG has been shown to reduce the IL-1 stimulated expression of 
collagenase mRNA (mediated by inhibition of the JNK/SAPK pathway), perhaps 
leading to higher collagen levels (Corps et al., 2004).  
 
Low levels of t-PA and high levels of PAI-1 are associated with peritoneal adhesion 
formation (Cheong et al., 2001; Ivarsson et al., 1998). PAI-1 is associated with 
adhesion formation as increased levels leads to excess fibrin deposition which in turn 
is believed to act as a scaffold for adhesion formation (Wojciak and Crossan, 1993). 
EGCG appeared to have little effect on PAI-1 gene expression with only endotenon 
derived cells showing a significant up-regulation at 4 hours. However, others have 
shown that green tea polyphenols inhibit PAI-1 expression and its release from 
endothelial cells (via PI3K/Akt pathway) (Liu et al., 2009).  
 
4.4.2 Resveratrol  
Resveratrol (trans-3, 4, 5-trihydroxystilbene) is a natural polyphenolic phytoalexin 
found in some plants including grapes and their related products. Resveratrol has been 
shown to reduce adhesions in animal models of peritoneal (Sogutlu et al., 2006) and 
pelvic (Ustűn et al., 2007) adhesion formation. A further study showed that 
Resveratrol can prevent fibrosis in a rat cirrhosis model, and that its action is probably 
associated with its ability to reduce NF-kappa activation and thus reduce levels of 
profibrinogenic TGF-β (Chavez et al., 2007). There are close associations between 
wound healing, fibrosis, excess scarring and adhesion formation. Hence, following 
these studies it was deemed worthwhile investigating the effects of Resveratrol on 
tendon healing and whether peri-tendinous adhesion formation can be reduced.  
Resveratrol is known to prevent the proliferation in a number of cell types and this 
was seen in this current study. However, unexpectedly, there was a statistically 
significant increase in proliferation at day 10 with 1000μM of Resveratrol. This could 
be due to experimental error as at high concentrations, Resveratrol was found to form 
precipitate which may not have been removed during the washing stage. Resveratrol 
has been found to prevent the adhesion of some cell types to collagen and fibrinogen 
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(Olas et al., 2002; Cao et al., 2005). In this current study Resveratrol also reduced the 
adhesion of sheath and epitenon derived tendon cells to collagen type I but there was 
no effect on adhesion to collagen type III and fibronectin in any cell type. There have 
been no studies on the effect of Resveratrol on the integrins involved in collagen 
adhesion or fibronectin, though the integrin αvβ3 has been shown to contain a binding 
site for Resveratrol (Lin et al., 2006). 
  
In a mouse dermal wound healing model, Resveratrol treatment has been associated 
with enhanced formation of epidermis, deposition of connective tissue and improved 
histological architecture (Khanna et al., 2002) which implies an organised production 
of ECM collagen. However, in cultured human liver fibroblasts, although Resveratrol 
reduced proliferation of myofibroblasts and decreased expression of alpha smooth 
muscle actin (associated with reduced scarring and fibrosis) there was inhibition of 
expression of type I collagen mRNA (Godichaud et al., 2000) and this was also seen 
in osteoblast-like cells (Rucinski et al., 2006). However, this current study showed a 
statistically significant up-regulation of collagen type I (at 4 and 24 hours) in epitenon 
derived cells and up-regulation of collagen type III in sheath derived cells (at 16 and 
48 hours).  
 
Epitenon cells treated with Resveratrol showed a statistically significant down-
regulation of fibronectin (6 and 48 hours). Similarly, tendon sheath cells treated with 
Resveratrol showed a statistically significant down-regulation of fibronectin (2, 4, 6, 
and 24 hours). Recently, Resveratrol has been shown to reduce fibronectin protein 
synthesis in glomerular epithelial cells (Lee et al., 2010). A low level of fibronectin 
has a therapeutic advantage as there would be less scaffolding for tendon adhesion 
formation (Wojciak and Crossan, 1993). 
 
Resveratrol has been shown to reduce PAI-1 gene expression in adipocytes (Ahn et 
al., 2007). This finding was mirrored in this current study with epitenon and sheath 
derived cells showing a statistically significant down-regulation, with the exception at 
the long time course in sheath cells at 48 hours. This equates to more fibrinolysis 
around the site of tendon injury at early and late time points. In theory, an increase in 
fibrinolysis leads to reduced fibrin and less adhesion formation. Also, an increase in t-
PA at 48 hours corresponds well with a down-regulation of PAI-1 at the same time 
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point and may be synergistic to a reduction in adhesion formation. This result is 
expected as physiologically t-PA and PAI-1 are opposing forces in the fibrinolytic 
pathway. In addition polyphenolics, including Resveratrol, have been shown in 
cultured human endothelial cells to increase t-PA protein and mRNA levels (RT-
PCR), concomitant with an increase in sustained (24 hours) surface localised 
fibrinolytic activity (Abou-Agag et al., 2001). This increase in local fibrinolytic 
activity, has labelled Resveratrol together with ethanol, as the responsible compounds 
for reducing cardiovascular risk associated with moderate wine consumption (Pasten 
et al., 2006). Moreover, Resveratrol has been shown to have a direct inhibitory action 
on cardiac fibroblasts (inhibition of cardiac proliferation and myofibroblast 
differentiation) and might be useful in inhibiting the progression of cardiac fibrosis 
(Olson et al., 2005). 
 
4.4.3 Pumactant  
Pumactant is a mixture of two naturally occurring phospholipids: a 7:3 mixture of 
dipalmitoylphosphatidylcholine and unsaturated phosphatidylglycerol. In a murine 
peritoneal adhesion model it has been shown that Pumactant produced a dose-
dependent reduction in adhesion formation when applied to the caecum and sidewall 
following surgery (unpublished studies at Cardiff University). A number of 
publications have either identified phospholipids in joints, tendons or tendon sheath 
fluid (Mills et al., 2005; Hills et al., 1996), or more specifically shown a role for 
phospholipids in the prevention of tendon adhesion formation using animal models 
(Moro-oka et al., 2000). Pumactant could act as a boundary lubricant in improving 
tendon glide, as a barrier preventing adhesions, and may show advantages in cell 
proliferation and tendon healing.  
 
Endotenon cells treated with various concentrations of Pumactant showed a 
statistically significant increase in proliferation on day 3 (10mg/ml). Epitenon cells 
treated with Pumactant also showed a statistically significant increase in proliferation 
at day 3 (1mg/ml and 8mg/ml) and day 10 (1mg/ml). Although, tendon sheath cells 
treated with Pumactant showed a statistically significant reduction in proliferation at 
day 7 (2mg/ml) there was a statistically significant increase in proliferation at day 10 
(10mg/ml). In accordance with this study, Pumactant has been shown to accelerate 
mesothelial and keratinocyte cell proliferation. This proliferation appeared to be 
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unique to this specific compound, as other phospholipids appear to inhibit cell 
proliferation and cause a reduction in cell viability (Kremlev et al., 1994; Topley and 
Woodcock, 2010).  
 
No matrix or cell type showed any statistical significant difference when cells were 
pre-treated with Pumactant. Phospholipids in other studies have been shown to inhibit 
gastric cancer cell adherence to collagen type IV, laminin and fibronectin (Jansen et 
al., 2004). The mechanism of action was unknown but may be due in part to the 
barrier properties of phospholipids.  This current study did not show the same effect. 
 
Endotenon cells treated with Pumactant showed a statistically significant up-
regulation of collagen type III mRNA at late time points (24 and 48 hours). Collagen 
type III is produced in the initial stages of tendon healing and later this is replaced 
with collagen type I. An increase in collagen type III gene expression in endotenon 
cells at the core of the tendon may allow for optimisation of tendon healing. There 
was also a statistically significant up-regulation of PAI-1 at early time points (1 and 2 
hours) which was followed by a significant down-regulation (6, 8, and 16 hours). 
Also, tendon sheath cells when treated with Pumactant showed a statistically 
significant down-regulation of PAI-1 at 1 hour. Overall there appears to be a 
reduction in PAI-1 between the different cell types which may be beneficial in 
preventing adhesions, as already described (Cheong et al., 2001; Ivarsson et al., 
1998). To date there has been no previous work studying the effect of Pumactant on 
gene expression in tendons or any other tissues.  
 
4.5 Conclusions 
 The optimal in vitro doses for each treatment based on this study and the 
current literature are as follows: EGCG 50μM, Resveratrol 50μM and 
Pumactant 1mg/ml.  
 
 EGCG caused increased adhesion of pre-treated endotenon and epitenon cells 
to collagen type III. Conversely, there was decreased adhesion of EGCG pre-
treated sheath cells to collagen type I.  
 
Chapter 4 
 153 
 Resveratrol caused reduced adhesion of pre-treated epitenon and tendon sheath 
cells to collagen type I.  
 
 Treatment with Resveratrol caused the most optimal changes to gene 
expression as collagen type I, collagen type III and t-PA were up-regulated, 
whereas fibronectin and PAI-1 were down-regulated. These changes were seen 
mainly in epitenon and tendon sheath cells. 
 
 Pumactant treated endotenon cells up-regulated collagen type III gene 
expression at late time points and there was an increase in PAI-1 gene 
expression early but then a later down-regulation. There was also a down-
regulation of PAI-1 in tendon sheath cells. These results indicate a moderate 
therapeutic advantage. 
 
Tendon healing and the formation of adhesions is a multi-factorial process with many 
different biological pathways involved. This study and work of others has alluded to 
some of the mechanisms involved but does not complete our understanding. 
Following our work with TGB-β1 and our three potential treatments in vitro we next 
developed an in vivo model to further assess the efficacy of each treatment.  
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5.1 Introduction 
Having studied the in vitro effects of EGCG, Resveratrol and Pumactant using 
tenocytes from different areas of the tendon-sheath complex, this study aims to assess 
the effects on flexor tendon adhesion formation using a standard in vivo model. The 
latter is essential to prove efficacy and safety prior to human trials. From Chapter 4 it 
is clear that all three treatments show potentially beneficial changes in flexor tendon 
cells. The Resveratrol-treated group showed the most optimal effects when examining 
changes in genetic expression (up-regulation of collagen type I, collagen type III and 
t-PA with a down-regulation of fibronectin and PAI-1). These effects were mainly 
found in the epitenon and tendon sheath cells i.e. the tendon-sheath interface. 
However, Pumactant had more of an influence on the endotenon cells (gene up-
regulation of collagen type III and a late down-regulation of PAI-1) and some effect 
on tendon sheath cells (down-regulation of PAI-1). Although, EGCG showed no 
significant changes in genetic expression there were positive findings in our cell 
adhesion study (i.e. a reduction of epitenon cell adhesion to fibronectin). There was 
certainly evidence to justify further investigation of all three treatments using a flexor 
tendon in vivo model. 
 
The rabbit model has been used in many previous studies and is well established 
(Abrahamsson et al., 1989; Abrahamsson et al., 1991; Chang et al., 1997; Chang et 
al., 1998; Kang and Kang, 1999; Kakar et al., 1998; Khan et al., 1996; Manske et al., 
1984; Matthews and Richards, 1976; Moro-oka et al., 2000; Rank et al., 1980). In 
particular, this model has been used at RAFT by previous researchers and techniques 
have been accordingly modified and refined (Branford et al., 2008; Jones et al., 2000; 
Jones et al., 2002).  
 
5.1.1 Hypothesis 
The aim of this chapter was to test the hypothesis: 
 
‘The three novel compounds, EGCG, Resveratrol and Pumactant are able to reduce 
or modify flexor tendon adhesion formation using an in vivo model’. 
 
5.1.2 Objectives 
 Selection and design of an appropriate flexor tendon adhesion animal model.  
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 Evaluation of each treatment using mechanical testing. 
 Evaluation of each treatment using histological scoring methods. 
 
5.2 Materials and Methods 
All animal care complied with the “UK Home Office Guide for the Care and the Use 
of Laboratory Animals” 1996. New Zealand White (NZW) Rabbits were 
anaesthetised for Surgery using general anaesthesia with recovery. A partial tenotomy 
was conducted on digits 2 and 4 of the right forepaw of 8 NZW rabbits in each 
treatment group, with injured untreated tendons acting as adhesion controls (n=8). All 
injured tendons were immobilised via a proximal tendon transection. Only one paw 
per rabbit was subjected to an operation so as to minimize suffering to the animal after 
recovery from anaesthesia. The left paw acted as the unoperated untreated control.  
 
5.2.1 Mode of Anaesthesia 
General anaesthesia was induced as previously described (Chapter 2, section 2.4.1). 
 
5.2.2 Preparation of Treatments 
EGCG 
A 0.45mg/ml (1mM) solution of EGCG was dissolved in sterile water and incubated 
for 1hour at 37ºC in a water bath to ensure adequate dispersal. The solution was then 
drawn up into a 1ml sterile syringe immediately prior to surgery in preparation for 
infiltration.  
 
Resveratrol 
A 2.28mg/ml (10mM) solution of Resveratrol was dissolved in sterile water and 
incubated for 1hour at 37ºC in a water bath to ensure adequate dispersal. The solution 
was then drawn up into a 1ml sterile syringe immediately prior to surgery in 
preparation for infiltration.  
 
Pumactant 
A 10mg/ml (unknown molecular weight) solution was dissolved in sterile water in a 
sterile 50ml container. Following brief agitation the sample was incubated for 1 hour 
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at 37ºC in a water bath to ensure adequate dispersal. The solution was then drawn up 
into a 1ml sterile syringe immediately prior to surgery in preparation for infiltration.  
 
5.2.3 Operative Procedure 
The procedure is fully described in Chapter 2, section 2.4. Following induction of 
general anaesthesia, a V-Shaped incision was made in the palmar aspect of the right 
forepaw, to access both flexor digitorum profundus (FDP) tendons and to avoid direct 
injury to the synovial sheath. With a scalpel a partial tenotomy was performed (half 
the width of the tendon and 5mm in length). To immobilise each specific tendon, a 
proximal transection was performed at the level of the carpus. The tendon sheaths 
were then infiltrated with 0.5mls of treatment solution (H2O, EGCG, Resveratrol or 
Pumactant solutions as described above) and the wounds were closed. The partial 
tenotomy controls received no treatment or water only (as diluent for all treatments). 
Two weeks later the rabbits were humanely killed by anaesthetic overdose (Schedule 
1). Tendons and associated tissues were harvested at post mortem. Harvested digits 
were then randomised to: 
 
1. Mechanical Assessment of Adhesion Strength. 
 
2. Histological Analysis.  
 
5.2.4 Mechanical Assessment of Adhesion Strength 
Forepaws were freshly assessed (as described in Chapter 2, section 2.4.2). Prior to 
testing the V-shaped wounds were re-opened and the proximal free ends of each 
treated tendon were identified. A distal transection was made over the insertion of the 
FDP into the distal phalanx. This allows the tendon to lie freely within the sheath, 
disconnected at either end such that a force applied proximally would measure solely 
the strength of any adhesion between the tendon and the sheath. The digital claw was 
held using a clamp and the proximal FDP tendon transfixed to a tensile testing 
machine (Mecmesin). The proximal tendon was then pulled from its sheath (at a rate 
of 5mm/min) until the adhesion failed. The peak force was measured in Newtons.   
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5.2.5 Histological Analysis 
The tendon-adhesion complex of each digit was fixed and paraffin embedded (as 
described in Chapter 2, section 2.4.3).  Digits were divided into halves in the sagittal 
plane, and 5 micron sections were cut from longitudinal equally spaced zones. The 
area of adhesion or zone of injury was selected and sections were concentrated 
around this.  
 
Haematoxylin and Eosin staining was performed (Appendix I). Presence of a 
characteristic dense cellular band, connecting tendon to the surrounding tissues was 
recorded as an adhesion. A semi-quantitative method using an adhesion score, as 
described by Tang et al. (1996) was used to further characterise adhesion formation. 
This scoring system combines the scores for quantity (0-3) and quality (0-3) to give 
an overall grading score (0-6) for each adhesion (Table 2.3).  
 
The average cell count for each adhesion was assessed by examination under a light 
microscope (x40 magnification) following H&E staining. Images were recorded 
(using a digital camera and saved as TIFF files) and with the use of an 100 x 100μm 
grid and image analysis software (Adobe Systems, Inc., San Jose, Calif.), the average 
cell count was calculated. This was performed by counting the number of cells in 5 
random squares and the mean used to determine cell number.  
 
For both scoring methods described above three independent observers were used 
and mean scores recorded.        
 
Tendon and adhesion specimens were stained with Masson‟s trichrome stain to 
identify collagen fibril formation (Appendix I).  
 
5.2.6 Data Analysis 
Statistical assessment of these data was performed using SigmaStat 2.0 (Jandel 
Scientific Software, San Rafael, Calif.). The Student t-test, Wilcoxon Rank Sum Test 
and the Pearson correlation coefficient where appropriate.   
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5.3 Results 
5.3.1 Mechanical Assessment of Adhesion Strength  
The raw data from the tensile testing machine (Figure 5.1) demonstrates an observable 
difference between the operated untreated (OUT) and unoperated untreated groups 
(UOUT). These two groups represent the positive and negative control groups for this 
study respectively. Tendon injury or surgical tenotomy followed by a period of 
immobilisation (as in this study) will lead to adhesion formation as identified in the 
OUT-group. A mean force of 3.78N (Figure 5.1) is a typical finding for this group. As 
expected, there were no observable adhesions in the UOUT-group. However, in this 
latter group we do occasionally find small increases in load (0.2-0.6N) as discussed 
later. 
 
The data in Figure 5.3 represents the mean mechanical force in newtons (N) required 
for the adhesion to fail in the following groups: unoperated untreated (UOUT); 
operated untreated (OUT); operated and treated with sterile water (H2O, diluent for all 
treatments), EGCG (EGCG), Resveratrol (RES) or Pumactant (PUM). There was an 
observable difference between the OUT-group (positive control) and the treatment 
groups. Clearly, the OUT-group produced the most adhesions over the two-week 
period with a mean force of 2.81N ±1.13. There was a statistically significant 
difference between the OUT- and UOUT-groups (p<0.001). Interestingly, treatment 
with H2O shows an observable reduction in the force required to rupture adhesions 
compared to the OUT group, however this difference was not shown to be statistically 
significant (p=0.07). Each treatment showed a statistically significant reduction in the 
force required for adhesion failure (EGCG 1.66N ±0.486, p=0.02; Resveratrol 1.24N 
±0.621, p=0.006; Pumactant 0.81N ±0.824, p=0.001) when compared to the OUT-
group. The diluent (sterile H2O) appears to show some biological effect in reducing 
adhesion formation as there was no statistically significant difference between the 
H2O-group and the EGCG (p=0.706) or Resveratrol groups (p=0.128). However, 
Pumactant showed a statistically significant reduction in force required compared the 
OUT-group (p=0.001) and the H2O (p=0.034). Also, all the groups showed a 
statistically significant difference compared to the UOUT-group (p<0.001) except for 
the Pumactant treated group (p=0.07). This demonstrates that the amount of adhesion 
formation in the Pumactant treated group is comparable to the negative control group 
(UOUT). 
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5.3.2 Histological Assessment  
All unoperated and untreated (UOUT) samples showed, as expected, no evidence of 
adhesion formation on macroscopic or microscopic examination (Figure 5.4). 
Masson‟s trichrome staining demonstrated a more organised collagen fibril formation 
in the unoperated compared to the operated tendon groups. It also showed new 
extracellular matrix (ECM) deposition as demonstrated by red staining (Figure 5.5). 
Operated untreated (OUT) tendons frequently showed a dense and irregular adhesion 
pattern between the tendon and tendon sheath (Figure 5.6).  
 
Adhesions and repairs were scored based on the system developed by Tang. The 
OUT-group showed a mean adhesion score of 5.13 ±0.3; H2O-group 4.2 ±0.37; 
EGCG 3 ±0.53; Resveratrol 3.13 ±0.67 and Pumactant 1.88 ±0.74 (Figure 5.7). There 
was no statistically significant difference in the adhesion scores between the OUT and 
H2O groups (p=0.08). The EGCG and Resveratrol groups also showed no statistically 
significant difference when compared with the H2O-group (EGCG p=0.14; 
Resveratrol p=0.26) but they did show a statistically significant difference when 
compared with the OUT-group (EGCG p=0.004; Resveratrol p=0.016). Pumactant 
was the only treatment that did show a statistically significant difference when 
compared with both the H2O-group (p=0.04) and the OUT-group (p=0.001). In fact in 
some tendons treated with Pumactant no adhesions could be identified (Figure 5.8).  
 
Tendon adhesion cell numbers were recorded using the counting method as 
previously (Chapter 2, section 2.4). Although there was a reduction in mean cell 
number when comparing all treatments to the OUT and H2O groups, these changes 
were not statistically significant (Figure 5.9). Tendons treated with Pumactant that 
developed adhesions showed the lowest cell number though, this was not statistically 
significant (p=0.11). Interestingly, there was a greater correlation between adhesion 
cell number and the scoring by Tang when tendons were treated with Pumactant 
(Figure 5.11, r = 0.81) compared to other treatments (Figure 5.12, r = 0.43). 
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Figure 5.1 This graph represents a typical example of the raw data from the 
mechanical tensile testing machine (Mecmesin) using the Emperor™ Software.  It 
shows the load (force in Newtons, N) as a rabbit tendon is displaced (mm) from its 
tendon sheath (at a rate of 10mm/min). The peak force measured is the point when the 
adhesion fails. This graph compares the two control groups: operated untreated and 
unoperated untreated.  
Adhesion 
Breakage at 
3.78N  
Operated 
untreated 
Unoperated untreated 
Chapter 5 
 
 
162 
 
 
 
Figure 5.2 This graph represents a typical example of the raw data from the 
mechanical tensile testing machine (Mecmesin) using the Emperor™ Software. It 
shows the load (force in Newtons, N) as a rabbit tendon is displaced (mm) from its 
tendon sheath (at a rate of 10mm/min). The peak force measured is the point when the 
adhesion fails. This graph compares the operated Pumactant treated group with the 
unoperated untreated group.  
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Figure 5.3 Graph representing the mean force in Newtons (N) for the tendon adhesion 
to fail for each group (n=8): UOUT (unoperated untreated control), OUT (operated 
untreated control), H2O (sterile H2O control), EGCG, RES (Resveratrol) and PUM 
(Pumactant). Error bars=SEM. A statistically significant difference was demonstrated 
between: OUT and EGCG (**p=0.02), RES (**p=0.006), PUM (**p=0.0012) and 
UOUT (†p=0.0005) groups. Pumactant was the only treatment to show a statistically 
significant difference when compared with its diluent, H2O (*p=0.03). There was also 
a statistically significant difference between UOUT and OUT, H2O, EGCG, RES 
groups (§p<0.001).  
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Figure 5.4 Light microscopy photograph (x40 magnification) of unoperated untreated 
(UOUT) tendon, showing bundles of collagen fibrils stained blue (Masson‟s 
Trichrome Stain).  
 
 
 
 
Figure 5.5 Light microscopy photograph (x40 magnification) of injured tendon, 
showing blue (Masson‟s Trichrome Stain) collagen fibrils but also new matrix being 
laid down in the tendon (stained red). 
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Figure 5.6 Light microscopy photograph (x40 magnification, H&E Stain) of an 
injured tendon (T) without treatment showing an obvious „adhesion‟ bridge (A) 
between the tendon and the tendon sheath (TS).  
A 
T 
TS 
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Figure 5.7 Graph representing the histological adhesion scores, according the Tang 
adhesion scoring system, comparing the mean values between the following groups 
(n=8): OUT (operated untreated control), H2O (sterile H2O control), EGCG, RES 
(Resveratrol) and PUM (Pumactant). Error bars=SEM. A statistically significant 
difference was demonstrated between: OUT and EGCG (**p=0.003), RES 
(**p=0.02), PUM (**p=0.001) groups. Pumactant was the only treatment to show a 
statistically significant difference when compared with its diluent, H2O (*p=0.04).  
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* 
Chapter 5 
 
 
167 
 
 
Figure 5.8 Light microscopy photograph (x40 magnification, H&E Stain) of an 
injured tendon (T) treated with Pumactant showing no evidence of adhesion formation 
between the tendon sheath (TS) and the site of tendon injury (TI).  
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Figure 5.9 Graph representing the mean tendon adhesion cell numbers, comparing the 
mean values between the following groups (n=8): OUT (operated untreated control), 
H2O (sterile H2O control), EGCG, RES (Resveratrol) and PUM (Pumactant). Error 
bars=SEM. There was no statistically significant difference between groups.
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Figure 5.10 Scatter plot showing linear relationship between histological adhesion 
scores (Tang) and adhesion cell number (n=5) with Pumactant treated flexor tendons 
(correlation coefficient, r = 0.81).  
 
 
ALL TENDON ADHESIONS
0
5
10
15
20
25
0 1 2 3 4 5 6 7
TANG SCORE
A
D
H
E
S
IO
N
 C
E
L
L
 C
O
U
N
T
OUT
PUM
EGCG
RES
H20
 
 
Figure 5.11 Scatter plot showing linear relationship between histological adhesion 
scores (Tang) and adhesion cell number for all flexor tendon adhesions (correlation 
coefficient, r = 0.43). 
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5.4 Discussion 
Despite the best surgical technique, optimal suture material and careful post-operative 
rehabilitation, tendon adhesions still occur. Further, it can be difficult to predict which 
patients will develop adhesions following surgery. Many different chemical 
modulators (Chang et al., 2000; Frykman et al., 1993; Green et al., 1986; Hagberg, 
1992; Jones et al, 2002; Khan et al., 2000; Komurcu et al., 1997; Kulick et al., 1984; 
Moran et al., 2000; Salti et al., 1993; Weiss et al., 1986) and physical barriers (Ashley 
et al. 1959; Ashley et al. 1964; Austin and Walker, 1979; Golash et al., 2003; Hanff 
and Hagberg, 1998; Rank et al., 1977; Strauch et al., 1985) have been used in the past 
in an attempt to reduce adhesion formation. Unfortunately, there have been various 
problems with each of these treatments including: increased rupture rates, poor 
gliding of the tendon within the sheath and unwanted systemic effects. This study has 
set out to assess three novel treatments that may prevent tendon adhesion formation 
but ideally without added complications.  
 
In vitro work at RAFT (see Chapter 4) has demonstrated that EGCG, Resveratrol and 
Pumactant show potential beneficial effects on gene expression associated with 
tendon healing and production of adhesions. It was therefore necessary to trial these 
compounds using an in vivo model of flexor tendon adhesion formation before a pilot 
clinical trial could be undertaken. A rabbit model was selected as it has been widely 
used in similar studies (Abrahamsson et al., 1989; Abrahamsson et al., 1991; Branford 
et al., 2008; Chang et al., 1997; Chang et al., 1998; Jones et al., 2000; Jones et al., 
2003; Kang and Kang, 1999; Kakar et al., 1998; Khan et al., 1996; Manske et al., 
1984; Matthews and Richards, 1976; Moro-oka et al., 2000; Rank et al., 1980), and is 
a well established model. Furthermore, adhesions can be produced reliably following 
tendon injury in a rabbit model.  
 
Some tendon adhesion studies have focused on quantifiable or histological 
assessments (Akali et al., 1999; Tang et al., 1996) but few have combined 
biomechanical and histological methods (Strick et al., 2004; Branford et al., 2008). 
The combination of mechanical tensile testing with histological scoring methods 
allows for a thorough investigation of adhesion formation by observing the physical 
properties and the histological architecture respectively. This particular study has not 
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assessed in vivo tendon healing as others have done, but suggestions for further work 
to be carried out in this area are made later.  
 
From the mechanical (tensiometer) data it is clear that Pumactant appears to have the 
most marked effect on the reduction of force required for adhesions to fail (H2O v 
PUM, p = 0.03). The other two treatments showed a reduction in adhesion formation 
compared to the OUT-group (p<0.05) but not when compared to the H2O-group. 
Interestingly, there appears to be a reduction in adhesions seen in the H2O-group 
compared to the OUT-group although this effect was not statistically significant 
(p=0.07). Sterile water appears to be having some form of biological or physical 
effect reducing the formation of adhesions. This difference may be due to the physical 
injection into the tendon sheath at the time of surgery. In the OUT-control group 
although a tenotomy is performed there is no solution infiltrated into the tendon 
sheath. There is an observable degree of tendon sheath expansion that occurs during 
infiltration and this may lead to a greater gap between the tendon and the sheath, 
therefore increasing the distance that adhesions need to form to create a bridge 
between the two structures. The injection of water may also clear away any fibrin clot 
which can act as a precursor for adhesion formation. Tendons have a high percentage 
weight of water and gliding function is optimal in a moist environment. However, 
water also exerts an osmotic effect on tissues such that they swell and may interfere 
with cellular function and possibly tendon healing.  
 
There was no statistical difference between the Pumactant group and the UOUT-
group, which suggests that the use of Pumactant on operated tendons makes them 
behave like negative controls (i.e. no tenotomy). Paradoxically, in the UOUT-group 
there were occasionally small increases in load (0.2-0.6N) as displacement increased. 
This increase in load may be explained by the vinculae that supply blood and nutrients 
to the tendon. However, as the forces involved are small their influence should not 
affect the overall outcome of this study. 
 
The histological findings support the mechanical data extremely well as the same 
pattern of adhesion reduction emerges. The Tang scoring showed again that 
Pumactant was the only treatment to reduce tendon adhesions with a statistically 
significant difference compared to the H2O group (p= 0.04). However, there was a 
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significant reduction in scores when the EGCG and Resveratrol groups were 
compared to the OUT-group (p<0.05). Although, there appeared to be a reduction of 
adhesion cell number between the Pumactant (mean = 9.4 ± 2.94) and H2O (mean = 
16.12 ± 0.78) or OUT (mean = 15.1 ± 1.54) groups this change was not significant. 
The Tang scores combined with the results from adhesion cell number confirm that 
Pumactant reduces the size and density of adhesions, but does not significantly reduce 
cellularity in any adhesion formed. However, the strong correlation between Tang 
scoring and adhesion cell number with Pumactant compared to other treatments (r = 
0.81, 0.43 respectively) suggests there is a direct relationship between these factors 
i.e. a predictable response.  
  
It has been previously established, that cells on the tendon surface are known to 
contain lipid-containing vesicles. Further, it has been estimated that lipids account for 
up to 43% of the epitenon matrix (whereas collagen accounts for only 23% of the 
matrix) (Banes et al., 1988). Pumactant is a mixture of two naturally occurring 
phospholipids: a 7:3 mixture of dipalmitoylphosphatidycholine and unsaturated 
phosphatidylglycerol.  Phospholipids have a biomembrane with two important roles 
(Ansell and Hawthorne, 1964; Briscoe et al., 2006; Higaki et al. 1998; Moro-oka et 
al., 2000): the physical role of forming a hydrophobic boundary-lubricating 
environment, and the functional role as a second messenger or agonist. It is most 
likely that Pumactant is acting as a barrier to preventing adhesion formation, but there 
may be secondary functional properties specific to this phospholipid mixture. 
Certainly, in our study (Chapter 4) Pumactant has demonstrated a significant 
biological effect with the gene up-regulation of collagen type III and late down-
regulation of PAI-1 in endotenon cells combined with the down-regulation of PAI-1 
in tendon sheath cells.  
 
Previously, Pumactant has shown a dose dependent reduction in abdominal adhesion 
formation in a murine model (unpublished studies at Cardiff University). Pumactant 
was found to accelerate mesothelial and keratinocyte cell proliferation (Topley and 
Woodcock, 2010). This proliferation appeared to be unique to this specific compound, 
as other phospholipids seem to inhibit cell proliferation and cause a reduction in cell 
viability (Kremlev et al., 1994; unpublished work performed at Cardiff University). 
Our study corroborates an increase in proliferation and is demonstrated in tendon cells 
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(all types) with various doses of Pumactant (8-10mg/ml) (Chapter 4). Phospholipids 
have been identified in joints, tendons or tendon sheath fluid (Mills et al., 2005; Hills 
et al., 1996) and have been shown to play a major role in joint lubrication (Hills et al., 
1989; 2002b). Others have shown a role in the prevention of articular cartilage 
degeneration (Kawanao et al., 2003) and a deficiency has been associated with 
osteoarthritis in humans (Hills and Monds, 1998). Moreover, phospholipids have been 
shown to prevent flexor tendon adhesion formation in a rabbit model (Moro-oka et al., 
2000). In the latter study a mixture of phospholipid and hyaluronic acid reduced 
adhesion formation compared to saline or hyaluronic acid alone but phospholipid 
alone was not tested (as previously discussed in Chapter 1, section 1.9.3). This group 
measured the friction coefficient of the gliding tendon followed by the work required 
to tear the tendon from the sheath (a similar mechanical method as used in our study). 
There is also evidence (Topley and Woodcock, 2010) to suggest that Pumactant may 
achieve some of its effects through the induction of hyaluronic acid synthase, which 
presents the possibility that phospholipids might aid lubrication and also participate, 
through hyaluronic acid production, in tendon repair and healing.  
 
A final mechanism of action is the possibility that phospholipids interact with 
collagen type I fibril formation, which may interfere with the extracellular matrix 
organisation within the adhesion complex (Martinez Del Pozo et al., 1989). This 
current study did not examine the effect of Pumactant on tendon healing, however, as 
phospholipids are present in the normal tendon sheath fluid and joints it is unlikely to 
cause any impairment. Further, this current in vivo study did not demonstrate excess 
inflammation nor was there evidence of Pumactant itself present two weeks following 
surgery.  
 
EGCG and Resveratrol showed a statistically significant reduction in force required 
for adhesions to fail and a reduction in the grade of adhesion formation by the Tang 
method but only compared to the OUT and not the H2O group. As discussed 
previously H2O appears to be having unknown physical or biological effects.  
 
The results in this current study for Resveratrol are comparable to a study using a rat 
model, which demonstrated a reduction in peritoneal adhesion formation following 
laparotomy and intra-operative application of Resveratrol when compared to saline 
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(Sogutlu et al., 2006). In the above study, tissue levels of malondialdehyde (MDA) 
and nitric oxide (NO), markers of tissue injury and inflammation, were significantly 
reduced in the Resveratrol group whereas glutathione (GSH), a cellular anti-oxidant, 
showed increased levels. From these findings, they concluded that Resveratrol 
reduces surgically induced peritoneal adhesions possibly through reduction of lipid 
peroxidation products. In vitro work discussed in Chapter 4 demonstrates that 
Resveratrol could be having an anti-adhesion effect via the down-regulation of both 
fibronectin and PAI-1 (changes seen mainly in epitenon and tendon sheath cells). 
Other studies with Resveratrol have shown a wide biological effect in various tissues 
(Brakenhielm et al., 2001; Sgambato et al., 2001; Surh et al., 1999). Furthermore, 
Resveratrol has been shown to prevent fibrosis in a rat cirrhosis model, and its action 
is probably associated with its ability to reduce the activation of a transcription factor, 
NF-kappa, and thus reduce levels of profibrinogenic TGF-β (Chavez et al., 2007). 
These mechanisms may be occurring in tendons, but further work is required to 
measure these specific compounds.   
 
EGCG may still offer a therapeutic benefit in the reduction of tendon adhesion 
formation. So far studies have shown EGCG suppresses collagen production and may 
have a role in the treatment of keloids and liver fibrosis (Zhang et al., 2006). Various 
mechanisms of action have been investigated: One study, using human tendon-
derived fibroblasts, showed that EGCG reduces chemokine (IL-1) stimulated 
expression of collagenase and stromelysin (MMP‟s) mRNA via JNK/SAPK pathway 
(Corps et al., 2004). Other theories suggest that EGCG inhibits ECM gene expression, 
by interrupting TGF-β1 signalling through attenuating oxidative stress (Yumei et al., 
2006), or enhancing the transcription of collagen type 1 (although collagen production 
was actually inhibited in this study) and TIMP-1 and reduces the transcription of 
MMP-1 (Nakumata et al., 2005). Chapter 4 of this study shows that EGCG reduce the 
adhesion of epitenon cells to fibronectin. Conversely, Hung et al., (2005) in 
melanoma derived stromal fibroblasts, showed that EGCG binds to fibronectin and 
fibrinogen but not to collagen. This group also showed that EGCG attenuated the 
antibody binding to the fibroblast integrin receptor α2β1, indicating an effect on the 
expression and affinity of integrin α2β1. Others (Suzuki and Isemura, 2001) showed 
that EGCG inhibited cell adhesion to fibronectin by its binding to the carboxyl-
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terminal heparin-binding II domain and not to the cell binding domain. Further 
research into this area may be a potential strategy for adhesion reduction.  
 
The doses of EGCG, Resveratrol and Pumactant used for this in vivo study were 
higher than used in our in vitro work. This is based on several factors. Firstly, as 
rabbit numbers were limited it was decided to optimise doses so that maximum 
therapeutic effects could be assessed. A range of doses would have led to higher 
rabbit numbers and have cost implications. EGCG toxicity has been studied in detail 
and it has been demonstrated that oral administration of 500, 1000 or 2000mg 
EGCG/kg in mice or intravenous injection of 10, 25 and 50mg EGCG/kg/day to rats 
showed absence of genotoxic effects (Isbrucker et al., 2006, Part 1). Also, the dietary 
administration of EGCG to rats over 13 weeks was not toxic at doses up to 
500mg/kg/day. Furthermore, although topical EGCG preparations caused minor 
irritation in rats and guinea pigs, there was no effect in rabbits (4 hour dermal 
exposure to 0.47g EGCG under semi-occluded patch) (Isbrucker et al., 2006, Part 2). 
In this study an EGCG dose of 0.45mg/ml (1mM solution) should not have induced 
any adverse reaction as this was a local injection into the tendon sheath and well 
below the topical or oral dose used in the studies as cited above. In a phase 1 
pharmacokinetic study (Chow et al., 2001) EGCG has been shown to be present in the 
plasma (predominantly in conjugated form) and urine after oral administration. The 
systemic availability of EGCG increased at higher doses possibly due to saturable pre-
systemic elimination of the orally administered green tea polyphenols. The 
Resveratrol dose in this study was also increased as high doses (10mg) have been 
shown to be effective in the prevention of surgery-induced peritoneal adhesions in a 
rat model (Sogutlu et al., 2006). Also, high doses of Resveratrol (10mg/kg/day) were 
administered orally to successfully alleviate bleomycin-induced lung injury in rats 
(Sener et al., 2007). In male Sprague-Dawley rats, 20mg Resveratrol/kg/day given for 
28 days did not induce systemic toxicity (Juan et al., 2002). In the current study a 
Resveratrol dose of 2.28mg/ml (10mM solution) was infiltrated into the tendon 
sheath, well below the doses used in the studies as mentioned above. Resveratrol is 
rapidly absorbed after oral intake with a maximal plasma concentration after 30-
60minutes. In one study the level of Resveratrol in the blood was found to be low, 
likely caused by rapid metabolism to glucuronide and sulphate conjugates (Walle et 
al., 2004). Lastly, a Pumactant dose of 10mg/ml was found in this study to 
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significantly increase proliferation in all tendon cell types (Chapter 4.3.1) and 
therefore deemed the appropriate dose for use in the in vivo assessment. Pumactant is 
non-toxic and produced no apparent toxic affect when administered to rats as a single 
oral dose of 2000mg/kg bodyweight (communication with the Britannia 
Pharmaceuticals). 
 
Unfortunately, the tissue distribution and absorbance rate of EGCG, Resveratrol & 
Pumactant were not studied in this work but it would be worthwhile for future pre-
clinical studies. 
 
5.5 Conclusions 
All three treatments showed a statistically significant reduction of tendon adhesion 
formation when compared to the operated untreated controls in both the mechanical 
and histological assessments (p<0.05). However, Pumactant was the only treatment to 
show a statistically significant reduction in adhesion formation when compared to the 
H2O-group in both of these assessments. There was no significant difference in 
adhesion cell counts between groups; however, Pumactant cell counts showed better 
correlation with the histological adhesion scores (Tang scores) indicating more of a 
predictable response compared to other treatments.  
 
Pumactant has been shown to reduce adhesion formation following partial tenotomy 
in a flexor tendon model. When combined with an active post-operative mobilization 
regime, functional improvement in outcome appears a distinct possibility for patients. 
Furthermore, Pumactant may also improve the outcome in patients who were not 
compliant with their mobilization protocol. Further work is required to confirm the 
effectiveness of EGCG and Resveratrol however there is still potential for benefit in 
tendon surgery.  
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Although there have been many recent advances in the repair of injured flexor 
tendons, range of movement, strength of digit and overall hand function are often still 
far from ideal. Flexor tendon adhesion formation remains a significant problem 
especially for those with poor compliance to early active mobilisation protocols. This 
study has set out to examine the potential of three novel treatments which may in the 
future act as surgical adjuncts in the prevention of tendon adhesions.       
 
6.1 The In Vitro Flexor Tendon Cell Response to TGF-β1 
The growth factor TGF-β1 appears to have an important role in both tendon healing 
(Chang et al., 1997; Klein et al., 2002; Tsubone et al., 2006) and tendon adhesion 
formation (Chang et al., 2000). TGF-β receptors have also been shown to be up-
regulated after tendon injury and there is a strong correlation between the expression 
of the receptors and ligands (Ngo et al., 2001), indicating that tenocytes may be 
responsive to TGF-β signalling. 
 
This current study demonstrates that when epitenon and tendon sheath cells were 
stimulated with TGF-β1 there was a statistically significant increase in proliferation at 
late time points (72 hours but not at 24 or 48 hours).  Endotenon cells showed no 
significant increase in proliferation with TGF-β1 when compared to those cultured in 
minimal media and this is likely to be due to the general slow proliferation and non-
reactivity of this cell type. It appears that epitenon and sheath cells are behaving 
differently to endotenon cells in such a way that reflects modern tendon healing 
concepts (Berglund et al., 2006). 
 
Fibroblasts derived from various tissues have shown that collagen type I gene 
expression is increased in response to TGF-β1 (Rolfe et al., 2007, Varga et al., 1987, 
Tiggleman et al., 1995; Chai et al., 2003). Collagen is known to be important in 
maintaining the mechanical properties of the tendon (Benjamin et al., 2002; Purslow, 
2002). Although, collagen type III is rapidly deposited after injury its presence 
appears only temporary as during the remodelling phase of tendon healing collagen 
type III is replaced with collagen type I (Jaibaji, 2000). This and other studies 
(Gelberman et al., 1992), epitenon cells show an increase in collagen type I gene 
expression, whereas the endotenon cells show no expression during the early healing 
phases. This increase in gene expression appears to also mirror an increase in protein 
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expression, though not statistically significant, with an increase in soluble collagen 
identified in epitenon and sheath derived cells following stimulation with TGF-β1. 
Collagen types I and III have been shown to be up-regulated in an uninjured tendon 
model (Klein et al., 2002). In this study, interestingly stimulation of epitenon cells 
with TGF-β1 showed no increase in collagen type III gene expression though both 
sheath and endotenon derived cells showed some statistically significant increase 
during the time course. Similarly, Berglund et al., (2006) also showed an increase in 
collagen type III in both tendon and tendon derived sheath cells in an in vivo model, 
over a longer period of time and in a post injury model, however, their tendon cells 
were not classified as either epitenon or endotenon derived (Berglund et al., 2006).  
 
TGF-β1 is known to be able to alter the production of fibronectin (Saika et al., 1998). 
Fibronectin is known to be deposited at an early stage of tendon healing (granulation 
phase) and is thought to play a role in the formation of an adhesion bridge (Kurtz et 
al., 2001; Wojciak and Crossan, 1993). TGF-β1 increased fibronectin gene expression 
in all cells derived from the tendon-sheath complex. Plasminogen activator inhibitor 1 
(PAI-1) gene transcription is increased in a number of cell types (Rolfe et al., 2007; 
Zhao et al., 2006) in response to TGF-β1. High PAI-1 levels, and therefore the 
inhibition of fibrinolysis has been associated with peritoneal adhesion formation (Di 
Filippo et al., 2006), while low levels of tissue plasminogen activator (t-PA) have 
been associated with a reduction in adhesion formation in the peritoneum and pelvis 
(Orita et al., 1991; Doody et al., 1989). In this current study, PAI-1 gene expression 
was found to be increased in endotenon and tendon sheath cells in response to TGF-
β1. Although, all tendon-derived cells showed a down-regulation in t-PA gene 
expression statistical significance was reached in only endotenon and sheath derived 
cells. Similarly, in mesothelial cells, TGF-β1 increased PAI-1 gene transcription and 
caused a reduction in t-PA (Falk et al., 2001). 
 
This increase in PAI-1 in sheath-
derived cells in conjunction with a decrease in t-PA, following stimulation with TGF-
β1, could potentially lead to adhesion formation (Figure 1.10). This mechanism could 
be one explanation for the excess scarring and adhesion formation associated with 
TGF-β1.  
 
TGF-β1 has been associated with tendon adhesion formation in several studies 
(Chang et al., 2000; Khan et al., 2000; Ngo et al., 2001). In this current study there is 
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a demonstrable spatial and temporal variability in response to tendon cells of different 
origin when treated with a multipotent growth factor, TGF-β1. Additionally, the novel 
treatments studied in this thesis may affect specific TGF-β1 pathways which could be 
further manipulated to achieve an optimal therapy.        
  
6.2 The In Vitro and In Vivo Assessment of 3 Novel Flexor Tendon Anti-Adhesion 
Treatments 
Over the years many different chemical (Kulick et al., 1984; Green et al., 1986; 
Hagberg, 1992; Moran et al., 2000; Chang et al., 2000) and physical barrier (Austin 
and Walker, 1979; Hanff and Hagberg, 1998; Golash et al., 2003) treatments have 
been studied, but none have yet proven to be successful in improving the outcome of 
tendon surgery without significant side effects. The purpose of this investigation was 
to test three proposed flexor tendon anti-adhesion treatments in vitro to discover their 
potential in the prevention of adhesions and optimise the environment for tendon 
healing. Epigallocatechin-3-gallate (EGCG) and Resveratrol are naturally occurring 
plant extracts and Pumactant is a mixture of two naturally occurring phospholipids. 
The advantages of non-synthetic compounds are their high abundance, relative low 
cost to manufacture and general low toxicity.  
 
6.2.1 EGCG 
EGCG, as previously discussed (Chapter 1, section 1.9.1), is a catechin extract, major 
polyphenol and the most potent antioxidant found in green tea (Ahmad and Mukhtar, 
1999). EGCG has been shown to play a role in treating a number of diseases (Suzuki 
and Isemura, 2001; Abe, 2007) including the reduction of fibrosis in a number of 
organs and improving scarring and wound healing in cutaneous wounds (Kapoor et 
al., 2004; Nakamuta et al., 2005; Zhang et al., 2006; Klass et al., 2010).  
 
Based on this work and other studies (Hung et al., 2005; Chen et al., 2002; Nakamuta 
et al., 2005) an EGCG dose of 50μM was selected as the optimal treatment dose. 
Adhesion studies were performed to investigate the effect of each treatment on the 
adhesion of different tendon cell types to various extracellular matrices. Changes in 
adhesion properties of cells to specific matrix components may influence formation of 
adhesion, in particular at the epitenon-tendon sheath interface. Sheath derived cells 
showed a statistical significant reduction in adhesion to collagen type I following 
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treatment with EGCG, though other tendon derived cells showed no significant 
difference. This effect on collagen type I may be due to the effects of EGCG on the 
α2β1 receptor (Hung et al., 2005). Hung et al showed that EGCG blocks α2β1 either 
through an interaction with the integrin receptor itself or through the decrease of 
intracellular H2O2. Endotenon and epitenon cells showed no difference with adhesion 
to collagen type I and it is possible that they express more α1β1, a further collagen 
type I receptor. Interestingly both epitenon and endotenon derived cells showed an 
increase in adhesion to collagen type III following treatment with EGCG. Collagen 
type III binds by both α1β1 and α2β1 and is known to have a novel binding site, 
which may explain this effect (Kim et al., 2005).  In contrast to other studies (Hung et 
al., 2005), EGCG showed no effect on fibroblast adhesion to fibronectin and this 
difference remains unclear.  
 
EGCG showed no significant change in collagen type I, type III and fibronectin gene 
expression in the tendon-sheath derived cells compared to untreated controls, with the 
exception being endotenon derived cells which showed a statistically significant 
reduction in collagen type III gene expression. Other studies have shown that EGCG 
also inhibits collagen type I production in a number of cell types even when the cells 
exposed to a fibrotic stimuli such as TGF-β1 (Zhang et al., 2006; Nakamuta et al., 
2005; Hashem et al., 2008; Park et al., 2008; Klass et al., 2010). However, other 
studies suggest that though EGCG reduces collagen production it appears to improve 
the maturity and organisation of the collagen fibres (Kapoor et al., 2004; Kim et al., 
2008). Also, in human tendon fibroblasts, EGCG has been shown to reduce the 
expression of collagenase mRNA, which may lead to higher collagen levels (Corps et 
al., 2004).  
 
EGCG appeared to have little effect on PAI-1 gene expression with only endotenon 
derived cells showing a significant up-regulation at an early time point. Others have 
shown that green tea polyphenols inhibit PAI-1 gene expression and its release from 
endothelial cells (Liu et al., 2009) i.e. increased fibrinolysis and potential reduction of 
adhesions. Epitenon derived cells demonstrated a statistically significant down-
regulation of t-PA at 2 and 4 hours which could potentially lead to unfavourable 
conditions for increased adhesion formation. Fortunately, the changes seen in both 
PAI-1 and t-PA gene expression are seen at early time points and a prolonged effect 
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may be required for adhesions to develop. In a post-surgical peritoneal model, low 
levels of t-PA and high levels of PAI-1 have been associated with increased adhesions 
(Cheong et al., 2001 and Ivarsson et al., 1998), to date there have been no studies 
looking at the role of PAI-1 and t-PA in tendon adhesion formation. 
  
EGCG in vivo showed a statistically significant reduction in both mechanical and 
histological adhesions when compared to the operated untreated group (OUT-group). 
However, there was no difference when compared to the diluent or H2O-group. As 
discussed in Chapter 5 it appears that water may be exerting an as yet unknown 
physical or biological effect.  Although saline would have been a suitable alternative 
as a control it was not recommended as a diluent for Pumactant (based on 
proliferation studies at Cardiff University). An additional saline group in the in vivo 
model would have been useful but it was deemed important to keep animal numbers 
and cost to a minimum. This study refinement including reduction of animal numbers 
is a necessary part of animal welfare and the project license application process 
(Handbook of Laboratory Animal Management and Welfare, Wolfensohn and Lloyd, 
2003). 
 
EGCG has previously demonstrated anti-fibrotic potential and in this current study 
there was a reduction of zone II flexor tendon adhesion formation in an animal model. 
The effect on tendon healing in vivo has not been assessed fully and this would be the 
next phase of work to be undertaken.  Other studies in compromised wounds, such as 
those in a diabetic mouse model, show that EGCG accelerates re-epithelialisation 
(Kim et al., 2008) and this suggests that tendon healing may also benefit from such 
treatment.   
 
6.2.2 Resveratrol  
Resveratrol (trans-3, 4, 5-trihydroxystilbene) is a natural polyphenol found in some 
plants including grapes and has been shown to be effective in preventing fibrosis and 
peritoneal and pelvic adhesions in animal models (Chavez et al., 2007; Ustűn et al., 
2007; Sogutlu et al., 2006). Following previous discussion (Chapter 1, section 1.9.2) it 
was deemed worthwhile investigating the effects of Resveratrol on tendon healing and 
whether peri-tendinous adhesion formation can be reduced.  
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Resveratrol treated epitenon cells showed a statistically significant reduction in 
proliferation at several different doses. Comparison with other studies suggest using 
doses between 25-100μM (Olas et al., 2002). For this study a dose of 50μm was 
selected to maximise any biological effect. Resveratrol reduced the adhesion of sheath 
and epitenon derived tendon cells to collagen type I but no other extracellular matrix 
component. Similarly, Resveratrol has been found to prevent the adhesion of some 
cell types to collagen and fibrinogen (Olas et al., 2002; Cao et al., 2005) and the 
mechanism for this may be related to its antioxidant properties (Olas et al., 2002). 
Additionally, the integrin αvβ3 has been shown to contain a binding site for 
Resveratrol (Lin et al., 2006), and αvβ3 is known to bind to a number of extracellular 
matrices (Tandon et al., 2005).  
  
Resveratrol treatment has been associated with enhanced formation of epidermis, 
deposition of connective tissue and improved histological architecture in a cutaneous 
wound (Khanna et al., 2002) which implies an organised production of collagen.  
Resveratrol in other studies can inhibit expression of type I collagen gene expression 
in a number of cell types (Godichaud et al., 2000; Rucinski et al., 2006). This current 
study showed a statistically significant up-regulation of collagen type I gene 
expression in epitenon derived cells and up-regulation of collagen type III in sheath 
derived cells. Epitenon cells and tendon sheath cells treated with Resveratrol showed 
a statistically significant down-regulation of fibronectin. Similarly, Resveratrol has 
been shown to reduce fibronectin synthesis in other tissues (Lee et al., 2010). An 
intact fibronectin framework is critical for maintaining the composition of cell-matrix 
adhesion sites (Sottile and Hocking, 2002). Hence a reduction of fibronectin 
production could lead to less tendon adhesion formation.  
 
Epitenon and sheath derived cells treated with Resveratrol showed a statistically 
significant down-regulation of PAI-1 gene expression, with the exception at 48 hours 
in sheath derived cells. This reduction in PAI-1 gene expression has been confirmed 
in a study in adipocytes treated with Resveratrol (Ahn et al., 2007). Essentially, this 
equates to more predicted adhesion formation (as explained in Chapter 4). Also, there 
was a synchronous up-regulation in t-PA with a down-regulation of PAI-1 at 48 
hours. This result is expected as physiologically t-PA and PAI-1 are opposing forces 
in the fibrinolytic pathway. Also, polyphenolics, including Resveratrol, have been 
Chapter 6 
 184 
shown in cultured human endothelial cells to increase t-PA protein and gene levels 
(RT-PCR), concomitant with an increase in sustained surface localised fibrinolytic 
activity (Abou-Agag et al., 2001) thus showing the ability to reduce adhesion 
formation.   
 
Resveratrol in vivo showed a very similar response to EGCG with a statistically 
significant reduction in both mechanical and histological adhesions when compared to 
the operated untreated group (OUT-group). However, again there was no difference 
when compared to the H2O-group. Resveratrol and EGCG are both potent 
antioxidants and they possibly share a common anti-adhesion effect via this pathway. 
Certainly, increased oxidative stress has been associated with adhesion formation in 
various tissues (Ksiazek et al., 2010; Heydrick et al., 2010) and antioxidants may play 
a role in prevention by increasing fibrinolytic activity (Heydrick et al., 2010). The 
effect of Resveratrol on tendon healing in vivo has also not been assessed and this 
would be the next phase of work to be undertaken. Though, others have shown that 
dermal wounds heal with enhanced re-epithelialisation and therefore indicate that 
Resveratrol should not affect tendon healing (Khanna et al., 2002). 
 
6.2.3 Pumactant  
The properties of Pumactant have been discussed (Chapter 1, section 1.9.3) and the 
functional role and effects of various phospholipids have been previously described 
(Chapter 5, section 5.4). Recently, a phospholipid emulsion has been shown to reduce 
adhesion formation in a rat model of peritoneal adhesions (Aritas et al., 2009). 
Moreover, phospholipids have been shown to play a role in the prevention of flexor 
tendon adhesion formation in a rabbit model (Moro-oka et al., 2000).  
 
All tendon cell types showed a statistically significant increase in proliferation when 
treated with Pumactant. However, tendon sheath cells treated with Pumactant also 
showed a statistically significant reduction in proliferation at day 7 (2mg/ml). 
Similarly, Pumactant has been shown to accelerate mesothelial and keratinocyte cell 
proliferation. This response appeared to be unique to this specific compound, as other 
phospholipids appear to inhibit cell proliferation and can cause a reduction in cell 
viability (Kremlev et al., 1994; unpublished work performed at Cardiff University). 
From this current work and previous studies (unpublished work performed at Cardiff 
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University) a Pumactant dose of 1 and 2mg/ml was used for further in vitro studies 
and 10mg/ml for our in vivo study as described in Chapter 5. 
 
Phospholipids in other studies have been shown to inhibit gastric cancer cell 
adherence to collagen type IV, laminin and fibronectin (Jansen et al., 2004). The 
mechanism of action is unknown but may be due in part to the barrier properties of 
phospholipids. In this current study Pumactant showed no significant effects on cell 
adhesion to different extracellular matrices and this may be explained by the different 
cell type and alternative matrices employed.  
  
Pumactant treated endotenon cells showed a statistically significant up-regulation of 
collagen type III gene expression at late time. An increase in collagen type III gene 
expression in cells at the core (endotenon) of the tendon may allow for optimisation of 
tendon healing. Endotenon cells also showed a statistically significant up-regulation 
of PAI-1 at early time points which was followed by a later down-regulation. Tendon 
sheath cells showed a statistically significant down-regulation of PAI-1 at 1 hour. 
Overall there appears to be a reduction in PAI-1 between endotenon and sheath cell 
types which may be beneficial in preventing adhesions, as already described (Cheong 
et al., 2001; Ivarsson et al., 1998).  
 
Pumactant in vivo appeared to have the most marked effect on the reduction of force 
required for adhesions to fail. There was also no statistical difference between the 
Pumactant treated group and the unoperated untreated group (UOUT-group) which 
suggests that the use of Pumactant on injured tendons makes them behave like 
uninjured ones. The histological findings (Tang scoring) showed again that Pumactant 
was the only treatment to reduce tendon adhesions with a statistically significant 
difference compared to the H2O group. The Tang scores combined with the adhesion 
cell number results confirm that Pumactant reduces the size and density of adhesions 
but does not significantly reduce adhesion cellularity.  
 
Cells on the tendon surface are known to contain lipid-containing vesicles and it has 
been estimated that lipids account for up to 43 percent of the epitenon matrix, whereas 
collagen accounts for only 23 percent (Banes et al., 1988). Phospholipids have a 
biomembrane with two important roles (Ansell and Hawthorne, 1964; Briscoe et al., 
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2006; Higaki et al., 1998; Moro-oka et al., 2000): the physical role of forming a 
hydrophobic boundary-lubricating environment, and the functional role as a second 
messenger or agonist. Surface-active phospholipids, like Pumactant, commonly form 
multiple layers when in contact with solid surfaces, providing the basis for 
lubrication. The lamellar body (enclosed multi-layered structure) is the surface active 
form of surfactant first described in alveolar type II cells in the lung (Ueda et al., 
1984). Lamellar bodies are secreted onto the surface to be lubricated where they 
unravel and coat the epithelial surface (Ueda et al., 1984; Hills 1989). Boundary 
lubrication occurs when rubbing surfaces are coated with molecular monolayers. Such 
monolayers generally consist of amphiphilic (molecule containing both hydrophilic 
and hydrophobic parts) surfactants anchored by their polar headgroups; sliding occurs 
at the interface between the layers, greatly reducing friction and especially wear of the 
underlying substrates. Interestingly, this friction is greatly reduced when the two 
sliding surfaces bearing surfactant monolayers are immersed in water, to as little as 
one per cent or less of its value in air (Briscoe et al., 2006).  
 
Pumactant could act as a boundary lubricant in improving tendon glide, as a barrier 
preventing adhesions, and may show advantages in cell proliferation and tendon 
healing. Certainly, in this current study (Chapter 4) Pumactant has demonstrated a 
significant biological effect on gene expression mainly in endotenon cells. A further 
study showed that a mixture of phospholipid and hyaluronic acid reduced adhesion 
formation compared to saline or hyaluronic acid alone though the group did not study 
solely phospholipid (Moro-oka et al., 2000). This same group measured the friction 
coefficient of the gliding tendon followed by the work required to tear the tendon 
from the sheath (a similar mechanical method as used in this current study). There is 
evidence (Topley et al., 2010) to suggest that Pumactant may achieve some of its 
effects through the induction of hyaluronic acid synthase, which presents the 
possibility that phospholipids might aid lubrication and also participate, through 
hyaluronic acid production, in tendon repair and healing. A final further mechanism 
of action may be that phospholipids interact with collagen type I fibril formation 
which may interfere with extracellular matrix organisation within the adhesion 
complex (Martinez Del Pozo et al., 1989). We are unable to comment on the effect of 
Pumactant directly on tendon healing but as phospholipids are present in normal 
tendon sheath fluid and joints this is unlikely to cause any impairment. There was 
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certainly no excess inflammation or evidence of Pumactant present at two weeks 
following surgery. The effect of Pumactant and the other treatments on tendon healing 
in vivo has not been assessed and further work in this area is required before clinical 
trials.   
 
6.3 Critique 
There are several factors that can affect the interpretation of the current findings. Cells 
cultured were from previously uninjured rabbit flexor tendons and ideally cells from 
injured flexor tendons would have offered additional information. Further, there are 
differences with cells grown in culture to those in vivo; as it is impossible to exclude 
the effects of other cytokines in vivo whereas in vitro studies allow an environment 
which can be tightly controlled. Though tendon cells in vitro are believed to have 
undergone differentiation due to culture conditions it is also believed that during 
tendon healing the cells also undergo some form of differentiation (Gelberman et al., 
1985). 
 
Animal models can never fully reproduce the clinical environment. However, they are 
essential before human trials can be undertaken. New treatments can be fully tested in 
a controlled manner whilst monitoring efficacy and safety. Refinements, including 
dosing regimes, routes of administration and pharmacokinetics can be assessed. In 
this study it was necessary to create an accurate model of tendon adhesion formation 
but keep confounding factors to a minimum. The New Zealand White rabbit model is 
widely recognised for use in flexor tendon studies. By incorporating this model the 
clinical situation could be mimicked very closely as flexor tendons were selected from 
Zone II of the rabbit forepaw which is equivalent to Zone II in the human hand. A 
standardised tendon injury was performed (tenotomy) and the treatment infiltrated 
into the sheath. Classically, injured tendons are repaired with a non-absorbable core 
suture using a modified Kessler technique and a second non-absorbable epitendinous 
suture. This was not used in the current model as suture material at the site of 
adhesion formation could potentially bias the results. However, there is scope for a 
suture repair model as discussed later.      
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6.4 Further Work  
Testing three treatments required a large number of animals, considerable time and 
cost however it has been beneficial in that two of the compounds have shown promise 
and one, Pumactant, has shown great potential in the prevention of tendon adhesions. 
Further work is required, specifically looking at tendon healing rather than adhesion 
formation. There will be no clinical benefit if adhesions can be prevented but the 
tendon ruptures due to poor healing.  
 
To determine the effects of each treatment on tendon healing, a similar rabbit flexor 
tendon model (as described in Chapter 2) could be employed. However, the surgical 
tenotomy would be replaced with a complete tendon transection followed by a 
standard modified Kessler repair using a non-absorbable monofilament suture 
material. The treatments would be added using the same infiltrating technique but 
harvesting would not occur until six weeks post-operatively. This would allow 
adequate time for tendon healing and the formation of adhesions. Tendon healing 
could be assessed using the same techniques: mechanical tensile testing (ultimate 
tensile strength or cyclical testing of the healed tendon and the related adhesion) and 
histological assessment (endotenon and epitenon repair, inflammatory markers and 
further adhesion scoring). It would also be interesting to use different doses to study if 
there is a dose dependent effect and use fluorescent typing to follow the absorption 
rate and metabolism of Pumactant. Lastly, it may be useful to leave a cannula within 
the sheath so that several treatment doses can be applied over a period of time 
however this approach may not be clinically applicable.         
 
6.5 Conclusions  
6.5.1 Chapter 3 
 Proliferation results demonstrate that when sheath cells were treated with 
TGF-β1 there was a statistically significant increase at 0.5ng/ml at 72 hours 
but not at 24 or 48 hours.   
 
 Epitenon cells showed a similar significant response with fetal calf serum 
compared to serum free media. Also, although there was not an early increase 
(24 and 48 hours) in proliferation with TGF-β1 compared to cells grown in 
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minimal media there was a statistically significant increase at 72 hours when 
using a higher dose (2ng/ml).  
 
 Endotenon cells showed no significant increase in proliferation with TGF-β1 
when compared to serum free media. It appears that epitenon and sheath cells 
are behaving differently to endotenon cells in such a way that reflects modern 
tendon healing concepts {Berglund et al, 2006}. 
 
 Epitenon cells treated with TGF-β1 showed an increase in collagen type I gene 
expression, whereas the endotenon cells showed no detectable expression 
during the early time points. 
 
 Stimulation of epitenon cells with TGF-β1 showed no increase in collagen 
type III expression over the whole time course though both sheath and 
endotenon derived cells showed some statistically significant increase during 
the time course 
 
 All tendon-derived cells treated with TGF-β1 showed at some time point a 
statistically significant increase in fibronectin gene expression compared to the 
untreated controls. 
 
 PAI-1 gene expression was found to be statistically significantly increased 
compared to untreated controls in endotenon cells treated with TGF-β1 in the 
early part of the time course, whereas sheath derived cells showed a 
statistically significant increase at 48 hours. 
 
 All tendon-derived cells treated with TGF-β1 showed a reduction in t-PA gene 
expression over the time course with endotenon and sheath derived cells 
showing a statistically significant down regulation. 
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6.5.2 Chapter 4 
 The optimal in vitro doses for each treatment based on this study and the 
current literature are as follows: EGCG 50μM, Resveratrol 50μM and 
Pumactant 1mg/ml.  
 
 EGCG caused increased adhesion of pre-treated endotenon and epitenon cells 
to collagen type III. Conversely, there was decreased adhesion of EGCG pre-
treated sheath cells to collagen type I.  
 
 Resveratrol caused reduced adhesion of pre-treated epitenon and tendon sheath 
cells to collagen type I.  
 
 Treatment with Resveratrol caused the most optimal changes to gene 
expression as collagen type I, collagen type III and t-PA were up-regulated, 
whereas fibronectin and PAI-1 were down-regulated. These changes were seen 
mainly in epitenon and tendon sheath cells. 
 
 Pumactant treated endotenon cells up-regulated collagen type III gene 
expression at late time points and there was an increase in PAI-1 gene 
expression early but then a later down-regulation. There was also a down-
regulation of PAI-1 in tendon sheath cells. These results indicate a moderate 
therapeutic advantage. 
 
6.5.3 Chapter 5 
 All three treatments showed a statistically significant reduction of tendon 
adhesion formation when compared to the operated untreated controls in both 
the mechanical and histological assessments (p<0.05).  
 
 Pumactant was the only treatment to show a statistically significant reduction 
in adhesion formation when compared to the H2O group in both mechanical 
and histological assessments (p<0.05).  
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 There was no significant difference in adhesion cell counts between groups; 
however, Pumactant cell counts showed better correlation with the histological 
adhesion scores (Tang scores) indicating more of a predictable response 
compared to other treatments.  
 
This study has examined the effect of a multipotent growth factor, TGF-β1 on 
cultured uninjured flexor tendon cells derived from different parts of the tendon-
sheath complex. Following this three novel treatments were assessed using in vitro 
and in vivo methods to determine their potential use in the prevention of flexor tendon 
adhesion formation. All three treatments have demonstrated an ability to modify 
tendon adhesion factors and one treatment in particular (Pumactant) has shown a 
statistically significant mechanical and histological reduction of adhesion formation in 
a flexor tendon animal model. EGCG and Resveratrol appear to have some biological 
effects whereas it appears Pumactant may be acting via both biological and physical 
mechanisms (e.g. steric hindrance) therefore offering a greater therapeutic advantage. 
A second stage investigation using Pumactant is warranted and ultimately this may 
prove to be a successful adjunct to surgery in patients who sustain tendon injuries in 
the future. The overall goal of research into this area is to improve outcome of surgery 
in patients with hand injuries such that they recover function with minimal 
physiotherapy, return to work more promptly and develop fewer complications.  
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Appendix I 
 
Histology Protocols 
 
Haematoxylin and eosin stain for paraffin sections 
Haemotoxylin and eosin (H&E) staining allows visualisation of cell nuclei 
(haematoxylin: blue) and cytoplasm (eosin: pink) and is useful for assessing cell 
morphology.  
 
The sections were de-waxed, hydrated through graded alcohols to water and stained in 
Harris‟ haematoxylin for 5 minutes. The sections were washed well with running tap 
water, differentiated with 1% acid alcohol and then „blued‟ in running tap water for 5 
minutes or less. Sections were stained with 1% eosin for 10 minutes and washed in 
running tap water for 1-5 minutes. Finally, sections were dehydrated with alcohols, 
cleared with xylene and mounted with DePX (BDH). 
 
Masson’s trichrome stain 
The Masson‟s trichrome staining method is used for the detection of collagen fibers in 
various tissues on formalin-fixed, paraffin-embedded sections, and may be used for 
frozen sections as well. The collagen fibers will be stained blue, the nuclei will be 
stained black and the background is stained red. 
 
Solution A 
Acid fuchsin    0.5g 
Glacial acetic acid   0.5ml 
Distilled water     100ml 
 
Solution B  
Phosphomolybdic acid    1.0g 
Distilled water    100ml 
 
Solution C  
Methyl blue     2.0g 
Glacial acetic acid    2.5ml 
Distilled water     100ml 
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Method 
1. Deparaffinise sections and bring to water 
2. Wash in tap water 
3. Stain nuclei by the Celestin blue-haematoxylin method  
4. Differentiate with 1% acid alcohol 
5. Wash in tap water 
6. Stain in acid fuchsin solution A for 5 minutes 
7. Rinse in distilled water 
8. Treat with solution B for 5 minutes 
9. Drain 
10. Stain with solution C for 2-5 minutes 
11. Rinse in distilled water  
12. Treat with 1% acetic acid for 2 minutes 
13. Dehydrate through alcohols  
14. Clear in xylene and mount with DePX 
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Appendix II 
 
Preparation of Solutions 
 
Normal growth medium (NGM) for tendon cell culture 
500mls Dulbecco‟s Modified Eagle Medium containing 4500mg/L glucose and 4mM 
L-glutamine (Gibco)  
Add 50mls (10%) of fetal calf serum (FCS, Gibco)  
Add 5mls (1%) of 5000U/ml penicillin  
Add 5mls of 5000mg/ml streptomycin (Gibco)  
 
DEPC-ddH2O 
Add 0.1% DEPC to ddH2O in an RNase free glass bottle  
Stir vigorously in a fume hood overnight 
Autoclave and store at room temperature 
 
50x TAE buffer 
Dissolve 242g Tris-base (BDH) in 800ml sterile ddH2O  
Add 57.1ml glacial acetic acid (BDH) and 100ml 0.5M EDTA (pH 8.0) 
Adjust volume to 1L and store at room temperature 
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Appendix III - Results Data 
 
 The Biomechanical Assessment of Adhesion Formation (Chapter 5) 
 
 
 
NZW 
No. 
Rabbit 
Forepaw Digit Treatment Force N     
RT921 Left D2 UOUT 0.43     
RT921 Right D2 OUT 3.48     
RT941 Left D2 UOUT 0.39     
RT941 Right D2 OUT 2.02     
RT942 Left D2 UOUT 0.18     
RT942 Right D2 OT PUM 1.9     
RT925 Left D2 UOUT 0.19     
RT925 Right D2 OT PUM 0.19     
RT922 Left D2 UOUT 0.48     
RT922 Right D2 OUT 1.88     
RT938 Left D2 UOUT 0.22     
RT938 Right D2 OT PUM 2.3     
RT939 Left D2 UOUT 0.25     
RT939 Right D2 OUT 1.58     
RT940 Left D2 UOUT 0.82     
RT940 Right D2 OT PUM 0.14     
RT979 Left D2 UOUT 0.36     
RT979 Right D2 OUT 3.78     
RT980 Left D2 UOUT 0.31     
RT980 Right D2 OT PUM 0.43     
RT973 Left D2 UOUT 0.46     
RT973 Right D2 OUT 4.35     
RT974 Left D2 UOUT 0.75     
RT974 Right D2 OT PUM 0.6     
RT975 Left D2 UOUT 0.18     
RT975 Right D2 OUT 3.78     
RT976 Left D2 UOUT 0.73     
RT976 Right D2 OT PUM 0.28     
RT977 Left D2 UOUT 0.22     
RT977 Right D2 OUT 1.64     
RT978 Left D2 UOUT 0.4     
RT978 Right D2 OT PUM 0.61     
RT981 Right D2 OT RES 0.79     
RT982 Right D2 OT RES 2.11     
RT983 Right D2 OT RES 1.45     
RT984 Right D2 OT RES 1.72     
RT985 Right D2 OT RES 1.41     
RT986 Right D2 OT RES 9.82 Result excluded as wound dehiscence 
RT987 Right D2 OT RES 0.25     
RT988 Right D2 OT RES 0.97     
RT989 Right D2 OT EGCG 1.08     
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RT990 Right D2 OT EGCG 1.91     
RT991 Right D2 OT EGCG 1.67     
RT992 Right D2 OT EGCG 1.48     
RT993 Right D2 OT EGCG 2.14     
RT994 Right D2 OT EGCG 2.48     
RT995 Right D2 OT EGCG 1.29     
RT996 Right D2 OT EGCG 1.23     
RT997 Right D2 OUT H2O 1.63     
RT998 Right D2 OUT H2O 1.58     
RT999 Right D2 OUT H2O 1.6     
RT1000 Right D2 OUT H2O 1.64     
RT1100 Right D2 OUT H2O 2.27     
 
 
Results table (raw data) showing force (N) required for tendon adhesion breakage. 
UOUT, unoperated untreated; OUT, operated untreated; OT PUM, operated and 
treated with Pumactant; OT EGCG, operated and treated with EGCG; OT RES, 
operated and treated with Resveratrol; OUT H2O, operated and untreated with H2O as 
control. 
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Appendix III - Results Data  
 
The Histological Assessment of Adhesion Formation using Tang Scoring 
(Chapter 5) 
 
Slide 
No. 
NZW 
No. 
Rabbit 
Forepaw Digit Treatment 
Tang 
Score 
BK2 RT921 Right D4 OUT  5 
BK7 RT922 Right D4 OUT  4 
BK11 RT941 Right D4 OUT  6 
BK14 RT939 Right D4 OUT  5 
BK17 RT977 Right D4 OUT 4 
BK21 RT973 Right D4 OUT 6 
BK26 RT975 Right D4 OUT 6 
BK29 RT979 Right D4 OUT 5 
BK41 RT989 Right D4 OT EGCG 3 
BK42 RT990 Right D4 OT EGCG 4 
BK43 RT991 Right D4 OT EGCG 3 
BK44 RT992 Right D4 OT EGCG 3 
BK45 RT993 Right D4 OT EGCG 4 
BK46 RT994 Right D4 OT EGCG 0 
BK47 RT995 Right D4 OT EGCG 2 
BK48 RT996 Right D4 OT EGCG 5 
BK33 RT981 Right D4 OT RES 4 
BK34 RT982 Right D4 OT RES 1 
BK35 RT983 Right D4 OT RES 5 
BK36 RT984 Right D4 OT RES 0 
BK37 RT985 Right D4 OT RES 2 
BK38 RT986 Right D4 OT RES 5 
BK39 RT987 Right D4 OT RES 4 
BK40 RT988 Right D4 OT RES 4 
BK1 RT938 Right D4 OT PUM  2 
BK4 RT942 Right D4 OT PUM 0 
BK6 RT925 Right D4 OT PUM  5 
BK8 RT940 Right D4 OT PUM  0 
BK19 RT976 Right D4 OT PUM  5 
BK23 RT974 Right D4 OT PUM 0 
BK28 RT978 Right D4 OT PUM 2 
BK32 RT980 Right D4 OT PUM 1 
BK49 RT997 Right D4 OUT H2O  4 
BK50 RT998 Right D4 OUT H2O 5 
BK51 RT999 Right D4 OUT H2O 4 
BK52 RT1000 Right D4 OUT H2O 3 
BK53 RT1100 Right D4 OUT H2O 5 
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Results table (raw data) showing histological assessment of adhesion formation using 
Tang scoring. OUT, operated untreated; OT PUM, operated and treated with 
Pumactant; OT EGCG, operated and treated with EGCG; OT RES, operated and 
treated with Resveratrol; OUT H2O, operated and untreated with H2O as control.    
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Appendix IV 
 
Publications derived from this thesis 
 
Paper Published: 
In Vitro Flexor Tendon Cell Response to TGF-β1: A Gene Expression Study. 
B.R. Klass, K.J. Rolfe, A.O. Grobbelaar.  
Journal of Hand Surgery, American Volume, 2009, 34A (3), 495-503. 
 
